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hnRNP K is a member of the large family of ubiquitously expressed heterogeneous 
nuclear ribonucleoproteins (hnRNPs), which are involved in a wide array of cellular 
processes. hnRNP K has been consistently reported to be upregulated in various cancers 
that include hepatocellular carcinoma (HCC), the third highest cause of cancer-related 
deaths globally, with apoptosis dysregulation as one of its hallmarks. hnRNP K has been 
implicated in apoptosis but its precise role in this process has not been clearly defined. 
Hence, this study aims to investigate the role of hnRNP K in the dysregulation of 
apoptosis in HCC. 
Consistent with previous reports of hnRNP K upregulation in HCC, the results from 
this current study revealed that hnRNP K was detected abundantly in a panel of 17 HCC 
cell lines examined, suggesting its importance in HCC. 5-Fluorouracil (5-FU), a common 
anti-metabolite chemotherapeutic drug, was used to treat HCC cells and the experimental 
findings revealed that hnRNP K was downregulated independently of p53. Reduction of 
hnRNP K expression using specific siRNA was also shown to result in a decrease in HCC 
cell viability. The evidence for reduction in cell viability was demonstrated to be via 
apoptosis using various in-vitro functional analyses including TUNEL assay, PARP-1 
cleavage and caspase 3/7 assay. In addition, when HepG2 cells (p53+/+) and Hep 3B 
cells (p53-null) were treated with hnRNP K siRNA to examine whether p53 plays a role 
in hnRNP K-induced apoptosis, their similar caspase-3/7 activity profiles suggested that 
the apoptosis induced was p53-independent.  
To further investigate the underlying mechanism of hnRNP K-downregulation-
induced apoptosis, hnRNP K siRNA treated cells were simultaneously treated with either 
caspase-8 or caspase-9 siRNA. Intriguingly, the results revealed that only the addition of 
caspase-8 siRNA was able to abrogate the increase in caspase-3/7 activity. Thus, this 
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indicated that hnRNP K-downregulation-induced apoptosis is mediated predominantly via 
the caspase-8 apoptotic signalling pathway.  
A reduction in hnRNP K was also demonstrated to sensitise HCC cells towards 
apoptosis, where exposure of cells to TRAIL 24 hours post-treatment with hnRNP K 
siRNA significantly enhanced the potency of TRAIL. The enhanced caspase-3/7 activity 
was also observed to be independent of BID cleavage and revealed to be a direct effect of 
increased caspase-8 activity.  
In an attempt to better understand this novel hnRNP K-caspase-8 pathway, exon 
array was performed on hnRNP K siRNA treated Hep 3B cells and the genes associated 
with caspase-8 function were selected for further analysis. Among the 109 genes 
evaluated, TNFSF10 expression was strongly elevated while BIRC3, CFLAR and XIAP 
were distinctly downregulated. The expression levels of these 4 genes were also 
confirmed by real time PCR, which revealed that hnRNP K reduction causes a 
downregulation of anti-apoptotic genes BIRC3, XIAP and CFLAR at the mRNA level. 
Hence, the experimental findings suggested that hnRNP K exerts its anti-apoptotic effect 
by regulating the expression levels of various anti-apoptotic genes. 
In conclusion, this study has established the anti-apoptotic role of hnRNP K in HCC 
with the use of HCC cell lines, which was shown to be mainly mediated via the 
upregulation of anti-apoptotic proteins that can inhibit caspase activity. Thus, the 
experimental findings from this study have provided a molecular basis for understanding 
hnRNP K’s involvement in HCC, as well as aided in the identification of hnRNP K as a 
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1.1 Heterogeneous nuclear ribonucleoprotein K (hnRNP K) 
1.1.1 hnRNPs and PCBPs 
hnRNPs and functions 
Heterogeneous nuclear ribonucleoprotein K (hnRNP K) is a multifunctional 
protein that belongs to the subfamily of ubiquitously expressed heterogeneous nuclear 
ribonucleoproteins (hnRNPs). hnRNPs are predominantly nuclear RNA-binding 
proteins that associate with RNA polymerase II mRNA transcripts to form 
ribonucleoprotein (RNP) complexes, where processing of this subset of pre-mRNA 
into mature RNAs occurs (Dreyfuss et al., 1993). In addition, hnRNPs are among the 
most abundant nuclear proteins that form the major components of the nucleus when 
complexed to the pre-mRNAs (Chaudhury et al., 2010).  
The hnRNP subfamily consist of major hnRNP proteins designated hnRNP A1 
through hnRNP U, as well as other minor and less abundant hnRNP proteins 
(Dreyfuss et al., 2002). hnRNP A1, A2/B1, B2, C1 and C2 were first identified and 
termed the ‘core’ hnRNP proteins based on their strong association with pre-mRNAs 
(Beyer et al., 1977). As each hnRNP protein has a preferred nucleotide binding 
sequence and varies in abundance as well as post-translational modification, it has 
been hypothesized that a unique combination of hnRNP proteins forms for each pre-
mRNA, dictated by the nucleotide binding sequence as well as the hnRNPs’ relative 
expression levels (Chaudhury et al., 2010).  
However, major hnRNP proteins may possess additional functional roles, given 
that they are present in abundance and are likely to be in excess over its respective 
binding sites (Chaudhury et al., 2010). In support of this, it was demonstrated that the 
hnRNP proteins are ubiquitously expressed in all tissue types at varying levels of 
abundance and that their relative ratios differ across different cell types (Kamma et al., 
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1995). In addition, certain hnRNPs such as hnRNP K are not only localised in the 
nucleus, but also found to be present in the cytoplasm (Dreyfuss et al., 2002; Kamma 
et al., 1995). Indeed, apart from pre-mRNAs processing, e.g. splicing, hnRNP 
proteins can also exert an effect on other aspects of gene expression, which includes 
mRNA export, localisation, translation as well as mRNA stability (Dreyfuss et al., 
2002). Besides affecting the metabolism of mRNA, hnRNP proteins’ role in 
transcriptional regulation was also documented by Krecic and Swanson (1999). This 
was first demonstrated for hnRNP K that showed preferential binding to single 
stranded DNA (ssDNA) in vitro (Michelotti et al., 1996). Therefore, members of the 
hnRNPs, e.g. hnRNP K, are multifunctional proteins that can participate in a variety 
of cellular processes. 
 
Poly(C)-Binding Proteins (PCBPs) and functions  
Apart from being a member of the hnRNPs, hnRNP K also belongs to the group 
of poly(C)-binding proteins (PCBPs). RNA binding proteins are characterized based 
on their ability to bind to nucleic acid homopolymers, thus as its name suggests, 
PCBPs are able to bind to polycytosine, poly(C) with high sequence specificity and 
affinity. hnRNP K was the first among the hnRNPs to be identified to possess this 
capability to bind poly(C) (Swanson and Dreyfuss, 1988).  
Of the five mammalian PCBPs, hnRNP K, PCBP1 and PCBP2 (also known as 
hnRNPE1 and hnRNPE2 respectively) have been studied in great detail, as compared 
to PCBP3 and PCBP4 (also known as MCG10) that were discovered in 2000 (Choi et 
al., 2009; Makeyev and Liebhaber, 2002). Based on amino acid sequence analyses, 
the PCBP gene family had evolved from a single originating gene to five separate and 
dispersed mammalian loci (Makeyev and Liebhaber, 2002). Hence, these PCBPs 
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share an overall structural anatomy that contains three hnRNP K homology (KH) 
domains (first identified in hnRNP K), which likely confer them with the ability to 
bind poly(C). Two of the KH domains are located near the N-terminal while the third 
domain can be found at the C-terminal of the proteins (Figure 1.1) (Makeyev and 
Liebhaber, 2002). PCBPs also contain the nuclear localisation signal (NLS) sequence 
that allows for their transport from the cytoplasm to the nucleus. Additionally, hnRNP 
K contains a hnRNP K-specific nuclear shuttling (KNS) domain between KH II and 
KH III domain that allows for bi-directional transport through the nuclear pore 
complex (Choi et al., 2009). Thus, PCBPs’ ability to localize in both the cytoplasm 




Figure 1.1 Domain structure of PCBPs  
Members of the PCBP family are shown. Numbers shown indicate the respective 
amino acid residues from human sequence. KH (hnRNP K homology) domains I–III 
are shaded, and the NLS (nuclear localization sequence) signals are also indicated. 
hnRNP K also contains additional KI (hnRNP K interactive) domain as well as KNS 










Given their diverse functions, PCBPs have been reported to be involved in 
various post-transcriptional regulations, e.g. mRNA splicing, mRNA stabilisation as 
well as translational silencing or enhancement (Makeyev and Liebhaber, 2002). 
Notably, PCBPs have been implicated in the transcriptional regulation of genes due to 
their ability to bind poly(C) regions, of which hnRNP K has been the most frequently 
reported (Choi et al., 2009).  
 
1.1.2 hnRNP K and its biological functions 
Modular Structure of hnRNP K 
Interest in hnRNP K grew in the early 1990s as it does not possess the RNA-
binding domain that could be found in many of the other hnRNPs, but instead 
contained three repeats of KH domain that contain gly-arg-gly-gly (GRGG) sequences 
capable of binding RNA, single- and double-stranded DNA (Siomi et al., 1993). In 
addition, as many polypyrimidine tracts at the 3’ ends of pre-mRNA introns were 
reported to be rich in cytidine, hnRNP K’s ability to bind tenaciously to poly(C) 
garnered significant attention due to its possible role in mRNA splicing (Matunis et al., 
1992).  
Located on human chromosome 9q21.32-q21.33 (Tommerup and Leffers, 1996), 
the HNRNPK gene encodes for a 65kDa multi-modular protein that comprises of 
463/4 amino acids (Matunis et al., 1992). Four protein isoforms of hnRNP K were 
first identified with the use of a monoclonal antibody (Dejgaard et al., 1994), but to 
date, only three alternatively spliced mRNA variants have been described in detail. 
These three hnRNP K mRNA variants encode for isoform–a and –b with distinct C-





Figure 1.2 mRNA variants and protein isoforms of hnRNP K 
The three alternatively spliced hnRNP K mRNA variants that have been described in 
detail are shown. Transcript variants 1 and 3 make use of a different transcriptional 
start site (green arrow) as compared to variant 2 (purple arrow). Nonetheless, variants 
1 and 2 encode for the same protein isoform, isoform–a, while transcript variant 3 
uses an alternate acceptor splice site at the last coding exon, resulting in a frame-shift 
and encodes for isoform–b with a distinct C-terminus. 3’UTR, 3’ untranslated region; 
5’UTR, 5’ untranslated region; ORF, open reading frame. 
 
 
In addition to the three KH domains and NLS that all PCBPs possess, hnRNP K 
also contains a hnRNP K interactive (KI) as well as a nuclear shuttling (KNS) domain. 
The KH domains mediate hnRNP K’s binding to DNA and RNA, where the full 
cooperation between KH domains is required for a three-pronged interaction with 
DNA/RNA in order to create binding of high affinity and specificity (Baber et al., 
2000; Dejgaard and Leffers, 1996; Siomi et al., 1994). In addition, hnRNP K has been 
shown to preferentially bind single-stranded DNA over either RNA or native double-
stranded DNA (Tomonaga and Levens, 1995). 
The bipartite-type NLS and KNS domain on hnRNP K allows for its shuttling 
between the nucleus and cytoplasm to perform its diverse functions (Michael et al., 
1997), while the KI domain is responsible for its interaction with many other proteins 
(Bomsztyk et al., 2004). As shown in Figure 1.3, the KI region contains proline rich 
docking sites (Arg-X-X-Pro-X-X-Pro and Pro-X-X-Pro-X-Arg, where X is any amino 













as Src, Lck, Fyn, Vav and Lyn (Van Seuningen et al., 1995). Interactions with other 
proteins involved in gene expression, such as TATA box binding protein (TBP) and 
Zik1, are also mediated via the KI domain, though the structural basis for such 
interactions is not clear (Bomsztyk et al., 2004).  
Genetic studies on hnRNP K protein orthologs found in other species revealed the 
importance of hnRNP K protein. hnRNP K protein is highly conserved within 
mammals while the three KH domains of the mammalian hnRNP K are almost 
completely conserved in Xenopus laevis and well-conserved in Caenorhabditis 
elegans, Drosophila melanogaster as well as Saccharomyces cerevisiae (Bomsztyk et 
al., 2004; Siomi et al., 1993). However, the group of proline-rich SH3-docking sites 
located at the KI domain found in mammalian and X. laevis hnRNP K proteins are 
absent in other orthologs. Additionally, the KNS domain is only found in mammalian 
hnRNP K. These findings suggested that the KI and KNS domains only emerged at a 
later stage in evolution, allowing hnRNP K to gain additional new functions 
(Bomsztyk et al., 2004). 
 
The multifaceted and complex biological function of hnRNP K 
The observation that a large fraction of hnRNP K is not associated with the 
hnRNP particle has suggested that hnRNP K has many other cellular functions apart 
from RNA processing (Bomsztyk et al., 1997). Indeed, in addition to the various 
different structural domains that it possesses, hnRNP K can be subjected to a variety 
of post-translational modifications such as ubiquitination, phosphorylation by 
different kinases such as Src, JNK, ERK and PKCδ (Habelhah et al., 2001a; Habelhah 
et al., 2001b; Ostareck-Lederer et al., 2002; Ostrowski et al., 2000; Schullery et al., 





Figure 1.3 Modular structure of the multifunctional hnRNP K 
hnRNP K contains three KH (hnRNP K homology) domains responsible for its 
binding to nucleic acids, as well as the NLS (nuclear localisation signal) and KNS 
(hnRNP K nuclear shuttling) signal that allows it to shuttle between the nucleus and 
cytoplasm. It possesses a KI (hnRNP K interactive) domain that contains proline-rich 
docking sites that allows for interaction with multiple proteins and kinases 
(interaction regions highlighted in cyan) such as TBP, Src and Lck. Multiple amino 
acid residues on hnRNP K could be post-translationally modified by various kinases 
e.g. Src, JNK as well as arginine methylases e.g.PRMT1 that have been 
experimentally verified, as indicated by the black arrows. These have together 
contributed to the multifaceted and complex biological functions of hnRNP K. 
Numbers of amino acid residues indicate the respective human sequence. R, Arginine; 




There are up to 73 potential phosphorylation sites, including tyrosine residues that can 
serve as a docking sites for proteins with Src-homology-2 (SH2) domains upon 
phosphorylation (Mikula et al., 2006). As such, hnRNP K can mitigate extracellular 
changes when the various phosphorylation sites are modified in response to a host of 
signals. Thus, it has been proposed to be a docking platform that integrates and 
connects the signals from multiple cascades at sites of nucleic-acid directed processes 
(Bomsztyk et al., 2004). Furthermore, large scale screening study has identified more 
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than 140 potential protein binding partners of hnRNP K (Mikula et al., 2006). Hence, 
taking into account the various domains that hnRNP K possesses, its huge plethora of 
protein binding partners as well as the multiple amino acid residues that can be post-
translationally modified, it is not surprising that hnRNP K has many diverse functions.  
Hence, in addition to its involvement in mRNA splicing of genes such as β-
tropomyosin gene, glucose-6-phosphate dehydrogenase, Bcl-x and human 
immunodeficiency virus 1 (Expert-Bezancon et al., 2002; Griffith et al., 2006; 
Marchand et al., 2011; Revil et al., 2009), hnRNP K has been reported to be a 
multifunctional protein involved in signal transduction and other aspects of gene 
expression, e.g. chromatin remodelling, transcriptional regulation, stabilisation of 
mRNA, as well as translational regulation of genes (Bomsztyk et al., 2004). Of these 
functions, its roles in transcriptional and translational regulation have been reported 
fairly extensively. 
It has been shown that hnRNP K transcriptionally regulate genes in a manner that 
requires the CT-element found on the genes’ promoter. hnRNP K can associate with 
TATA box-binding protein (TBP) (Tomonaga and Levens, 1995) to enhance the 
expression of c-Myc (Michelotti et al., 1996) as well as translation initiation factor 
eIF4E (Lynch et al., 2005). Together with Sp1, hnRNP K can also transcriptionally 
activate c-Src via CT-rich regions found on the c-Src promoter (Ritchie et al., 2003). 
Apart from the transcriptional activation of genes, hnRNP K can also transcriptionally 
repress genes. hnRNP K was demonstrated to repress the expression of thymidine 
kinase via the CT motif (Hsieh et al., 1998), as well as the Sp1- and Sp3-mediated 
transactivation of neuronal acetylcholine receptor β4 subunit via a CT-rich region (Du 
et al., 1998). Other cofactors associated with hnRNP K also play a part in 
transcriptional regulation of genes, e.g. the androgen receptor (AR) gene is trans-
10 
 
repressed by hnRNP K together with Purα (Wang et al., 2008) while the association 
of hnRNP K, PARP-1, B-myb or c-Myc collectively activates the expression of AR 
(Shi et al., 2008a). In addition, hnRNP K can also transcriptionally regulate genes in 
the absence of CT-rich region(s) on the gene’s promoter (Lee et al., 1996). For 
example, hnRNP K can transcriptionally repress COX-2 at NF-κB binding regions 
(Shanmugam et al., 2008), associate with transcriptional repressors such as Zik1 
(Denisenko et al., 1996) and bind to C/EBP-β to repress its transcriptional activity 
(Miau et al., 1998). 
As hnRNP K has been observed to bind translation elongation factor-1α (EF-1α), 
Bomsztyk et al. (1997) suggested its involvement in translation regulation. Together 
with PCBP1/2, hnRNP K stimulates an internal ribosome entry site’s activity of c-
Myc mRNA, thereby translationally activating c-Myc gene expression (Evans et al., 
2003). In addition, hnRNP K has been shown to be involved in Angiotensin II 
stimulation of vascular endothelial growth factor (VEGF) mRNA translation 
(Sataranatarajan et al., 2008). Apart from translationally activating downstream 
targets, hnRNP K has been shown to inhibit the translation of AR (Mukhopadhyay et 
al., 2009) and together with PCBP1/2, repress the translation of human papillomavirus 
type 16 L2 mRNA (Collier et al., 1998). Moreover, the post-translational modification 
of hnRNP K, i.e. phosphorylation by different kinases, can greatly affect the 
translational regulation outcome of genes downstream of hnRNP K, such as the 
regulation of 15-lipoxygenase (15-LOX) mRNA translation.  
Taken together, it has been shown that the biological function of hnRNP K is 





1.1.3 Expression of hnRNP K and its association with cancer 
Expression and role of hnRNP K in normal cells and development 
Given that hnRNP K possesses diverse functions and is involved in a number of 
fundamental biological processes, it is intriguing to observe that hnRNP K is not 
ubiquitously expressed. In normal proliferating keratinocytes, only half of them 
expressed hnRNP K in the G1 and S phase of the cell cycle (Dejgaard et al., 1994). In 
addition, hnRNP K was found abundantly in most of the major mouse tissues types at 
varying levels, though it was barely detectable in some. In support of this, Blanchette 
et al. (2006) reported the differential expression of hnRNP K at different stages of rat 
embryonic development, as well as the absence of its expression in certain tissues at 
various stages. hnRNP K was also found to be localised primarily in the nuclei, 
excluding the nucleoli, with stronger nuclear than cytoplasmic staining (Kamma et al., 
1995). Together, these studies have indicated that hnRNP K is likely to function and 
be regulated in a spatial and temporal manner.  
Nevertheless, even though there is no hnRNP K knockout mouse to date, studies 
on hnRNP K orthologs have revealed its role in normal development. In yeast, hnRNP 
K orthologs are not essential for growth (Denisenko and Bomsztyk, 2002), but 
embryonic lethality with a penetrance of 10-25% was observed in C. elegans when 
the expression of hnRNP K ortholog was depleted (Piano et al., 2002). Additionally, 
mutants of hnRNP K ortholog in Drosophila resulted in a wide range of phenotypes, 
i.e. from normal viability with no defects to very low viability with developmental 
defects. Thus, hnRNP K was suggested to affect cell proliferation and regulate cell 
fate (Charroux et al., 1999). Interestingly, the knockdown of hnRNP K ortholog in 
two-cell stage embryos in X. laevis that is the most similar to the mammalian hnRNP 
K, inhibited axonal outgrowth but did not affect cellular proliferation. This strongly 
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suggested that hnRNP K is not obligatory in cellular proliferation and that it possesses 
more diverse functions later in evolution (Liu et al., 2008). 
 
Expression and role of hnRNP K in transformed cells and cancer 
Unlike normal cells where hnRNP K is not ubiquitously expressed, increased 
hnRNP K expression levels have been detected in transformed cells. In contrast to 
normal proliferating keratinocytes, it was observed that hnRNP K is constitutively 
expressed throughout cell cycle in simian virus 40-transformed keratinocytes as well 
as other mammalian cells that were transformed in vitro (Dejgaard et al., 1994). 
Moreover, hnRNP K has been found to be consistently upregulated in many different 
human cancers (Chen et al., 2008a; Hatakeyama et al., 2006; Klimek-Tomczak et al., 
2006; Li et al., 2004; Mandal et al., 2001; Nagano et al., 2004; Perrotti and Neviani, 
2007; Pino et al., 2003; Wen et al., 2010; Zhou et al., 2010).  
Though the role of hnRNP K in cancer is not well understood, various cellular 
functions of hnRNP K have suggested its involvement in tumourigenesis. For 
example, hnRNP K has been demonstrated to positively regulate tumour suppressors 
such as BRCA1 (Thakur et al., 2003), and serves as a transcriptional cofactor for p53 
to bring about DNA-damage-induced cell-cycle checkpoint arrest (Chen et al., 2008b; 
Moumen et al., 2005). This suggested that hnRNP K can suppress tumourigenesis.  
Nonetheless, hnRNP K has also been reported to be regulated by many oncogenic 
kinases such as Src and ERK (Bomsztyk et al., 2004). In addition, the promoter region 
of hnRNP K was found to possess upstream binding sites for oncogenes such as E2F, 
AP1 and c-Myc, indicating that it may be regulated by these oncogenes (Carpenter et 
al., 2006). Thus, as hnRNP K positively regulates several oncogenes such as c-Myc, 
c-Src and eIF-4E, this likely forms a positive feedback mechanism to drive 
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proliferation (Michelotti et al., 1996; Ritchie et al., 2003; Takimoto et al., 1993). This 
is further supported by the observation that the induction of cell proliferation is 
associated with increased hnRNP K gene expression (Ostrowski and Bomsztyk, 2003). 
Moreover, given that enhanced levels of cytoplasmic hnRNP K have been implicated 
in tumour metastasis (Inoue et al., 2007) and that hnRNP K has also been 
demonstrated to bind to the telomeric C-rich strand in vitro, this suggested its possible 
involvement in telomere functioning that is important in cellular transformation 
(Bandiera et al., 2003; Lacroix et al., 2000). Hence, these studies have indicated the 
potential ability of hnRNP K to drive tumourigenesis. 
Intriguingly, the expression levels of hnRNP K were observed to be affected in 
cells treated with agents associated with cancer growth or therapy. Apart from serum 
treatment that can increase the levels of hnRNP K, growth factors such as epidermal 
growth factor and heregulin-β1 (Mandal et al., 2001; Ostrowski and Bomsztyk, 2003) 
as well as DNA damage inducing agents such as ionizing radiation, ultraviolet 
treatment and phleomycin were also able to stabilise hnRNP K protein levels 
(Moumen et al., 2005).  
In contrast, a decrease in hnRNP K protein levels was observed in cells treated 
with anti-cancer drugs such as bicalutamide, mitomycin C, RITA and docetaxel 
(Barboro et al., 2009; Benelli et al., 2009; Enge et al., 2009; Rahman-Roblick et al., 
2007). A camptothecin analogue has also been reported to activate PKCδ, which 
resulted in the subsequent decrease in hnRNP K protein level (Gao et al., 2009). Apart 
from being downregulated by activated PKCδ, hnRNP K has been reported to be 
substrates of various endogenous proteases associated with cell death, including 
calpain, caspase and all human granzymes (Dix et al., 2008; Kimura et al., 2003; 
Mahrus et al., 2008; van Domselaar et al., 2012). Thus, the findings from the various 
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studies have suggested that the hnRNP K levels in the cell have an association with 
cell survival.  
Notably, recent reports have revealed the association of hnRNP K with apoptosis, 
albeit with contrasting results (Chen et al., 2010; Chen et al., 2009; Gao et al., 2009; 
Moumen et al., 2005; van Domselaar et al., 2012; White et al., 2010). Taken together, 
these studies further substantiated the complex role of hnRNP K in tumourigenesis 
and cancer cell survival, which deserves further characterization. 
 
1.2 Apoptosis 
1.2.1 Physiological and Pathological Significance of Apoptosis 
Cell death can be classified via its morphological appearances, enzymological 
criteria, functional aspects or immunological characteristics. Thus, typical cell death 
modes can be classified into: apoptosis, autophagy, cornification and necrosis 
(Kroemer et al., 2009). Apoptosis is one of the programmed cell suicidal mechanism 
that has been studied in great detail since its first description in 1972 (Kerr et al., 
1972). It is an energy-dependent mode of cell death, with classical morphological 
features, e.g. rounding-up of the cell, reduction of cellular and nuclear volume, 
nuclear condensation and fragmentation, and plasma blebbing (Kroemer et al., 2009). 
Since 1972, a large number of genes that control the initiation, execution and 
regulation of apoptosis in various species have been identified and evidence revealed 
that the mechanism of apoptosis is evolutionarily conserved (Danial and Korsmeyer, 
2004). 
In metazoan organisms, apoptosis is a vital cellular process during embryonic 
development and morphogenesis, normal tissue homeostasis via elimination of 
unnecessary and defective cells, proper development and functioning of the immune 
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system, aging, as well as a defensive mechanism against viral infection and the 
emergence of cancer (Elmore, 2007).  
Dysregulated apoptosis, either inadequate or in excess, can therefore result in 
many undesirable conditions including developmental defects, autoimmune diseases, 
neurodegeneration, or even cancer. When there is excessive apoptosis, conditions and 
pathologies can occur, such as excessive scarring and fibrosis during wound healing 
(Greenhalgh, 1998), autoimmune deficiency syndrome that results from infection with 
human immunodeficiency virus (Li et al., 1995), neurodegenerative disease such as 
Alzheimer’s disease (Ethell and Buhler, 2003) and Amyotrophic Lateral Sclerosis, as 
well as ischemia-associated injury such as myocardial ischemia (Freude et al., 2000). 
On the other hand, inadequate apoptosis results in autoimmune disease such as 
autoimmune lymphoproliferative syndrome (ALPS) with insufficient death of auto-
aggressive T lymphocytes and B lymphocytes (Worth et al., 2006), as well as the 
formation of many different types of cancer. Thus, apoptosis is an important process 
that has to be tightly regulated. 
 
1.2.2 Caspases – Regulators and Executors of Apoptosis 
Caspases have been considered as the central components of apoptotic response 
(Thornberry and Lazebnik, 1998), belonging to a family of cysteine proteases that 
typically cleave after an aspartate in their substrates (Alnemri et al., 1996). Even 
though the first caspase was identified in humans (Thornberry et al., 1992), the critical 
role that caspases play in apoptosis has only been revealed in C. elegans (Yuan et al., 
1993). Since then, at least 14 different mammalian caspases have been identified, with 
11 of them being found in human (Riedl and Shi, 2004). 
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Of the 14 different known mammalian caspases, at least seven have been shown 
to possess important roles in apoptosis (Shi, 2002). These caspases can be generally 
divided into two groups, namely the initiator caspases, i.e. caspase-2, -8, -9 and-10 
and the effector caspases, i.e. caspase-3, -6, -7 (Riedl and Shi, 2004). Initiator 
caspases are characterized by their N-terminal regions that comprise one or more 
adaptor domains important for their function, while effector caspases usually contain 
20-30 residues in their prodomain sequences. All of the caspases are produced in cells 
as catalytically inactive zymogens that require proteolytic activation during apoptosis 
(Riedl and Shi, 2004).  
Activation of an effector caspase such as caspase-3 is performed by an initiator 
caspase such as caspase-8 or caspase-9 via cleavage at specific aspartate residues that 
separate the large (~p20) and small (~p10) subunits and two of each subunits closely 
associate with each other to form an active caspase heterotetramer. In contrast, the 
initiator caspases are auto-activated via the formation of a multi-component complex 
under apoptotic conditions, which recruits and activates the protease by proximity-
induced dimerization. Once the caspase cascade is activated, the effector caspases 
(caspase-3, -6, -7) are responsible for the cleavage of a broad spectrum of cellular 
targets that leads to the apoptotic demise of the cell (Riedl and Shi, 2004). Hence, 
caspases could function as a substrate of another caspase. It should be noted that 
caspase-8 and -10 are the only caspases that have been demonstrated to cleave a wide 
array of other caspases including: caspase-1, -2, -3, -4, -6, -7, -8, -9 and -10 (Guo et 
al., 2002; Srinivasula et al., 1996). Additionally, caspase-3 has been demonstrated to 
cleave both caspase-8 as well as caspase-9, and is able to cleave caspase-2 and -6 
more efficiently than caspase-7 (Sohn et al., 2005; Walsh et al., 2008). 
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1.2.3 Intrinsic and Extrinsic Apoptotic Pathways  
The apoptotic response in mammalian cells is mediated mainly via two pathways, 
namely the intrinsic and the extrinsic pathways, depending on the origin of the death 
stimuli (Figure 1.4). Apart from these two main pathways, another oligomerisation 
platform called the PIDDosome has been described in recent years, which can 
promote the activation of caspase-2 in response to DNA damage via PIDD and 
RAIDD adaptor proteins. Nonetheless, alternative caspase-2 activation mechanisms 
may also exist (Manzl et al., 2009).  
 
Intrinsic pathway 
The intrinsic pathway is mediated via mitochondria, where cytochrome-C is 
released into the cytosol when cell stressors such as DNA damage alter the 
intracellular balance of interactions between pro- and anti-apoptotic members of the 
Bcl-2 protein family. The released cytochrome-C promotes the assembly of an 
oligomeric apoptosome that comprises of adaptor Apaf-1 and its cofactor dATP, 
which then recruits and activates caspase-9, thereby triggering a cascade of caspase 
activation to bring about apoptosis (Li et al., 1997). Apart from cytochrome-C, the 
other mitochondrial factors released include: second mitochondrial-derived activator 
of caspases (SMAC)/ direct inhibitor of apoptosis (IAP)-binding protein with low PI 
(DIABLO), apoptosis-inducing factor (AIF), endonuclease G (EndoG) and high-








The extrinsic pathway is initiated by the binding of an extracellular death ligand 
belonging to the tumour necrosis factor (TNF) superfamily to the death receptors, 
where activation of initiator caspase-8 and caspase-10 occurs via an oligomerisation 
platform known as the death-inducing signalling complex (DISC) (Wilson et al., 
2009). The death ligands (i.e. FAS-ligand, TRAIL, TNFα) upon binding induce 
clustering of death receptors such as Fas, DR4 or DR5 at the cell surface that 
assembles a DISC by further recruiting caspase-8 or -10 via the adaptor Fas-
associated death domain (FADD). Dimerization of caspase-8 or -10 within the DISC 
triggers activation of these initiator caspases, which is reinforced by the excision of 
the intercatalytic domain linker and by polyubiquitination on the p10 subunit 
(Fuentes-Prior and Salvesen, 2004; Jin et al., 2009). Apart from the classical DISC 
described, a cytoplasmic complex nucleated downstream of TNF receptor 1 by kinase 
RIP-1 and FADD can also activate caspase-8 (Salvesen and Ashkenazi, 2011).  
Following the activation of caspase-8 or -10, these initiator caspases can cleave 
and activate effector caspases directly in Type I cells, or indirectly in Type II cells 
(Barnhart et al., 2003). In Type I cells, induction of apoptosis by Fas-ligand is 
executed by activation of large amounts of caspase-8 at the DISC formed, which are 
sufficient to directly cleave and activate effector caspase-3 to bring about apoptosis 
(Scaffidi et al., 1999b). However, in the more commonly found Type II cells, such as 
Jurkat T-lymphocyte cell line and hepatocytes, induction of apoptosis by death 
ligands produces very little activation of caspase-8 at the DISC and hence requires the 
amplification of death signals via the intrinsic pathway (Scaffidi et al., 1999b). 
Caspase-8 would cleave Bid to produce truncated-Bid (tBid) that translocates to the 
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mitochondria where it induces the release of mitochondrial factors, e.g. cytochrome C, 
which ultimately enhances the apoptotic signal (Li et al., 1998).  
Nonetheless, recent reports have revealed that the distinction between Type I and 
Type II cells could be a result of the varying levels of cellular factors present. When 
the levels of these cellular factors are perturbed, activated caspase-8 could result in 
the direct activation of caspase-3, without the obligatory involvement of 
mitochondrial signalling as previously observed in Type II. The use of membrane 
bound Fas-ligand instead of soluble Fas-ligand to induce apoptosis (Schneider et al., 
1998), increased cell surface expression levels of the death receptors (Meng et al., 
2011), reduction in levels of X-linked IAP (XIAP) (Jost et al., 2009), increased cell 
adhesion and reduced levels of keratin 8/18-intermediate filament (Gilbert et al., 2008; 







Figure 1.4 The extrinsic and intrinsic pathways of caspase activation and 
apoptosis 
The extrinsic pathway involves oligomerisation of death receptors by their ligands, 
resulting in the formation of DISC that recruits and activates initiator caspase-8/10 
that executes apoptosis by cleaving and activating effector caspase-3/7 or by cleaving 
Bid that translocates to the mitochondria for initiation of the intrinsic pathway. The 
intrinsic pathway is activated by cell stressors such as DNA damage that alters the 
intracellular balance of interaction between members of the Bcl2 family, thereby 
activating the pro-apoptotic Bcl2 family of proteins (green) that triggers 
mitochondrial release of cytochrome-C into the cytosol. This is necessary for the 
formation of apoptosome with Apaf-1 and pro-caspase-9 for the activation of caspase-
9 and the subsequent activation of caspase-3/7. Caspase inhibitors such as cFLIP, 
cIAP1, cIAP2 and XIAP are also indicated.  
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1.2.4 Inhibitors of Caspases and Apoptosis 
As caspases are the key molecules of apoptosis, moderation of caspase activity is 
considered to be an important means of regulating apoptosis. Nonetheless, other 
molecules have also been reported to be able to regulate apoptosis signalling without 
directly regulating caspases, such as heat shock proteins (Takayama et al., 2003) and 
Tumour necrosis factor alpha-induced protein 3 (Liuwantara et al., 2006). Various 
methods of caspase regulation have been described and these include decoy inhibitors, 
caspase inhibition and caspase degradation (Pop and Salvesen, 2009). Various 
molecules involved in caspase regulation have also been described, including cellular 
FLICE-like inhibitory protein (cFLIP) as well as members of the inhibitor of 
apoptosis (IAP) protein family (Pop and Salvesen, 2009). 
 
Cellular FLICE-like inhibitory protein (cFLIP) 
cFLIP was first identified to be a major inhibitor of caspase-8 activation at DISC 
mediated by death receptors (Irmler et al., 1997). It has several spliced variants and 
three of them have been characterized: cFLIPL, cFLIPS and cFLIPR. cFLIPS and 
cFLIPR are shorter isoforms with similar N-terminals but different C-terminals as 
compared to cFLIPL (Lavrik and Krammer, 2012). cFLIPL is structurally similar to 
caspase-8 with two death effector domains (DEDs) at the N-terminus and a C-
terminal caspase-like domain, but its C-terminus lacks the catalytic cysteine residue 
that confers the proteolytic activity of caspase-8 (Irmler et al., 1997). Nonetheless, all 
three isoforms of cFLIP are able to bind to DISC and block activation of caspase-8 
and apoptosis (Lavrik and Krammer, 2012). However, c-FLIPL can only inhibit 
apoptosis when it is present in high concentrations at DISC (Chang et al., 2002; 
Krueger et al., 2001). When cFLIPL is present in low concentrations with strong 
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receptor stimulation or in the presence of one of the short cFLIP isoforms, it can 
facilitate the activation of caspase-8 at the DISC (Chang et al., 2002; Fricker et al., 
2010). cFLIP can be cleaved by pro-caspase-8 at Asp376 to form p43-FLIP and at 
Asp196 to form p22-FLIP, both of which can induce NF-κB survival signalling 
(Golks et al., 2006; Scaffidi et al., 1999a).  
As cFLIP was detected to be over-expressed in many different cancers and has 
been associated with increased resistance to Fas- and TRAIL-mediated apoptosis 
(Korkolopoulou et al., 2004; Okano et al., 2003; Salon et al., 2006; Shirley and 
Micheau, 2010; Zong et al., 2009), the regulation of c-FLIP was extensively studied. 
It has been shown to be transcriptionally activated by a wide variety of transcription 
factors, i.e. NF-κB, p53, hnRNP K, and is transcriptionally repressed by various 
transcription factors, i.e. c-Myc and c-Fos (Shirley and Micheau, 2010). This accounts 
for the differential regulation of cFLIP isoforms in a cell-type dependent manner and 
ultimately determines cell fate from a given stimulus. However, more studies would 
be required to understand the molecular mechanisms behind the regulation of cFLIP 
mRNA variants’ alternative splicing, which is still poorly understood (Shirley and 
Micheau, 2010). cFLIP isoforms are also tightly regulated at the post-transcriptional 
level by a myriad of compounds that can induce the degradation of cFLIP, including 
chemotherapeutic drugs as well as cellular E3 ubiquitin ligase Itch that is under the 
control of JNK (Shirley and Micheau, 2010). Hence, coupled with the fact that the 
isoforms of cFLIP are short-lived proteins (Fulda et al., 2000; Hernandez et al., 2001), 






Inhibitors of Apoptosis (IAP) 
The most well-known inhibitors of caspases belong to the conserved inhibitor of 
apoptosis (IAP) protein family. The IAPs were originally identified in the genome of 
baculovirus by their ability to suppress apoptosis in infected host cells (Crook et al., 
1993) and have been identified in mammals, Drosophila, C. elegans and yeast (Wei et 
al., 2008). There are eight mammalian IAPs, which are XIAP, cIAP1, cIAP2, 
melanoma IAP (ML-IAP)/Livin, IAP-like protein-2 (ILP2), neuronal apoptosis-
inhibitory protein (NAIP), Bruce/Apollon and Survivin (Riedl and Shi, 2004). The 
defining characteristics of an IAP molecule is the presence of the BIR domain, which 
can be present in a single copy or up to two to three repeats in the N-terminal portion 
of IAPs. In addition, the IAPs also contain other functional regions such as a ‘Really 
Interesting New Gene’ (RING) domain or caspase-associated recruitment domain 
(CARD) near the C-terminus (Srinivasula and Ashwell, 2008). IAPs have been 
demonstrated to inhibit caspase activity by binding directly to caspase at the active 
site or allosterically and could also be involved in the proteasomal degradation of 
active caspases or reduce the activity of caspase via the ubiquitin ligase activity that 
they possess (Wei et al., 2008). 
Even though initial biochemical studies using GST-IAP fusion proteins and 
overexpression analyses demonstrated that human Survivin, XIAP, cIAP1 and cIAP2 
can bind and effectively inhibit caspase-3, -7 and-9, subsequent quantitative studies 
revealed XIAP to be the only bona fide caspase inhibitor (Eckelman and Salvesen, 
2006; Eckelman et al., 2006; Srinivasula and Ashwell, 2008).  
XIAP is the best characterized IAP thus far, and is recognised as the most potent 
endogenous caspase inhibitor. XIAP contains three BIR domains, an ubiquitin (Ub)-
binding domain and a RING domain. The second BIR domain (BIR2) and linker 
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region between BIR1 and BIR2 of XIAP inhibits the activity of processed caspase-3 
and -7 by binding to their active sites, while its BIR3 domain allosterically inhibits 
processed caspase-9, sequestering it in a monomeric state (Shiozaki and Shi, 2004). 
Similar to cIAP1 and cIAP2 that contain the RING domain, XIAP possesses ubiquitin 
protein ligase (E3) activity and all three of them are able catalyse their own RING-
dependent ubiquitination in cells subjected to a pro-apoptotic stimulus (Li et al., 2002; 
Yang et al., 2000). In addition, it has been demonstrated that XIAP was able to target 
activated caspase-3 for ubiquitination and proteasomal degradation (Suzuki et al., 
2001b), hence downregulating caspase-3 activity (Schile et al., 2008). 
Given that IAPs are potent inhibitors of caspases, especially XIAP, it was of no 
surprise that they were found to be upregulated in cancers (Berezovskaya et al., 2005; 
Ferreira et al., 2001; Hofmann et al., 2002; Krajewska et al., 2003; Shi et al., 2008b; 
Shiraki et al., 2003; Tamm et al., 2000). XIAP has been shown to be positively 
regulated by NF-κB at the transcriptional level (Campbell et al., 2004; Stehlik et al., 
1998) and this applies to cIAP1, cIAP2 and Survivin as well (Dutta et al., 2006). 
Apart from being regulated at the transcriptional level, XIAP has also been 
demonstrated to be tightly regulated post-transcriptionally and post-translationally 
(Holcik, 2003; Holcik et al., 2003; Lewis et al., 2007; Sohn et al., 2006) with a short 
half-life (McNeish et al., 2005; Rosato et al., 2004).  
Apart from regulation at the gene expression level, IAPs can also be counteracted 
by the presence of endogenous cellular factors, i.e. IAP antagonists, during the 
initiation of apoptosis. Notably, these IAP antagonists have been extensively studied 
and utilised in the design of anti-cancer drugs, such as the development of SMAC 
mimetics (Chen and Huerta, 2009; Sun et al., 2008). IAP antagonists are among the 
mitochondrial factors released via the activation of the intrinsic apoptotic pathway 
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and the best characterised include SMAC/DIABLO (Du et al., 2000) and 
HTRA2/OMI (Suzuki et al., 2001a). They have been shown bind and inhibit IAPs 
directly such as XIAP, cIAP1 and cIAP2, as well as induce their auto-ubiquitination 
activity, proteasomal degradation or even direct cleavage (Fu et al., 2003; Verhagen et 
al., 2002; Wei et al., 2008; Wu et al., 2000; Yang et al., 2003).  
 
1.3 Hepatocellular Carcinoma (HCC) 
1.3.1 Epidemiology and etiology of HCC 
Being the fifth most common cancer in the world, hepatocellular carcinoma 
(HCC) is ranked as the third highest cause of cancer-related death globally (El-Serag 
and Rudolph, 2007). HCC represents the most common type of liver cancer that also 
broadly includes intrahepatic bile duct carcinoma (cholangiocarcinoma), 
hepatoblastoma, bile duct cystadenocarcinoma, haemangiosarcoma and epithelioid 
haemangioendothelioma (Farazi and DePinho, 2006).  
Every year, more than half a million people worldwide are diagnosed with HCC. 
The incidence of HCC varies geographically, reflecting the regional differences in the 
prevalence of specific etiological factors and ethnicity (El-Serag, 2011). The most 
prominent risk factors associated with HCC include chronic hepatitis B (HBV) and C 
(HCV) viral infection, intake of aflatoxin-B1-contaminated food as well as chronic 
alcohol consumption. In addition, gender can also influence the risk and outcome of 
HCC, with more males accounting for HCC cases (Farazi and DePinho, 2006). 
It has been estimated that 350 million and 170 million people worldwide harbour 
chronic HBV and HCV viral infections respectively (Cha and Dematteo, 2005). HBV 
causes an estimated 320,000 deaths annually, with 30-50% of deaths attributable to 
HCC that chronic HBV carriers have a 100-fold relative risk of developing as 
26 
 
compared to non-carriers (Llovet et al., 2003). Various mechanisms have been 
proposed for HBV’s contribution towards the development of HCC, which includes 
genome integration, inflammation and p53 inactivation (Farazi and DePinho, 2006). 
However, with development of the HBV vaccine and administration in endemic areas, 
the incidence of HCC associated with HBV infection is likely to be reduced within the 
next generation of people living in the endemic area such as Southeast Asia and sub-
Saharan Africa (Feitelson et al., 2002).  
On the contrary, an effective vaccine against HCV has not been developed and 
thus the incidence of HCV infection has been continuously on the rise in 
economically developed countries, e.g. Japan and the United States (Thomas and Zhu, 
2005). Approximately 20% of the chronic HCV cases develop liver cirrhosis and 2.5% 
develop HCC (Bowen and Walker, 2005). HCV’s role in hepatocarcinogenesis has 
been generally assumed to be mediated via chronic neo-inflammatory process and 
viral proteins that could have an effect on the host cells that HCV is replicating in 
(Severi et al., 2010). Nonetheless, these factors presumably contribute to the 
development of liver fibrosis or cirrhosis, which alone is an independent risk factor 
for HCC (Farazi and DePinho, 2006). 
The clinical outcome of HCC is poor with an average life expectancy of six 
months from time of diagnosis (Feitelson et al., 2002) and survival rates of 17.5% and 
7.3% for untreated cancer over one and two years respectively (Cabibbo and Craxi, 
2010). Currently, the most effective treatment options for HCC are surgical resection 
and liver transplantation, which are applicable only to early HCC. However, most of 
the HCC patients are diagnosed at advanced stages, hence very few patients are 
suitable for operative intervention at the time of presentation (Ryder, 2003). As such, 
the detailed understanding of the molecular mechanisms associated with HCC and the 
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characterization of potential new gene targets are essential for improving the 
diagnosis and treatment for HCC. 
 
1.3.2 Multistate process of hepatocarcinogenesis  
The development of HCC usually progresses from chronic liver cell injury that 
arises as a consequence of the various etiological agents. Following liver cell injury, 
inflammation arises with hepatocyte regeneration and liver matrix remodelling with 
scar formation in liver fibrosis. Nonetheless, without the resolution of fibrosis, liver 
cirrhosis occurs that ultimately cumulates in the formation of HCC (Chakraborty et al., 
2012).  
Hepatocarcinogenesis has been proposed to be a complex multistate process that 
accumulates random genetic alterations after chronic exposure to several mitogenic 
and mutagenic environments during liver fibrosis and/or cirrhosis. It involves a 
normal cell accumulating genetic changes to form the initiated cell, which 
subsequently undergoes selective clonal expansion to become a pre-neoplastic lesion 
that develops into a malignant tumour and eventually clinical liver cancer (Wang et al., 
2002). In this model described by Wang et al. (2002), with the incorporation of 
several key dysregulated signalling pathways identified by genomic and gene 
expression analyses (Feitelson et al., 2002) (Figure 1.5), the molecular pathogenesis 
of HCC has been described to be accompanied by a sequential loss of differentiation, 
constitutive activation of selected signalling pathways that resulted in accelerated cell 
growth, prolonged cell survival and anti-apoptosis. Subsequently, with the eventual 
loss of normal cell adhesion and extracellular matrix, formation of aggressive and 






Figure 1.5 The molecular pathogenesis of HCC 
Hepatocarcinogenesis is a complex, multistep process, where normal hepatocytes 
accumulate genetic changes over time to form a pre-neoplastic lesion that develops 
into a malignant tumour and eventually clinical liver cancer. Various signalling 
pathways are dysregulated during this process, which include increased transforming 
growth factor-α (TGF-α), insulin like growth factor-2 (IGF-2), Ras-Raf-MAPK as 
well as NF-κB signal transduction pathways that accelerates hepatocyte growth and 
increase survival (Benn and Schneider, 1994; Lin et al., 2001; Lucito and Schneider, 
1992; Saito et al., 2001). Increased β-catenin in Wnt signalling may also play a role in 
activating c-Myc and Cyclin D1, and contribute to development of fibrosis and 
cirrhosis in early HCC as well as aggressive and metastatic HCC (Calvisi et al., 2001). 
Chromosomal aberrations result in the loss of heterozygosity (LOH) at various 
chromosomes that causes inactivation of various tumour suppressor genes, which 
normally limit growth and survival or are involved in other functions such as DNA 
repair, carcinogen metabolism or protection against oxidative damage. Evasion of 
apoptosis caused by defects in programmed cell death is also one of the hallmarks of 
hepatocarcinogenesis (boxed in red) (Feitelson et al., 2002). (Figure adapted from 




1.3.3 Dysregulation of apoptosis in HCC  
As in all other cancers, the dysregulation of apoptosis has been listed as a 
hallmark of HCC, which is deemed a vital contributor to the immunogenic, 
chemotherapeutic and radiotherapeutic resistance of many human cancers (Fabregat, 
2009; Hanahan and Weinberg, 2011).  
The dysregulation of apoptosis in HCC comprises of alterations in apoptotic 
signalling and an increase in survival pathways, such as the disruption of transforming 
growth factor-beta (TGF-β) signalling (Ito et al., 1991), PI3K/ Akt pathway (Horie et 
al., 2004) as well as epidermal growth factor (EGF) and Insulin-like growth factor 1 
(IGF-1) signalling pathways (Breuhahn et al., 2006; Llovet and Bruix, 2008). 
Multiple apoptotic signalling pathways are altered, i.e. the extrinsic and intrinsic 
apoptotic pathways, as well as the disruption of the p53 pathway.  
As various chemotherapeutic agents require the activation of p53 to induce 
apoptosis, the frequent mutation of TP53 gene from arginine 249 to serine associated 
with the exposure of Aflatoxin B1 is suggested to contribute to the dysregulation of 
apoptosis in HCC (Bressac et al., 1991; Hsu et al., 1991). However, the prognostic 
value of p53 in HCC has been controversial, as the overexpression of wild-type p53 
has been reported to be associated with a poorer prognosis of patients’ survival (Naka 
et al., 1998), more invasive tumour phenotypes, higher tumour recurrence rates (Jeng 
et al., 2000) and is likely to play a role in HCC progression, especially at later stages 
of hepatocarcinogenesis (Ng et al., 1995). 
Notably, HCC also shows resistance to apoptosis mediated via the extrinsic 
apoptotic pathway, where the down-regulation of Fas expression (Lee et al., 2001), 
FADD and caspase-8 (Shin et al., 1998) have been demonstrated. Nonetheless, it has 
been suggested that even though the expression of some pro-apoptotic genes 
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decreased, the dysregulation of the balance between survival and cell death in HCC is 
mainly due to the overexpression of molecules that counteract apoptosis (Fabregat, 
2009). Anti-apoptotic proteins such as cIAP1, Bcl-xL, Mcl1, and Survivin have also 
been shown to be overexpressed in HCC (Ito et al., 2000; Llovet et al., 2006; Sieghart 
et al., 2006; Takehara et al., 2001; Zender et al., 2006). Interestingly, XIAP, a 
caspase-3/7 inhibitor, is expressed at high levels in nearly 90% of clinical tumours 
from advanced HCC patients and the increased XIAP expression correlates positively 
with HCC metastasis and resistance to apoptosis (Shi et al., 2008b). In addition, 
cFLIP, an intracellular inhibitor of caspase-8 activation, has been shown to express 
constitutively in human HCC cell lines and at higher levels in HCC tissues as 
compared to non-tumour liver samples (Okano et al., 2003). Thus, the selective 
inhibition of anti-apoptotic signals in liver tumour cells could serve as a potential 
therapeutic strategy for the treatment of HCC (Fabregat, 2009). 
 
1.3.4 Overexpression of hnRNP K in HCC 
As in other cancer cell-types, the overexpression of hnRNP K in HCC has been 
similarly reported, especially at the protein level. In CBA-T6/W mice that develop 
spontaneous liver tumours (include hepatocellular adenoma and carcinoma), 
upregulation of hnRNP K expression at the mRNA and nuclear protein levels was 
observed in tumour tissues as compared to the surrounding non-tumour liver 
parenchyma (Ostrowski and Bomsztyk, 2003).  
In humans, there were at least five studies that reported the upregulation of 
hnRNP K in HCC. hnRNP K upregulation was reported in a human HCC cell line, 
HepG2 (Figure 1.6) as well as in various human HCC samples when compared to 
normal liver samples in a large scale immunohistochemistry study (Uhlen et al., 2010). 
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In addition, elevated hnRNP K expression was also reported in proteomic studies on 
HBV-associated and HCV-associated HCC (Kim et al., 2003; Li et al., 2004; Blanc et 
al., 2005). Intriguingly, hnRNP K has been associated with both HBV and HCV, 
which are the important etiological factors for HCC. It has been demonstrated to be a 
critical host factor that can augment the replication of HBV (Ng et al., 2005; Zhang et 
al., 2008). In addition, it was revealed to interact with the HCV core protein, which 
affects the ability of hnRNP K to trans-repress thymidine kinase promoter activity. 
Hence, Hsieh et al. (1998) proposed that the multiple functions of hnRNP K were 
disrupted by the core protein of HCV during infection, which could possibly 
contribute towards HCV pathogenesis.  
In a proteomics study that compared differentially expressed proteins in post-liver 
transplant patients with recurrent and non-recurrent HCC, hnRNP K was once again 
identified to be upregulated at both the mRNA and protein levels in patients with 
recurrent HCC (Bai et al., 2009). However, further examination by the authors failed 
to correlate the levels of hnRNP K in HCC cells studied with their invasiveness; this 
thus suggested that hnRNP K could play a supporting role in maintaining the growth 
of aggressive metastatic HCC. 
Notably, a recent proteomics study carried out to identify possible biomarkers to 
distinguish early- and late-stage HCC from liver cirrhosis detected elevated 
expression levels of nuclear hnRNP K in early- and late-stage HCC samples (Guo et 
al., 2012). Moreover, the authors also demonstrated that tissue hnRNP K had a higher 
capability in the detection of early HCC as compared to serum alpha-fetoprotein 
(AFP).   
Taken together, the findings from various studies have suggested a potential role 
of hnRNP K in hepatocarcinogenesis. Therefore, this warrants a more detailed 
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characterization of its function in HCC, which may aid in the improvement of this 




Figure 1.6 Immunohistochemical staining of HepG2 cells with antibody against 
hnRNP K  
Immunohistochemical staining of HepG2 cells was done with antibody (sc-28380) 
from Santa Cruz Biotechnology (brown) and counterstained with methylene blue. 
Strong nuclear staining revealed high expression levels of hnRNP K in the nucleus of 
HepG2 cells, with all cells positively stained. (Image was adapted from 







1.4 Aims of Study 
hnRNP K is a multifunctional and evolutionally conserved protein involved in a 
wide variety of biological processes (Bomsztyk et al., 2004), which has been 
demonstrated to be upregulated in many human cancers including HCC. As HCC is 
the fifth most common cancer and the third highest cause of cancer-related death 
globally (El-Serag and Rudolph, 2007), a better understanding of the associated 
molecular mechanisms and characterization of potential new gene targets would be 
instrumental for potential improvements in its diagnosis and treatment. 
Although the exact role of hnRNP K in cancer is currently not well-understood, 
its reported elevated levels in various cancer cells coupled with disparate pro- and 
anti-tumour functions suggested by its cellular functions (described in Section 1.1.3) 
have highlighted its complex role in tumourigenesis. Intriguingly, hnRNP K levels 
appear to be associated with cancer cell survival, as exemplified by the its reduction 
in cells treated with various chemotherapeutic agents (Barboro et al., 2009; Benelli et 
al., 2009; Enge et al., 2009; Rahman-Roblick et al., 2007). In fact, hnRNP K was 
recently reported to be downregulated in response to 5-Fluorouracil (5-FU), a 
chemotherapeutic drug, in colorectal cancer cells and was hence proposed as a 
predictive marker for 5-FU treatment (Zhang et al., 2010). 
Various studies have also suggested that hnRNP K has a role in apoptosis, though 
with discordant findings (Chen et al., 2010; Chen et al., 2009; Gao et al., 2009; 
Moumen et al., 2005; van Domselaar et al., 2012; White et al., 2010). Thus, its precise 
role in apoptosis remains to be elucidated.  
Given that apoptosis dysregulation is a hallmark of HCC (Fabregat, 2009), the 
primary aim of this study is to investigate hnRNP K’s role in the dysregulation of 
apoptosis in human HCC with the use of HCC cell lines. Firstly, the effect of 5-FU on 
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hnRNP K levels will be examined and verified in HCC cell lines. Consequently, the 
effect of hnRNP K downregulation on the induction of apoptosis will be investigated, 
coupled with the elucidation of its underlying mechanism. In addition, hnRNP K’s 
contribution as a transcription factor to the dysregulation of apoptosis in HCC will 
also be briefly explored. Taken together, the findings from this study would provide a 
molecular basis for the understanding of hnRNP K’s involvement in HCC, which may 
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Media, Buffers and Solutions 
Media, buffers and solutions utilised in this study are listed in Appendix I. 
 
2.1 Cell Culture Techniques 
2.1.1 Cell lines 
The HCC cell lines Hep3B (ATCC-8064) and HepG2 (ATCC HB-8065) were 
obtained from American Type Culture Collection (Manassas, VA). HCC cell lines 
HA22T, Huh-1, Huh-4, Tong, PLC/PRF/5, SNU182, SNU449, SNU475, Huh-6, Huh-
7, Mahlavu, SK-Hep1, SNU387, SNU398 and SNU423 were kindly provided by 
WHO Immunology Center, Singapore. The human colorectal carcinoma cell line 
HCT116 (p53+/+) and its derived isogenic p53-/- cells were kindly provided by Dr. 
Bert Vogelstein (John Hopkins University, Baltimore, MD). 
 
2.1.2 Growth and maintenance of cell lines 
The hepatocellular carcinoma and colorectal carcinoma cells stored frozen in 
liquid nitrogen were thawed quickly in 37°C water bath and re-suspended in 12 ml of 
Dulbecco’s modified Eagle Medium supplemented with 10% Fetal Bovine Serum 
(DMEM/ 10% FBS) (Appendix I) under sterile conditions. Following centrifugation 
at 800 rpm for 5 min, pelleted cells were gently re-suspended in 7 ml of DMEM/ 10% 
FBS and transferred into 25 ml culture flasks (Falcon, BD Biosciences, Franklin 
Lakes, NJ). The cell cultures were then maintained at 37°C in a humidified incubator 
with 5% carbon dioxide in atmospheric air. Density of the cells was monitored daily 
and culture medium was changed whenever necessary. Upon attaining 85-100% 
confluency, cells were trypsinised in 0.25% trypsin/ EDTA (Invitrogen, Carlsbad, CA) 
for 5 min at 37°C and reaction was halted with DMEM/ 10% FBS. All of the cells 
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were then transferred into a 75 ml culture flask and maintained in the 37°C, 
humidified incubator with 5% carbon dioxide in atmospheric air. Thereafter, 
depending on the number of cells required for experiments, cells were maintained 
either in 75 ml or expanded into 150 ml culture flasks. 
 
2.1.3 Cryopreservation of cells 
Having attained 80-90% confluent growth, cells cultured in 150 ml flask were 
trypsinised and pelleted down by centrifugation at 1000 rpm for 5 min. After 
discarding the supernatant, cell pellet was re-suspended in 5 ml of ice-cold freezing 
medium (Appendix I) and transferred 1 ml per tube into CryoTube vials (Thermo 
Fisher Scientific, Rochester, NY). These CryoTube vials were stored at -80°C in Cryo 
1°C Freezing Container (Thermo Fisher Scientific) filled with 100% isopropanol 
overnight, before they were transferred to liquid nitrogen for long term storage. 
 
2.1.4 Harvesting cell lines 
Once the required cell confluency or the specific time-point was attained, cell 
cultures in the cell culture flasks or plates were trypsinised and pelleted down by 
centrifugation for 5 min at 1000 rpm. Cell pellets were then washed with 1 ml of 
phosphate buffered saline (PBS) (Appendix I) each and transferred into 1.7 ml 
eppendorf tubes. These tubes were then further centrifuged at 500 × g for 5 min. 
Supernatants were discarded from the eppendorf tubes, washed with 500 μl of PBS 
and centrifuged at 500 × g for 5 min again. After the supernatants were discarded, cell 





2.2 Polymerase Chain Reaction (PCR) 
2.2.1 Total RNA extraction 
To verify the downregulation of hnRNP K or p53 by siRNA, as well as the 
verification of downstream genes regulated by hnRNP K, total RNA from Hep 3B and 
HepG2 transfected with siRNA specific against hnRNP K as well as HepG2 
transfected with siRNA specific against p53 was extracted using the RNA extraction 
kit with DNase-I treatment (NucleoSpin
®
 RNA II, Machery-Nagel GmbH & Co. Kg., 
Duren, Germany) according to manufacturer’s instructions. Newly extracted total 
RNA was subjected to 65°C for 10 min and was transferred immediately onto ice for 
5 min to denature the secondary structure of RNA. RNA concentration was 
subsequently quantified by Nanodrop (ND-1000) (Nanodrop Technologies, Delaware, 
USA), and RNA was subjected to cDNA synthesis, followed by either gel-based real-
time quantitative Reverse Transcription PCR (RT-PCR) or two-step real-time 
quantitative RT-PCR. 
 
2.2.2 Complementary DNA (cDNA) synthesis 
First strand cDNA was synthesised using Maxima
®
 First Strand cDNA Synthesis 
Kit (Thermo Fisher Scientific) according to manufacturer’s instructions with 1 μg of 
total RNA as template. Reaction was first incubated for 10 min at 25°C followed by 
15 min at 50°C and terminated upon incubation at 85°C for 5 min. First strand cDNA 
was then diluted 10 times with RNase/DNase free water (Invitrogen), aliquoted and 




2.2.3 Gel-based semi-quantitative RT-PCR 
RT-PCR was carried out using ABI GeneAmp PCR 9700 machine, in a reaction 
volume of 20 μl that contained 2 μl of 10x diluted cDNA as template, 0.5 μM each of 
the forward and reverse primers (Table 2.1) and 10 μl of the 2x High Fidelity PCR 
Master Mix (Roche Applied Science, Mannheim, Germany). After denaturing at 94°C 
for 2 min, amplification was carried out for 25-35 cycles each consisting of 
denaturing at 94°C for 30 sec, annealing at 55°C for 30 sec and extension at 72°C for 
20-60 sec. Thereafter, a final extension was carried out at 72°C for 7 min before 
cooling down to 4°C. PCR products were electrophoresed on 1-1.5% agarose gel 
precasted with GelRed
TM 
(Biotium, Hayward, CA) in 1x TBE buffer (Appendix I). 
Gels were visualised with UV transilluminator and imaged for recording purposes. 
 
 
Table 2.1 Oligonucleotide primers used in gel-based semi-quantitative RT-PCR 
Gene Primer Name Primer Sequence (5’-3’) Product size (bp) 
HNRNP K 
hnRNP K-3-F2 TGGTCAGCGGATTAAACAAA 232 (Isoform–a); 











2.2.4 Real-time quantitative RT-PCR 
Knockdown effect of genes with the use of gene specific siRNAs as well as the 
gene expression of the potential downstream targets of hnRNP K were examined with 
two-step real-time quantitative RT-PCR. Following total RNA extraction, first strand 
cDNA was synthesised as described above. 2 μl of the 10x diluted cDNA was utilised 
as the template in a 10 μl reaction in triplicates using KAPA SYBR® FAST Roche 
LightCycler®480 2x qPCR Master Mix (KapaBiosystems, Woburn, MA) according 
to manufacturer’s instructions in the Roche LightCycler® 480 System (Roche 
Applied Science). Primers designed to span across introns of genes are listed in Table 
2.2. Hypoxanthine-guanine phosphoribosyltransferase (HPRT) housekeeping gene 
was used for normalisation. 
 











hnRNP K-123-F1 TTCAGTCCCAGACAGCAGTG 
165 
































2.3 Molecular Cloning 
2.3.1 Gene ORF cloning 
The following section describes the steps undertaken in generating pXJ40-HA-
hnRNP K–a and –b (pXJ40-HA-hnRNP K-(a/b)) expression plasmids that expresses 
hnRNP K isoform–a and –b respectively. 
 
Insert preparation 
To prepare the insert DNA, the ORF of hnRNP K (isoform–a or –b) previously 
amplified from HepG2 and cloned into pcDNA3.1+ (Ng et al., 2005) were utilised as 
templates for PCR with the use of High Fidelity PCR Master Kit (Roche Applied 
Science) in ABI GeneAmp PCR 9700 system following the manufacturer’s 
instructions. The primer sequences employed to generate DNA inserts are listed in 
Table 2.3. The PCR conditions are as outlined: After denaturing at 94°C for 2 min, 
amplification was carried out for 25 cycles each consisting of denaturing at 94°C for 
30 sec, annealing at 55°C for 30 sec and extension at 72°C for 2 min before a final 
extension at 72°C for 20 min and cooling down to 4°C. PCR products generated were 
monitored for specificity and quality by 1-1.5% agarose gel electrophoresis. 
Subsequently the PCR products were gel-purified with QIAquick Gel Extraction Kit 
(Qiagen Gmbh, Hilden, Germany) according to manufacturer’s instructions. 
 
Enzyme Digestion 
 The purified PCR products and parental pXJ40-HA plasmid vectors were 
digested with the XhoI and SmaI for 2 h at 37°C in a 40-100 μl total reaction volume 
containing either 1-6 μg of PCR products or 6 μg of vector plasmid, 0.1 total volume 
of 10x appropriate NEB buffer, 1 μl 100x BSA (10 mg/ml), and 5-20 U of specific 
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restriction enzyme(s) (New England Biolabs, Ipswich, MA). Specific digested 
products with sticky ends generated were electrophoresed on 1-1.5% agarose gel and 
subsequently gel purified with QIAquick Gel Extraction Kit (Qiagen Gmbh, Hilden, 
Germany) according to manufacturer’s instructions. 
  
Ligation 
Ligation reactions were performed for 30 min at room temperature in a 20 μl 
reaction comprising of 4 μl 5x ligation buffer, 1 μl of linearised and gel-purified 
vector DNA, 1 μl of T4 DNA ligase (Invitrogen) and 1-14 μl of DNA insert(s). 
 
Transformation 
Library efficiency® DH5TM chemically competent Escherichia coli (Invitrogen) 
were employed for transformations. For each transformation reaction, 50 μl of the 
competent cells was first aliquoted into a 5 ml sterile polypropylene falcon tube, and 
1-2 μl of ligated product/ cloning reaction product was added in subsequently, 
followed by gentle mixing with tapping and 30 min incubation on ice. Mixture was 
heat shocked at 42°C for 45 sec, followed by immediate incubation on ice for 2 min. 
250 μl of S.O.C medium (Invitrogen) at room temperature or preheated to 42°C (for 
site-directed mutagenesis) was added into each reaction. Recovery of cells was 
performed, with reactions subsequently incubated at 37°C incubator with shaking at 
225 rpm for 40-60 min. 100 μl of the mixture was then plated out on a pre-warmed 
Luria-Bertani (LB) (Appendix I) plate containing 100 μg/ml ampicillin (Appendix I) 






Screening for Positive Clones 
6-8 colonies per plate were chosen and inoculated in 3 ml of LB containing 100 
μg/ml ampicillin (Appendix I) with shaking incubation at 37°C overnight. Small-scale 
preparation of plasmid DNA was then carried out with QIAprep® Miniprep Kit 
(Qiagen) according to manufacturer’s instructions. Isolated plasmids were further 
verified using enzyme digestion, followed by sequencing analysis. 
 
Sequencing Analysis 
Sequencing analyses were done by AITbiotech Pte Ltd, Singapore. Sequencing 
primers used are summarised in Table 2.4. 
 













PXJ40-hnRNP K-F AAACTCGAGATGGAAACTGAACAGCCAGAA 




PXJ40-hnRNP K-F AAACTCGAGATGGAAACTGAACAGCCAGAA 





hnRNP K-SDM-1F CTACACAAGTAACTATACCCAAAGATTTGGCTG 





hnRNP K-SDM-2F CTATACCCAAGGATTTGGCTGGATCTATTATTG 





hnRNP K-SDM-3F CCCAAGGATTTGGCAGGATCTATTATTGGC 





hnRNP K-SDM-4F GGATTTGGCAGGATCAATTATTGGCAAAGGTG 
hnRNP K-SDM-4R CTTTGCCAATAATTGATCCTGCCAAATCCTTG 






Table 2.4 Oligonucleotide primers used for sequencing 
Primer Name 
 






2.3.2 Site-Directed Mutagenesis 
For the generation of hnRNP K expression plasmids that harbours the four silent 
mutations, cloning was carried out using QuikChange® Site-Directed Mutagenesis 
Kit (Stratagene) according to manufacturer’s instructions with minor modifications. 
Briefly, pXJ40-HA-hnRNP K-(a/b) expression plasmids generated as outlined in 
Section 2.3.1 was utilised as the first set of templates in the PCR reactions to generate 
the first set of expression plasmids harbouring the first silent mutation with primers 
carrying single nucleotide mutation (Table 2.3). The PCR conditions are outlined as 
follows: After denaturing at 95°C for 30 sec, amplification was carried out for 14 
cycles each consisting of denaturing at 95°C for 30 sec, annealing at 55°C for 1 min 
and extension at 68°C for 7.5 min before cooling down to 4°C for 2 min. 
After which, reactions were incubated at 37°C for 1 h with 10 U of DpnI 
restriction enzyme provided in the kit, where parental strands without the single 
nucleotide mutation were digested. Subsequently, 1 μl of the DpnI-treated DNA was 
added into 50 μl of XL1 Blue Supercompetent cells for transformation and heat 
shocked. Thereafter, 500 μl of pre-warmed 42°C S.O.C. medium (Invitrogen) was 
added into each reaction and incubated at 37°C for an hour with shaking at 225 rpm. 
100 μl of the mixture was then plated onto LB plate containing 100 μg/ml of 
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ampicillin. Plasmid purification was then carried out and positive clones were verified 
by sequencing analysis with primers listed in Table 2.4. Having obtained the correct 
clones, the expression plasmids were utilised as templates for the next round of site-
directed mutagenesis with the subsequent set of site-directed mutagenesis primers 
(Table 2.3). This was done thrice till the plasmids harbouring the four silent mutations, 
SDM-pXJ40-HA-hnRNP K (a/b), were obtained. 
 
2.4 Transfection 
Transfection of expression plasmid(s) and/ or siRNA into the different cell lines 
was mediated by Lipofectamine2000 reagent (Invitrogen) with Opti-MEM® 
(Invitrogen). The optimal cell seeding amount for transfection of plasmid DNA and/ 
or siRNA for different cell lines are described in this section. Following 18-24 h post-
transfection, medium was discarded and replenished with fresh DMEM/ 10% FBS. 
 
2.4.1 siRNA Transfection  
The siRNA oligos utilised in this study were Stealth RNAi
TM
 siRNA synthesised 
by Invitrogen, Life Technologies Corp. (Carlsbad, CA) as listed in Table 2.5. The 
oligos were re-constituted in RNase-free water (supplied by Invitrogen) to obtain a 
stock concentration of 100 μM. Hep 3B and HepG2 were seeded at 0.65 × 106 cells 
and 1.2 × 10
6
 cells per well respectively in 6-well plate (BD, Falcon) and transient 
transfection of siRNA (10-40 nM) was mediated by Lipofectamine2000 reagent 
(Invitrogen) according to manufacturer’s instruction. In cases where the 
concentrations of gene-specific siRNA varied, non-specific control siRNA was added 




Table 2.5 siRNA oligos utilised for transfection 
Gene 
 





si-hnRNP K / hnRNP K siRNA 1 HSS179311 
hnRNP K siRNA 2 HSS179312 
TP53 si-p53 HSS186390 
CASP8 si-caspase-8 HSS141460 
CASP9 si-caspase-9 HSS141464 
Non-specific 
control siRNA 
si-ctrl  12935-300 
 
 
2.4.2 Plasmid transfection 
To examine the anti-apoptotic function of hnRNP K in TRAIL-induced apoptosis, 
expression plasmids, SDM-pXJ40-HA-hnRNP K-a and SDM-pXJ40-HA-hnRNP K-b 
were transiently transfected individually into both Hep 3B and HepG2 cells for the 
overexpression of hnRNP K isoform–a and –b for 30 h before the addition of TRAIL. 
Briefly, Hep 3B and HepG2 were seeded at 0.65 × 10
6
 cells and 1.2 × 10
6
 cells per 
well respectively in 6-well plate (BD, Falcon) and transient transfection of 2 μg of 
expression plasmids was mediated by Lipofectamine2000 reagent (Invitrogen) 
according to manufacturer’s instruction. 
 
2.4.3 Co-transfection of expression plasmid together with siRNA 
To restore the declining levels of hnRNP K for the examination of the specificity 
of hnRNP K in apoptosis induction, different combinations of (20 nM) siRNA (si-ctrl 
or si-hnRNP K) and (2 μg) expression plasmids (pXJ40-HA-hnRNP K –a or –b or 
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SDM-pXJ40-HA-hnRNP K–a or –b) were transiently transfected into both Hep 3B 
and HepG2 cells. Briefly, Hep 3B and HepG2 were seeded at 0.65 × 10
6
 cells and 1.2 
× 10
6
 cells per well respectively in 6-well plate (BD, Falcon) and transient co-
transfection of 20 nM of siRNA and 2 μg of expression plasmids was mediated by 
Lipofectamine2000 reagent (Invitrogen) according to manufacturer’s instruction. 
 
2.5 Western Blot Analysis of Protein 
2.5.1 SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
Protein Lysate Extraction 
For total cell lysate extraction, cultured cell samples were washed twice with PBS, 
and lysed with NP-40 lysis buffer (Appendix I) containing 1x complete mini protease 
inhibitor mixture (Roche Applied Science) and 1 mM phenylmethylsulfonyl fluoride 
(PMSF) (Sigma-Aldrich, St. Louis, MO) on ice for 30 min. After centrifuging lysates 
at 13,200 rpm at 4°C for 15 min, supernatants containing protein were aspirated and 
measured by Bradford method using a Protein Assay kit (Bio-Rad) to determine their 
concentration, with reference to four different bovine serum albumin (BSA) standards. 
All samples were stored in -80°C immediately until use. 
 
Preparation of SDS-PAGE Gels 
Resolving gels with acrylamide concentrations of 10% and 12.5% were 
employed in this study, and stacking gel of 5% acrylamide concentration was 
consistently applied. Gels were casted using the Mini-PROTEAN electrophoresis cell 
apparatus (Bio-Rad) according to manufacturer’s instructions. Recipes for SDS-
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polyacrylamide gels are listed SDS- polyacrylamide gel recipe in Appendix I and the 
components were added in and mixed in the order shown.  
 
Preparation of Samples and Electrophoresis 
Protein samples were mixed with equal amount of 2x SDS-PAGE sample buffer 
(Appendix I) and heated for 6 min at 95°C. The PageRuler
TM 
Prestained Protein 
Ladder (Thermo Fisher Scientific) was used as a marker as an indication of the 
protein molecular weight and for transfer efficiency. Approximately up to a maximum 
of 35 μl of each sample mixture with sample buffer could be loaded into each well. 
Electrophoresis was carried out in 1x Tris-Glycine SDS-PAGE running buffer 
(Appendix I) under a constant current of 20 mA per gel. Electrophoresis was stopped 
when the dye front reached the bottom of the separating gel and gel was removed 
from the gel apparatus for subsequent western blot. 
 
2.5.2 Western blot 
Approximately 20-30 μg of protein was separated on 10% and 12.5% SDS- gel 
electrophoresis, and transferred onto Immobilon-P
SQ
 PVDF membranes (Millipore, 
Billerica, MA) with semi-dry Transblot apparatus (Bio-Rad) after gel was equilibrated 
in 1xTransfer buffer (Appendix I) and PVDF membrane was activated with methanol 
and equilibrated in 1x Transfer buffer. A sandwich was assembled by placing an extra 
thick filter paper (100 × 70mm, Bio-Rad) pre-soaked in 1x Transfer buffer onto the 
platinum anode, followed by the pre-wetted PVDF membrane, the equilibrated gel, 
and another sheet of soaked filter paper. Air bubbles were carefully removed from in 
between each layer. Cathode and the safety cover were subsequently placed onto the 
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stack, and the electrophoretic transfer was performed at a constant voltage of 20 V for 
30 min at room temperature. 
After blocking with 5% non-fat milk in TBST buffer (Appendix I) overnight at 
4°C, antibodies against each protein of interest (as reflected in Table 2.6) were used 
as primary antibodies for protein detection, followed by reacting to the appropriate 
HRP-conjugated Goat-anti-Mouse or Donkey-anti-Rabbit secondary antibodies (Dako, 
Denmark). Equal loading of protein samples was verified with antibodies to β-actin. 
After extensive washing with TBST buffer, immunoreactive signals on membranes 
were visualised by reacting with SuperSignal West FemtoChemiluminescent 
Substrate reagents (Thermo Fisher Scientific) according to manufacturer’s 
instructions, followed by exposure to the Super RX Fuji Medical X-Ray film 
(Fujifilm Corporation, Tokyo, Japan). 
 
 














Anti-hnRNP K (6466) 64 1:1000 Rb iDNA (custom) 
Anti-β-actin 42 1:100,000 Mu Millipore MAB1501 
Anti-p53 (DO-1) 53 1:3000 Mu Santa Cruz Biotechnology sc-126 
Anti-cleaved PARP1 89 1:1000 Rb Cell Signaling #9541 
Anti-HA - 1:1000 Rb Sigma-Aldrich H6908 
Anti-BID 22 1:1000 Rb Cell Signaling #2002 
Anti-caspase-3 35,19,17 1:1000 Rb Cell Signaling #9662 
Anti-caspase-8 55 1:200 Mu Santa Cruz Biotechnology sc-56070 
Anti-XIAP 55 1:200 Mu Abcam ab28151 





2.6 Immunofluorescence Staining 
Subcellular localisation of hnRNP K was examined with immunofluorescence 
staining in untreated Hep 3B or Hep 3B cells transiently transfected with si-ctrl or si-
hnRNP K. Briefly, Hep 3B cells were seeded at 0.13 × 10
6
 cells per well into 12-well 
plates (BD, Falcon) with coverslips with or without transient transfection. 48 h post-
transfection or seeding, cells on coverslips were rinsed twice with PBS and fixed with 
4% paraformaldehyde (Sigma-Aldrich) (Appendix I) for 30 min at room temperature. 
Fixed cells were then rinsed with PBS thrice and permeabilised with 0.1% Triton-
X100 (Bio-rad) for 10 min. Cells were subsequently blocked with 1% BSA in PBST 
(Appendix I) for 1 h at room temperature before 2 h incubation at room temperature 
with primary antibody Anti-hnRNP K (6466) diluted in 1% BSA in PBST. Cells were 
washed thrice with PBST before incubation with goat-anti-rabbit secondary 
antibodies conjugated with Alexa Fluor® 488 (to view with FITC channel) or Alexa 
Fluor® 546 (to view with RhoD channel) for 1 h at room temperature. Cells were 
washed thrice with PBST before they were mounted with the Prolong Gold Antifade 
Reagent with DAPI (Molecular Probes). Cells were observed under the Zeiss 
Fluorescence Microscope (Carl Zeiss AG, Oberkochen, Germany) with the FITC and 
DAPI or RhoD and DAPI channels and imaged with the attached Canon Powershot 
camera (Canon, Tokyo, Japan). 
 
2.7 WST-1 Assay 
Proliferation of viable cells in monolayer was analysed with the use of a modified 
MTT assay, WST-1 reagent (Roche Applied Science), according to the 
manufacturer’s instructions. In brief, Hep 3B and HepG2 cells that were seeded at 
0.65 × 10
6
 cells and 1.2 × 10
6
 cells per well respectively in 6-well plates were 
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transiently transfected with siRNA. 24 h following transfection, cells were trypsinised 
with 0.05% trypsin/ EDTA (Invitrogen) and re-seeded into 96-well plates at a 
concentration of 1.5-2 × 10
4
 cells/well in 100 μl DMEM/10%FBS in triplicates and 
cultured for another 2-4 days. At each time point, 10 μl of WST-1 reagent was added 
into each well and further incubated for 40 min at 37°C. The absorbance was 
measured with Infinite® 200 PRO plate reader (Tecan, Männedorf, Switzerland) at 
450 nm with reference at 690 nm.  
 
2.8 TUNEL Assay 
Terminal deoxynucleotidyl transferase dUTP nick end labelling (TUNEL) assay 
was carried out with in-situ Cell Death Detection Kit, Fluorescein (Roche Applied 
Science), according to manufacturer’s instructions. Briefly, Hep 3B cells seeded in 6-
well plates at 0.65 × 10
6
 cells per well were transiently transfected with siRNA only, 
or co-transfected with 2 μg of pXJ40-HA or SDM-pXJ40-HA-hnRNP K-(a/b) 
together with 20 nM of si-ctrl or si-hnRNP K. Following 48 h post-transfection, cells 
were trypsinised with 0.05% trypsin/ EDTA (Invitrogen), re-seeded into 4-well 
culture slide (BD Biosciences) at 1 × 10
5
 cells/well in 500 μl DMEM/ 10% FBS and 
were cultured for additional 48 h. Cells on culture slides were rinsed twice with PBS 
and fixed with 4% paraformaldehyde for 1 h at room temperature with shaking. Fixed 
cells were then rinsed with PBS thrice and permeabilised with 1% Triton-X-100 in 0.1% 
sodium citrate for 2 min on ice. Cells were washed with PBS again before labelling 
with the TUNEL reaction mixture for 1 h in dark at 37°C. Following labelling, cells 
were rinsed with PBS and mounted with Prolong Gold Antifade reagent with DAPI 
(Invitrogen). Cells were observed under the Zeiss Fluorescence Microscope (Carl 
Zeiss AG) with the FITC and DAPI channels and imaged with the attached Canon 
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Powershot camera (Canon). Fluorescent cells on the images captured were counted 
with the ImagePro Software (Media Cybernetics, Bethesda, MD). 
 
2.9 Flow Cytometry 
Cell cycle analysis of Hep 3B transiently co-transfected with plasmid DNA and 
siRNA was done with the fluorescence-activated cell sorter (FACS) to investigate the 
specificity of hnRNP K-knockdown induced apoptosis. Hep 3B cells seeded in 6-well 
plates at 60-70% confluency were co-transfected with 2 μg of pXJ40-HA or SDM-
pXJ40-HA-hnRNP K-(a/b) together with 20 nM of si-ctrl or si-hnRNP K. At 72 h 
post transfection, cells were trypsinised with the use of 0.05% trypsin/ EDTA to 
obtain single-cell suspension and fixed with ice-cold 70% ethanol at least overnight. 
Subsequently, cells were washed with ice-cold PBS twice and treated with 100 μg/ml 
RNase A (Sigma-Aldrich) (Appendix I) for 5 min at room temperature. Treated cells 
were then stained with 50 μg/ml of propidium iodide (Sigma-Aldrich) (Appendix I) in 
dark for 1 h at room temperature. DNA content of stained cells was subsequently 
analysed with FACS Calibur and CellQuest software (BD Biosciences, Franklin 
Lakes, NJ).  
 
2.10 Caspase Assays 
2.10.1 Caspase Glo® 3/7 Assay 
To examine the activity of caspase-3/7 in differentially transfected or treated Hep 
3B and/ or HepG2 cells, Caspase Glo® 3/7 assay (Promega, Fitchburg, WI) was 
utilised and carried out according to manufacturer’s instructions. Briefly, the total cell 
lysates of the differentially transfected or treated cells were first collected and 
quantitated as detailed in protein lysate extraction in Section 2.5.1. 10 μg of total cell 
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lysates in 50 μl of NP-40 cell lysis buffer from each reaction was loaded into each 
well of 96-well Flat Bottom Black Polystyrene Plates (Corning Inc. Lindfield, 
Australia) in triplicates on ice. 50 μl of Caspase Glo® 3/7 reagent was added into 
each well and incubated for 1 h at room temperature before caspase activity was 
measured with GloMax® 96 Microplate Luminometer (Promega) with manufacturer’s 
pre-defined settings.  
 
2.10.2 Caspase Glo® 8 Assay 
To examine the activity of caspase-8 in differentially transfected and treated Hep 
3B and HepG2 cells, Caspase Glo® 8 assay (Promega, Fitchburg, WI) was utilised 
and carried out according to manufacturer’s instructions. Briefly, the total cell lysates 
of the differentially transfected or treated cells were first collected and quantitated as 
detailed in protein lysate extraction in Section 2.5.1. 10 μg of total cell lysates in 50 μl 
of NP-40 cell lysis buffer from each reaction was loaded into each well of 96-well 
Flat Bottom Black Polystyrene Plates (Corning Inc.) in triplicates on ice. Proteasome 
inhibitor MG-132 provided by the kit was first added to the Caspase-Glo® 8 reagent 
before 50 μl of the mixture was added into each well. Following incubation for 2 h at 
room temperature, caspase activity was measured with GloMax® 96 Microplate 
Luminometer (Promega) with manufacturer’s pre-defined settings. 
 
2.11 Chemical treatments  
2.11.1 5-Fluorouracil (5-FU) treatment 
Effects of 5-FU HCC cell viability 
To investigate the effect of 5-FU on HCC cell viability, Hep 3B and HepG2 were 
seeded at concentration of 1.5-2 × 10
4
 cells/well in 100 μl DMEM/ 10% FBS in 
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triplicates in 96-well plates. Following overnight incubation, medium was removed 
and replaced with 20-100 μg/ml of 5-FU (Sigma-aldrich) dissolved in DMEM/ 10% 
FBS. Cells were treated for up two days and cell viability was measured at each time 
point with WST-1 assay as detailed in Section 2.7. 
 
Effect of 5-FU on hnRNP K and p53 expression 
To investigate the effect of 5-FU on the expression of hnRNP K and p53 in HCC 
cell lines, the various HCC cell lines were first seeded in 6-well plates. Following 
overnight incubation where the cells obtain 50-60% confluency (i.e. Hep 3B, 0.65 × 
10
6
 cells/well; HepG2, 1.2 × 10
6
 cells/well), medium was removed and replaced with 
20-50 μg/ml of 5-FU (Sigma-aldrich) dissolved in DMEM/ 10% FBS. At different 
time points up to 48 h, treated cells were harvested for total cell lysate or RNA 
collection separately. Thereafter, these total cell lysates and RNA were subjected to 
Western blot analyses or real-time quantitative PCR with specific primers respectively. 
Similar process was carried out with colorectal cancer cell lines HCT116 (p53+/+) 




Examination of 5-FU induced hnRNP K downregulation 
To determine whether the downregulation of hnRNP K following 5-FU treatment 
was a consequence of apoptosis induction, i.e. cleaved by caspases, Hep 3B, HepG2 
and the pair of colorectal cancer cell lines (HCT116) were first seeded in 6-well plates. 
Following overnight incubation where the cells obtain 50-60% confluency (i.e. Hep 
3B, 0.65 × 10
6
 cells/ well; HepG2 and HCT116s, 1.2 × 10
6
 cells/well), cells were first 
treated with 10 μM of pan-caspase inhibitor, Z-VAD-fmk (R&D Systems, 
Minneapolis, MN) or DMSO for 30 min prior the addition of 5-FU (Sigma-aldrich) in 
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DMEM/ 10% FBS to yield a working concentration of 20-50 μg/ml. At different time 
points up to 48 h, treated cells were harvested for total cell lysate. Thereafter, these 
total cell lysates were subjected to Western blot analyses or Caspase Glo® 3/7 Assay.  
 
2.11.2 FasL treatment 
To examine the functionality of the Fas signalling pathway in HCC cell lines, 
Hep 3B and HepG2 were first seeded in 6-well plates. Following overnight incubation 
where the cells obtain 50-60% confluency (i.e. Hep 3B, 0.65 × 10
6
 cells/well; HepG2, 
1.2 × 10
6
 cells/well), medium was removed and replaced with 2-100 ng/ml of FasL 
(Enzo Life sciences, Inc., Farmingdale, NY, cat. no.ALX-522-020-C005) in DMEM/ 
10% FBS. At different time points up to 8 h post-treatment, cells were harvested for 
total cell lysate and subsequently subjected to Caspase Glo® 3/7 Assay. 
 
2.11.3 TRAIL treatment 
Examination of TRAIL signalling in HCC cells 
To examine the functionality of the TRAIL signalling pathway in HCC cell lines, 
Hep 3B and HepG2 were first seeded in 6-well plates. Following overnight incubation 
where the cells obtain 50-60% confluency (i.e. Hep 3B, 0.65 × 10
6
 cells/well; HepG2, 
1.2 × 10
6
 cells/well), medium was removed and replaced with 2-50 ng/ml of TRAIL 
(Enzo Life sciences, Inc., cat. no.ALX-201-115-C010) in DMEM/ 10% FBS. At 
different time points up to 8 h post-treatment, cells were harvested for total cell lysate 






Effect of hnRNP K downregulation or overexpression on TRAIL-induced caspase 
activity 
To examine the effect of hnRNP K reduction or overexpression on TRAIL-
induced caspase activity in HCC cell lines, Hep 3B and HepG2 were first seeded (i.e. 
Hep 3B, 0.65 × 10
6
 cells/well; HepG2, 1.2 × 10
6
 cells/well) and transfected with 
either siRNA or hnRNP K expression plasmids in 6-well plates. Following 24 h of 
transfection, medium was removed and replaced with 2 ng/ml of TRAIL in DMEM/ 
10% FBS. At 2 h and 8 h post-treatment, cells were harvested for total cell lysate and 
subsequently subjected to Caspase Glo® 3/7 Assay and Caspase Glo® 8 assay (for 
hnRNP K reduction experiment).  
To examine the profiles of TRAIL-induced caspase-3/7 activity in HepG2 cells 
treated with si-ctrl and si-hnRNP K, differentially transfected HepG2 cells were 
treated with 2-50 ng/ml of TRAIL for 8 h before caspase-3/7 activity was measured.  
 
Determination of BID levels in hnRNP K downregulation enhanced TRAIL-induced 
caspase activity 
To examine whether BID cleavage contributed to the enhanced TRAIL-induced 
caspase activity following hnRNP K reduction, HepG2 was seeded at a concentration 
of 1.2 × 10
6
 cells/well in 6-well plates overnight. Medium was removed and replaced 
with 2-50 ng/ml of TRAIL in DMEM/ 10% FBS. At 8 h post-treatment, cells were 
harvested for total cell lysate and levels of full length BID were determined with 
Western blot analyses. Levels of full length BID were also determined in total cell 
lysates from Hep 3B and HepG2 differentially transfected and treated with siRNA and 




2.11.4 Actinomycin D treatment 
To determine whether hnRNP K affects the expression of XIAP at the 
transcriptional or post-transcriptional level, Hep 3B cells were seeded and transfected 
with either 40 nM of si-ctrl or si-hnRNP K. Following 48 h of transfection, 5 μg/ml 
Actinomycin D (Sigma-Aldrich, Cat. No. A9415) was added to inhibit the de novo 
mRNA synthesis and incubated for the indicated periods of time. Total RNA was 
extracted and the levels of XIAP expression were determined with real-time 
quantitative PCR with specific primers. 
 
2.12 Whole- genome Exon Array Analysis 
40 nM of si-ctrl or si-hnRNP K were separately transfected into Hep 3B cells and 
the total RNA was extracted 24 h and 48 h post-transfection. 1 μg of total RNA was 
used as initial material for GeneChip Human Exon 1.0 ST Arrays (Affymetrix) 
according to manufacturer’s instructions. After washing and staining of hybridised 
arrays with an Affymetrix Fluidics Station, they were scanned on Gene Array Scanner 
2500 (Affymetrix) to capture the raw probe signal intensities in CEL files.  
Preliminary data analysis was done by Dr. Stanley Ng Kwong Loong (Singapore 
Immunology Network). Briefly, background subtraction, quantile normalisation, and 
summarizing probe sets from Affymetrix expression microarrays raw CEL files were 
done with Affymetrix Power Tools (APT) software at the gene level and the resulting 
probesets were annotated with Affymetrix annotation library file (HuEx-1_0-
stv2.na30.hg19.probeset.csv). With resultant probeset signals in log2 scale, log2 fold-
change was calculated by subtracting the log2 gene expression of the appropriate 
controls (si-ctrl at each time point) from that of the treated sample (si-hnRNP K at 
each time point). 
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2.13 Statistical Analyses 
All functional tests were done in triplicates and repeated at least twice with 
similar results obtained. Data shown as mean ± SD was from triplicates of a 
representative experiment. Differences of averages and percentages between the 
different plasmid/ siRNA transfectants or treatments were statistically analysed with 
Student’s t-test. p-value lesser than 0.05 was considered to be statistically significant 
(*: p<0.05; **: p<0.001). For data from flow cytometry, 10,000 events were counted 
per sample.  
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Chapter 3 hnRNP K Regulates survival in HCC cell lines 
  
CHAPTER 3 
hnRNP K regulates survival in 




As a member of the hnRNP family, hnRNP K is a multifunctional protein 
involved in many important biological processes that include transcription, translation 
and mRNA splicing (Bomsztyk et al., 2004). It has also been shown to play a role in 
cell proliferation (Ostrowski and Bomsztyk, 2003).  
While hnRNP K has been shown to be involved in many fundamental biological 
processes, expression levels of hnRNP K have been reported to vary depending on 
cell type and developmental stage, e.g. hnRNP K is not ubiquitously expressed in all 
normal mouse tissues (Kamma et al., 1995) and in a rat development study, there was 
no detectable hnRNP K expression at certain stages of embryonic development in 
some tissues and organs (Blanchette et al., 2006). In addition, silencing of hnRNP K 
in X. laevis two-cell stage embryos inhibited axonal outgrowth but not cellular 
proliferation (Liu et al., 2008), raising the possibility that hnRNP K may possess 
additional roles other than its known function in cell proliferation. 
In contrast to normal cells in development, hnRNP K has been reported to be 
upregulated in SV40-transformed cells (Dejgaard et al., 1994) as well as in various 
cancers studied (Table 3.1). In HCC, multiple studies have reported increased hnRNP 
K levels in tumour tissues compared to non-tumour tissues. Notably, an in-depth 
study reported elevated hnRNP K expression levels in early- and late-stage HCC as 
compared to cirrhotic liver samples (Guo et al., 2012). Thus, it could be hypothesised 
that hnRNP K has a role in cancer, given the significant difference in its expression 
levels observed between normal and cancer cells. In fact, hnRNP K has been reported 
to positively regulate several oncogenes as well as tumour suppressors, further 
suggesting its complex role in tumourigenesis (Michelotti et al., 1996; Moumen et al., 





Table 3.1 List of human cancers reported with upregulated hnRNP K. 





Mandal et al. (2001) 
Colorectal Cancer 
 
Klimek-Tomczak et al. (2006) 
Esophageal Cancer 
 
Hatakeyama et al. (2006) 
Hepatocellular Carcinoma 
 Bai et al. (2009); Blanc et al. (2005); Guo 
et al. (2012); Kim et al. (2003); Li et al. 
(2004); Ostrowski and Bomsztyk, (2003) 
Leukaemia (CML) 
 
Perrotti and Neviani, (2007) 
Lung Cancer 
 
Pino et al. (2003) 
Melanoma 
 
Wen et al. (2010) 
Nasopharyngeal Carcinoma 
 
Chen et al. (2008a) 
Pancreatic Cancer 
 
Zhou et al. (2010) 
Prostate Cancer 
 
Nagano et al. (2004) 
 
 
Intriguingly, when chemotherapeutic agents were used to induce cancer cell death, 
e.g. mitomycin C, RITA, docetaxel and bicalutamide, it was observed that hnRNP K 
expression levels were reduced (Barboro et al., 2009; Benelli et al., 2009; Enge et al., 
2009; Rahman-Roblick et al., 2007). Hence, there appears to be an association 
between hnRNP K levels and cancer cell survival. Indeed, a recent study conducted 
on colorectal cancer cell lines suggested the use of hnRNP K as a predictive marker to 
indicate response to 5-Fluorouracil (5-FU). Given that 5-FU is a first-line 
chemotherapeutic drug for HCC, the effect of 5-FU on hnRNP K levels was also 
examined in this study. 
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However, when the effect of hnRNP K downregulation in cancer cells was 
examined in various studies, the results were disparate. Reduction of hnRNP K via 
addition of siRNA has been reported to induce apoptosis in HeLa cells, HT29 
colorectal adenocarcinoma cell line and Sy5y neuroblastoma cell line (Chen et al, 
2010; White et al., 2010), but not in nasopharyngeal carcinoma cell lines and 
immortalised MRC5 lung fibroblast cell line (Moumen et al., 2005). However, it is to 
be noted that there were variations in experimental conditions across these studies, 
and that the extent of cell survival or death over the entire experimental period was 
neither tracked nor discussed. Thus, while hnRNP K has been reported to be 
associated with apoptosis by a few studies, the discordant findings highlight the need 
for further investigation into its role in apoptosis, i.e. if its downregulation induces 
apoptosis. Conversely, as hnRNP K is reported to be upregulated in HCC, it is of 
interest to investigate if this upregulation of hnRNP K plays a role in conferring 




3.2 hnRNP K is found abundantly in HCC, predominantly in the nucleus 
Given that hnRNP K was reported to be upregulated in HCC (Bai et al., 2009; 
Blanc et al., 2005; Kim et al., 2003; Li et al., 2004; Ostrowski and Bomsztyk, 2003), a 
panel of 17 HCC cell lines were examined for mRNA and protein levels of hnRNP K. 
In addition, as strong immunohistochemical hnRNP K staining has been demonstrated 
in HepG2 that alludes to its high expression levels (Uhlen et al., 2010) (Figure 1.6), it 
was of interest to investigate whether the other HCC cell lines in the panel also 
possess similarly high levels of hnRNP K. 
mRNA levels of hnRNP K in HCC cell lines were first examined, where total 
RNA was extracted and reverse-transcribed to obtain cDNA, followed by PCR 
amplification using HNRNPK and GAPDH primers as detailed in Chapter 2. The 
primers were able to amplify both isoforms of hnRNP K, which could be 
distinguished by differences in their amplicon length. As shown in Figure 3.1, both 
isoforms of hnRNP K were detected in abundance in the panel of HCC cell lines 
tested, except for HepG2 that had low mRNA expression levels of both isoforms 
(Figure 3.1A) despite the strong hnRNP K staining reported by Uhlen et al. (2010). It 
could also be observed that the expression level of isoform b was generally lower as 
compared to isoform a. Possible mutation(s) in the coding region of hnRNP K in 
HepG2 was ruled out as the use of different primer sets amplifying different regions 
of hnRNP K gave similar results for HepG2 (Appendix II Figure 1).  
On the contrary, when hnRNP K protein levels were examined in the total cell 
lysates of the HCC cell lines (Figure 3.1B), the protein expression levels of hnRNP K 
were comparable and present in abundance across all HCC cell lines. No particular 
HCC cell line showed a lack of hnRNP K protein expression. Hence, this indicated 
that the low hnRNP K mRNA expression level in HepG2 did not correlate with its 
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hnRNP K protein expression level. This could be due to the increased stability of 
hnRNP K protein or rapid turnover of hnRNP K mRNA in HepG2 cells, which could 
be focused on in future studies. Nonetheless, the abundance of hnRNP K protein 
found in all HCC cell lines is in agreement with previous studies that reported hnRNP 
K upregulation in HCC cells. 
In addition to the mRNA and protein expression levels of hnRNP K, the 
subcellular localisation of hnRNP K in HCC cells was examined in Hep 3B cells with 
the use of immunofluorescence microscopy. hnRNP K was observed to locate 
predominantly in the nuclei (Figure 3.2), which is in agreement with a study by Guo 
et al. (2012) that reported elevated hnRNP K nuclear expression levels in early- and 






















Figure 3.1 Expression levels of hnRNP K in a panel of 17 HCC cell lines 
(A) mRNA expression levels of hnRNP K isoform–a and –b in 17 HCC cell lines. 
Total RNA was extracted from the 17 HCC cell lines, reverse-transcribed to form 
cDNA and subjected to subsequent PCR. Primers specific for hnRNP K were utilised 
for PCR to amplify the two hnRNP K isoforms and primers specific for GAPDH were 
also used for PCR to serve as loading control. (B) Western blot analyses revealed that 
hnRNP K protein was found in abundance in all HCC cell lines. 20 μg of total cell 
lysate was loaded into each lane and blotted with polyclonal antibody against hnRNP 
K. The antibody used was against common amino acids present in both isoforms and 
not isoform-specific. The blot was stripped and re-blotted with monoclonal antibody 

















Figure 3.2 hnRNP K localises predominantly in the nucleus of HCC cells 
Cultured Hep 3B cells were fixed, permeabilised and subjected to 
immunofluorescence staining. The localisation of hnRNP K (green) strongly 
correlated with DAPI nucleic acid stain (blue), revealing that hnRNP K is located 
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3.3 p53-independent regulation of HCC cell survival 
3.3.1 5-Fluorouracil affects HCC cell viability and downregulates hnRNP K 
independently of p53 
Upon addition of chemotherapeutic drugs that decreased cancer cell viability, 
hnRNP K expression level was observed to be reduced (Barboro et al., 2009; Benelli 
et al., 2009; Enge et al., 2009; Rahman-Roblick et al., 2007). Coupled with the 
suggestion that hnRNP K could serve as a predictive marker indicating response to 5-
FU (Zhang et al., 2010), it was therefore of interest to examine the effect of 5-FU on 
hnRNP K expression. 5-FU is a commonly used anti-metabolite chemotherapeutic 
drug to treat various cancers but its usage has been limited due to the development of 
multi-drug resistance; nonetheless it is accepted as a first-line anti-cancer drug for 
HCC chemotherapy and has been used in combination with other agents such as 
leucovorin and interferon-α in the chemotherapeutic treatment of advanced 
unresectable HCC (Abdel-Hamid and Morsy, 2010; Patt et al., 2003; Porta et al., 1995; 
Stuart, 2012; Tetef et al., 1995; Tong et al., 2012; Uchibori et al., 2012). As 5-FU 
induces the upregulation of p53 at the protein level (Ju et al., 2007) and is associated 
with p53-dependent apoptosis (Enge et al., 2009), hence its effect on hnRNP K was 
examined in light of prior suggestions that hnRNP K is regulated by p53 (Mirza et al., 
2003; Rahman-Roblick et al., 2007).   
Viability of HCC cells was first examined with the use of WST-1 assay following 
exposure to different doses of 5-FU. Commonly used HCC cell lines Hep 3B and 
HepG2 were chosen for preliminary analysis as Hep 3B is a p53-null HCC cell line 
while HepG2 possesses wild-type p53 (Petitjean et al., 2007). 
From Figure 3.3, it could be observed that 5-FU treatment reduced the viability of 
HCC cells regardless of p53. In Hep 3B, the percentage absorbance of cells treated 
with 20 ng/μl of 5-FU for two days was 20.6% that of dimethyl sulfoxide (DMSO)-
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treated cells. In HepG2, the percentage absorbance of cells treated with 20 ng/μl of 5-
FU for two days was 17.3% that of DMSO-treated cells. This is in agreement with a 
previous report that 5-FU induced apoptosis via p53-independent pathways in 
laryngeal squamous cell carcinoma (Liu et al., 2006). In addition, the reduced 
viability in p53-null Hep 3B was in agreement with previous studies where 5-FU has 
been demonstrated to induce apoptosis in this cell line (Koike et al., 2006; Ma et al., 
2011). The greater reduction in cell viability of HepG2 cells as compared to Hep 3B 
cells observed at higher 5-FU doses could have been due to activation of wild-type 
p53 in HepG2.  
Following the observation that HCC cell viability decreased upon 5-FU treatment, 
the protein expression levels of hnRNP K and p53 were examined via western blot in 
12 HCC cells lines that were treated with 5-FU or DMSO over different time points. 
The results revealed that 5-FU treatment resulted in an accumulation of p53 in 
HCC cell lines with wild-type p53 and to a certain extent, in cell lines with p53 
mutants (Figure 3.4), which was consistent with a previous report by Ju et al. (2007). 
Interestingly, hnRNP K was observed to be downregulated in all 12 HCC cell lines 
upon 5-FU treatment regardless of their p53 status, indicating that the hnRNP K 
reduction was independent of p53. In addition, as 5-FU has been demonstrated to 
induce apoptosis in both p53–dependent and –independent manners (Enge et al., 2009; 
Liu et al., 2006), the experimental findings suggest that the reduction of hnRNP K 










Figure 3.3   5-Fluorouracil treatment reduces viability of HCC cells 
WST-1 cell viability results of Hep 3B and HepG2 cells (top and bottom panels 
respectively) treated with the indicated concentrations of 5-FU. Cells were treated 
with the indicated 5-FU concentration one day after they were plated into 96-well 
plates. Data presented as mean ± SD% absorbance of triplicates and expressed as the 
percentage absorbance relative to the absorbance of DMSO control at each time point. 




































































































































































Figure 3.4  5-Fluorouracil reduces hnRNP K in HCC cells regardless of p53 
status 
12 HCC cell lines were treated with 20 ng/μl 5-Fluorouracil (5FU) or DMSO as 
indicated for 24 h or 48 h and subjected to western blot analyses for the examination 
of hnRNP K and p53 protein levels with the use of specific antibodies. β-actin was re-
blotted and served as a loading control. 5-FU treatment stabilised and increased p53 
protein level only in cells with p53 but decreased hnRNP K level across all HCC cell 
lines regardless of p53 status. (A) Western blot analyses for the HCC cell lines were 
displayed based on their p53 status. (B) Corresponding densitometry measurements 
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3.3.2 Downregulation of hnRNP K by 5-Fluorouracil occurs at the mRNA level 
In an attempt to demonstrate that 5-FU-induced downregulation of hnRNP K is 
not only restricted to HCC cells, colorectal cancer cells sensitive to both p53–
dependent and –independent 5-FU induced apoptosis, HCT116 (p53+/+) and HCT116 
(p53-/-) (Chan et al., 2008; Zhao et al., 2008) were examined in addition to Hep 3B 
and HepG2 cells. As revealed by the western blot analyses, 5-FU was able to 
downregulate hnRNP K in Hep 3B, HepG2 and both HCT116 cell lines in a time and 
dose-dependent manner (Figure 3.5). In addition, it could be further concluded that 
reduction of hnRNP K by 5-FU was p53-independent, given the reduction observed in 





Figure 3.5   5-Fluorouracil treatment downregulates hnRNP K in a dose- and 
time-dependent manner 
HCC cell lines Hep 3B and HepG2, as well as colorectal cancer cell lines HCT116 
(p53+/+) and HCT116 (p53-/-) were treated with DMSO, 20 ng/μl or 50 ng/μl of 5-
FU over time points of 12 h and 48 h. Total cell lysates were analysed with western 
blots for the levels of hnRNP K, p53 and β-actin that served as a loading control.  
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In previous studies, hnRNP K has been suggested to be a caspase substrate (Dix 
et al., 2008; Mahrus et al., 2008). Therefore, to investigate if the observed 5-FU-
induced downregulation of hnRNP K was a consequence of apoptosis, i.e. due to 
cleavage by caspases, both pairs of HCC and HCT116 cell lines were pre-treated with 
either 10 μM of pan-caspase inhibitor or its control (DMSO) prior to 5-FU treatment. 
Following this, the protein levels of the hnRNP K and p53 from the differentially 
treated cells were examined with the use of western blot. Caspase-3/7 activity in these 
cells was also subsequently measured with Caspase-Glo® 3/7 Assay, in order to 
demonstrate the successful inhibition of caspases by the pan-caspase inhibitor. 
Despite the addition of pan-caspase inhibitor, the results from Figure 3.6A 
revealed that hnRNP K downregulation induced by 5-FU persisted in a dose-
dependent manner. In addition, as the results from the caspase-3/7 assay revealed the 
inhibition of caspase-3/7 activity by the pan-caspase inhibitor, this indicated that the 
observed hnRNP K downregulation was not a consequence of apoptosis, i.e. not 
cleaved by caspases (Figure 3.6B).  
Without the addition of the pan-caspase inhibitor, increased caspase-3/7 activity 
was observed following 5-FU treatment, which concurred with previous reports that 
5-FU treatment can result in p53–dependent and –independent apoptosis (Chan et al., 





Figure 3.6   5-Fluorouracil mediated downregulation of hnRNP K is independent 
of cleavage by caspase 
HCC cell lines (Hep 3B and HepG2) as well as colorectal cancer HCT116 cell lines 
(both p53+/+ and p53-/-) were pre-treated with 10 μM of pan-caspase inhibitor (Z-
VAD-fmk) or DMSO solvent as control for half an hour before the addition of DMSO 
or 20 ng/μl or 50 ng/μl of 5-FU. Total DMSO concentration used was 0.15%. Total 
cell lysates were collected after 48 h of treatment and were subjected to (A) Western 
blot analyses of hnRNP K, p53 and β-actin that served as a loading control and (B) 
Caspase-Glo® 3/7 Assay as described in Chapter 2. Data presented as caspase-3/7 
activity of cells relative to DMSO-treated cells as mean ± SD % of triplicates. Results 
shown are from a representative experiment of at least two with similar trend.  
 























































































Having demonstrated that the 5-FU-induced hnRNP K downregulation observed 
is not a consequence of apoptosis, real-time quantitative PCR was subsequently 
utilised to examine whether the downregulation of hnRNP K by 5-FU occurs at the 
mRNA level. As shown in Figure 3.7, there was a decrease in hnRNP K mRNA level 
in both Hep 3B and HepG2 following 12 h and 24 h of 5-FU treatment, indicating that 
the hnRNP K downregulation after 5-FU treatment was likely due to a reduction in 
mRNA. 
Taken together, the experimental findings from this current study show that 5-
FU is a chemotherapeutic agent capable of downregulating hnRNP K at the mRNA 
level independently of p53, thus making hnRNP K likely one of the proteins that 





Figure 3.7   5-Fluorouracil downregulates hnRNP K at the mRNA level 
Real-time quantitative PCR analyses of mRNA level of hnRNP K (both isoform–a 
and –b) in Hep 3B and HepG2 12 h and 24 h after treatment with 20 ng/μl of 5-FU. 
Data presented as mean ± SD of duplicates and expressed relative to untreated control 
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3.4 Effect of hnRNP K downregulation on cell morphology and viability 
3.4.1 siRNA reduces hnRNP K expression levels effectively 
In this study, addition of 5-FU has been demonstrated to downregulate hnRNP K 
levels, alongside a decrease in HCC cell viability. Thus, in order to determine whether 
a reduction in hnRNP K levels could be associated with decreased cell viability, as 
well as to investigate the role of hnRNP K in HCC, siRNAs were utilised to 
downregulate its expression in HCC cells.   
To first determine the efficiency of hnRNP K downregulation by siRNAs, two 
siRNAs (hnRNP K siRNA 1 and 2) targeting different regions of the ORF that are 
common to both hnRNP K isoform–a and –b were transfected either individually or 
together into Hep 3B and HepG2 cells. Real-time quantitative PCR results revealed 
that the siRNAs could downregulate hnRNP K mRNA levels as early as 10h post-
transfection, with an approximate reduction of 80% total hnRNP K mRNA as 
compared to the control (Figure 3.8A).  
Western blot analyses of hnRNP K following siRNA transfection in the HCC 
cells revealed that it was significantly reduced at the protein level at 24 h post-
transfection, which was more evident in Hep 3B than HepG2 (Figure 3.8B). hnRNP K 
level was observed to be at its lowest at 72 h post-transfection in both cell lines.   
In addition, as hnRNP K localises predominantly in the nucleus of HCC cells, its 
subcellular localisation following siRNA treatment was examined in Hep 3B cells 
transfected with hnRNP K siRNA 1, which was more effective in downregulating 
hnRNP K at 48 h post-transfection (Figure 3.8B). siRNA treatment was observed to 
significantly decrease hnRNP K in the nucleus (Figure 3.9), suggesting that its nuclear 
functions, which include transcription and alternative splicing, are likely to be 
affected in HCC cells following its reduction with siRNA. Taken together, the results 
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reflected that the siRNAs specific against hnRNP K were effective in reducing 







Figure 3.8 siRNA treatment efficiently downregulates hnRNP K 
(A) Real-time quantitative PCR analyses of mRNA level of hnRNP K (all isoforms) 
in Hep 3B and HepG2 10h after transfection with siRNA specific against hnRNP K 
(40 nM). Data presented as mean ± SD of duplicates and expressed relative to cells 
transfected with non-specific control siRNA after normalisation to HPRT expression 
level. (B) Western blot analyses of hnRNP K protein level in total cell lysates of Hep 
3B and HepG2 cells over different time point post- siRNA (40 nM) treatments with 
the use of polyclonal antibody against hnRNP K. Membranes were subsequently re-
blotted with β-actin, which served as a loading control. si-ctrl, Non-specific control 
siRNA; hnRNP K siRNA 1, hnRNP K-specific siRNA Stealth Select RNAi
TM
 
siRNA (HSS179311); hnRNP K siRNA 2, hnRNP K-specific siRNA Stealth Select 
RNAi
TM









































































Figure 3.9 Downregulation of hnRNP K with siRNA decreases its expression in 
the nucleus 
Hep 3B cells were transfected with 40 nM of either non-specific control siRNA or 
hnRNP K siRNA 1 for 48 h before immunofluorescence staining analysis of the 
subcellular localisation of hnRNP K. In Hep 3B cells  transfected with  si-ctrl, strong 
hnRNP K staining  (Orange-red visualised with Rhodamine D channel) was observed 
to co-localise with DAPI staining (blue) in the nuclei while those transfected with 
hnRNP K siRNA 1 showed weaker hnRNP K staining  and the residual hnRNP K 
staining could be observed in the cytoplasm. si-ctrl, Non-specific control siRNA; 
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3.4.2 hnRNP K reduction alters cell morphology and decreases cell viability 
Following the demonstration that hnRNP K expression levels could be reduced 
effectively with siRNA treatment, the treated Hep 3B and HepG2 cells were also 
monitored for any phenotypic differences over time under phase-contrast microscope. 
The greatest visible cell number difference was observed at 96 h post-transfection, 
where control cells of Hep 3B attained approximately 90-100% confluency and 
HepG2 grew in clusters, while cells in both cell lines transfected with hnRNP K-
specific siRNAs were scattered and lower in numbers (Figure 3.10A). A change in 
cell morphology was also observed at higher magnification; where both Hep 3B and 
HepG2 cells with hnRNP K-knocked down had ‘bleb-like’ structures and were 
rounder with clear cell boundaries as compared to control cells that possessed a 
‘polyhedral’ shape and were close to neighbouring cells (Figure 3.10B). The findings 
indicate that the downregulation of hnRNP K expression levels in HCC cells caused 
cell morphology changes as well as reduced cell numbers.  
In comparison to hnRNP K siRNA 2 as well as the combination of both siRNA 1 
and 2, hnRNP K siRNA 1 resulted in more efficient reduction in both hnRNP K 
expression levels (Figure 3.8) and visible cell numbers (Figure 3.10). Hence, hnRNP 
K siRNA 1 (henceforth named as si-hnRNP K) was utilised for all subsequent 




Figure 3.10 Downregulation of hnRNP K results in a change of cell morphology 
Hep 3B and HepG2 cells were treated with control siRNA or hnRNP K specific 
siRNA(s) (40 nM) and observed under phase-contrast light microscope 96 h post 
transfection. (A) Knockdown of hnRNP K reduces visible HCC cell numbers. (B) 
Observation of HCC cells with hnRNP K downregulated at higher magnification 
revealed a change in cell morphology.  si-ctrl, Non-specific control siRNA (si-
control); hnRNP K siRNA 1, hnRNP K-specific siRNA Stealth Select RNAi
TM
 
siRNA (HSS179311); hnRNP K siRNA 2, hnRNP K-specific siRNA Stealth Select 
RNAi
TM































































 As a decrease in cell numbers was observed following hnRNP K reduction, the 
viability of HCC cells treated with si-hnRNP K was monitored closely over time with 
the use of WST-1 assay.   
Consistent with prior observations made with the phase-contrast microscope 
(Figure 3.10), cell viability was significantly reduced in si-hnRNP K transfected cells 
as compared to control cells over time (Figure 3.11). At Day 4 post-transfection, the 
percentage absorbance of si-hnRNP K transfected Hep 3B and HepG2 was 17.7% 
(p<0.05) and 32.5% (p<0.05) of their control cells respectively (Figure 3.11B and C). 
A greater cell viability reduction was observed in Hep 3B as compared to HepG2 
following siRNA treatment, which could be a result of the more significant reduction 
in hnRNP K expression in Hep 3B by si-hnRNP K as depicted in Figure 3.8B. 
In summary, as presented with the use of Hep 3B and HepG2, the transient 
knockdown of hnRNP K in HCC cells resulted in a change in cell morphology and a 
pronounced reduction in cell viability, which could be due to an increase in cell death 













Figure 3.11 Reduction of hnRNP K reduces cell viability  
(A) Experimental process for WST-1 viability and proliferation assay. Hep 3B and 
HepG2 cells were transfected with either si-control (si-ctrl) or si-hnRNP K in 6-well 
plates and reseeded into 96-well plates in triplicates 24 h later. Cell viability was 
monitored and measured daily. (B) and (C) WST-1 data of Hep 3B and HepG2 cells 
respectively transfected with si-control (dark grey) or si-hnRNP K (light grey). Cell 
viability data presented as mean ± SD% absorbance of triplicates and expressed as the 
percentage absorbance relative to control. Results are from a representative 
experiment of at least two with similar trend. 


































































































3.5 Downregulation of hnRNP K results in p53-independent apoptosis  
Having demonstrated that the reduction of hnRNP K decreases cell viability, the 
role that hnRNP K could possibly play in apoptosis was investigated. There are 
various forms of programmed cell death, but the term ‘apoptosis’ has frequently been 
incorrectly used interchangeably with ‘programmed cell death’. In fact, it has been 
recommended that various approaches should be employed to accurately classify a 
particular type of cell death as apoptosis instead of relying solely upon a single 
biochemical analysis method (Kroemer et al., 2009). Hence, various functional assays 
covering different biochemical features of apoptosis were used in this study to 
determine whether the decreased cell viability observed following hnRNP K 
downregulation was due to apoptosis. In addition, p53-null Hep 3B was chosen for 
experimental analyses of hnRNP K’s role in apoptosis in order to exclude the 
contribution by p53, which is a well-known regulator of apoptosis (Fridman and 
Lowe, 2003).  
To determine whether the reduced cell viability following hnRNP K 
downregulation was a result of apoptosis induction, the presence of caspase-cleaved 
PARP-1(poly ADP-ribose polymerase) was first determined in Hep 3B cells treated 
with si-hnRNP K using western blot. PARP-1, a 113kDa nuclear enzyme, is cleaved 
by caspase-3/7 during apoptosis to yield 24kDa and 89kDa fragments (Soldani and 
Scovassi, 2002), but is cleaved during necrosis to produce 55kDa and 62kDa 
fragments (Gobeil et al., 2001). Thus, to verify the induction of apoptosis, an antibody 
specific against the larger 89kDa caspase-cleaved PARP-1 fragment was utilised in 
western blot.  
As depicted in Figure 3.12A, a decrease in the level of hnRNP K led to a 
corresponding increase in the level of caspase-cleaved PARP-1. The emergence of 
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PARP‐1 cleavage in si-hnRNP K transfected Hep3B was specific, as cleaved PARP‐1 
was not detected in control cells. The results have indicated that apoptosis induction 
likely resulted in the reduced cell viability following hnRNP K reduction. In addition, 
the initial appearance of the 89kDa cleaved PARP-1 fragment was at 72 h post-
transfection of Hep 3B cells with si-hnRNP K and featured most prominently at 96 h 
post-transfection. This suggested that the initiation of apoptosis was likely to be 
between 48 h and 72 h post-hnRNP K reduction as the cleavage of PARP-1 has been 
suggested to be an early critical biochemical event in apoptosis (Kaufmann et al., 
1993).  
Next, terminal deoxynucleotidyl transferase dUTP nick end labelling (TUNEL) 
was employed to further examine the induction of apoptosis by the knockdown of 
hnRNP K. Even though the labelling of cells that are necrotic or with extensive DNA 
damage have been reported (Grasl-Kraupp et al., 1995), TUNEL remains to be a 
commonly used method for labelling and identifying cells in the late phase of 
apoptosis by detecting oligonucleosomal DNA fragmentation (Kroemer et al., 2009; 
Negoescu et al., 1998; Negoescu et al., 1996).  
Hep 3B cells with hnRNP K reduction for 96 h were subjected to TUNEL 
staining and the results in Figure 3.12B revealed a significant increase in TUNEL 
positive cells as compared to control. hnRNP K downregulated cells had 27.9 ± 4.5% 
TUNEL positive cells while control cells had only 3.8±1.2% TUNEL positive cells in 
the entire cell population (p<0.05). This observation also provide support that the 




Figure 3.12 hnRNP K downregulation induces apoptosis 
(A) Western blot analyses of hnRNP K protein level and cleaved PARP-1 in total cell 
lysates of Hep 3B over different time points post-siRNA (40 nM) treatments with the 
use of polyclonal antibody against hnRNP K and polyclonal antibody specifically 
against the 89kDa fragment of caspase-cleaved PARP-1. β-actin was re-blotted to 
serve as a loading control. (B) TUNEL assay revealed an increase in apoptotic cells 
following the downregulation of hnRNP K at 96 h post-transfection. The left panel 
shows the differentially transfected cells observed under the fluorescence microscope, 
where DAPI-stained cells represent the total cell population and FITC-stained cells 
represent TUNEL-positive cells that were undergoing apoptosis. DAPI-stained cells 
and TUNEL positive cells for each slide were counted with Image-Pro software. The 
right panel shows the percentage of TUNEL positive cells from Hep 3B transfected 
with si-control (dark grey) and si-hnRNP K (light grey) expressed as the mean ± SD 
percentages of FITC‐stained cells of the total cell population (DAPI‐stained) obtained 
from triplicates. (**p<0.01). Results are from a representative experiment of at least 




















































Apart from the detection of caspase-cleaved PARP-1 and TUNEL assay, 
activation of caspase is one of the most important determinants that identifies if cell-
death was via apoptosis. Nevertheless, activation of caspases could also occur under 
non-lethal biological processes (Galluzzi et al., 2008). While caspases are activated in 
apoptosis, calpains and/or cathepsins are activated in necrosis (Kroemer et al., 2009). 
As such, having demonstrated that the knockdown of hnRNP K resulted in the 
production of cleaved PARP-1 and increased the number of TUNEL positive cells, it 
was of interest to examine the activation of the effector caspases. 
To examine the activation of effector caspases over the course of hnRNP K 
reduction, Caspase-Glo® 3/7 assay was utilised to measure the activity of caspase-3/7.  
Total cell lysates of Hep 3B over the course of hnRNP K downregulation were 
collected and subjected to Caspase-Glo® 3/7 assay. As shown in Figure 3.13A, there 
was no significant difference in caspase-3/7 activity between hnRNP K 
downregulated and control cells at 24 h and 48 h post-transfection. However, a 
significant increase in caspase-3/7 activity was observed in cells with hnRNP K 
reduced as compared to control at 72 h post-transfection (p<0.05), and the observed 
increase in caspase-3/7 activity was the greatest at 96 h post-transfection (p<0.05) . 
Together with the TUNEL assay results as well as the detection of cleaved PARP-1, 
the above results have confirmed that the induction of apoptosis has contributed to the 
reduction in cell viability upon hnRNP K downregulation.  
In addition, the significant increase in caspase-3/7 activity observed in Hep 3B 
with hnRNP K reduced as compared to control cells at 72 h and 96 h post-transfection 
was in concordance with the western blot analysis of cleaved PARP-1 protein level 
(Figure 3.12A), where induction of apoptosis was not detected in cells transfected 
with si-hnRNP K at 24 h and 48 h post-transfection, but only from 72 h post-
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transfection onwards. These findings reflected that apoptosis is only induced 
following extended period of hnRNP K downregulation; hence suggesting that 
hnRNP K possibly functions as an anti-apoptotic protein in HCC, where its reduction 
increases the cells' susceptibility to apoptosis.   
Having observed that apoptosis was induced following hnRNP K reduction in 
Hep 3B that is p53-null, indicating that the induction of apoptosis was p53-
independent, the profile of caspase-3/7 activity in HepG2 cells with wild-type p53 
following hnRNP K downregulation was similarly examined. Particularly, it was of 
interest to examine whether the presence of wild-type p53 in HepG2 could possibly 
contribute to the apoptosis induction following hnRNP K downregulation. As 
observed in Figure 3.13B, the profiles of caspase-3/7 activity in HepG2 was similar to 
that in Hep 3B over the course of hnRNP K downregulation (Figure 3.13A): there was 
no significant differences in caspase-3/7 activity between the differentially transfected 
HepG2 cells at 24 h and 48 h post-transfection, while caspase-3/7 activity was higher 
in cells with hnRNP K reduced at 72 h post-transfection (p<0.01) and this difference 
was the greatest at 96 h post-transfection (p<0.01). This thus suggested that the wild-
type p53 that HepG2 possesses did not contribute to the apoptosis induced by the 












Figure 3.13 Activation of caspase-3/7 following 72 h of hnRNP K reduction 
(A)Hep 3B  and (B) HepG2 cells were transfected with either 40 nM of si-control 
(dark grey lines and bars) or si-hnRNP K (light grey lines and bars) over the different 
time points indicated; total cell lysates were collected and caspase-3/7 activities were 
measured with the use of Caspase-Glo® 3/7 assay. The left panels reflected the 
caspase-3/7 activities expressed as raw relative light units (RLUs) of triplicates while 
the right panels showed the relative caspase-3/7 activities of si-hnRNP K transfected 
cells after normalisation to si-control transfected cells at each time point stated and 
data were expressed as mean ± SD% of triplicates. (*p<0.05, **p<0.01). Results are 
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To further establish that p53 was not involved in the apoptosis induction, it was 
knocked-down in HepG2 simultaneously with hnRNP K, and caspase-3/7 activity was 
determined over the course of downregulation. As shown in Figure 3.14A, it could be 
observed that the downregulation of p53 did not affect the activity of caspase-3/7 over 
the entire course of hnRNP K reduction. Real-time quantitative PCR results for 48 h 
and 72 h post-transfection had also demonstrated that the mRNA levels of p53 and 
hnRNP K were reduced by the siRNAs effectively (Figure 3.14B). The results thus 
verified the reduction of both proteins and indicated that the increased caspase-3/7 
activity observed in cells with hnRNP K downregulation was contributed by the 
reduction of hnRNP K alone, without the involvement of p53. 
Intriguingly, when HepG2 cells were transfected with a lower amount of si-
hnRNP K (20 nM) as seen in Figure 3.14A, the profile and extent of caspase-3/7 
activation over the course of its reduction was similar to those cells transfected with 
twice the amount of siRNA (40 nM) as seen in Figure 3.13B. Notably, apoptosis 
induction occurred at 72 h post-transfection, regardless of the amount of si-hnRNP K 
transfected. This hence indicated that the downregulation of hnRNP K most likely 















Figure 3.14 Downregulation of hnRNP K induces p53-independent apoptosis 
HepG2 that possesses wild-type p53 was differentially transfected with the stated 
transfection combinations over different time points indicated. (A) Caspase-3/7 
activities were measured and shown as normalised caspase-3/7 activity of each 
transfection combination relative to that transfected with si-control (both si-hnRNP K 
and si-p53 negative) at each time point. (B) mRNA levels of p53 and hnRNP K were 
examined in differentially transfected HepG2 with the with the use of real-time 
quantitative PCR with specific primers at 48 h and 72 h post-transfection and data 
were presented as mean ± SD of duplicates and expressed relative to cells transfected 
with si-control (both si-hnRNP K and si-p53 negative) after normalisation to HPRT 
expression level. (**p<0.01). si-p53, p53-specific siRNA. Transfection combinations 
comprise a total of 40 nM worth of siRNA where 20 nM of gene specific siRNA was 
used in each reaction and topped up with non-specific siRNA to 40 nM when required. 
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3.6 hnRNP K possess anti-apoptotic function 
3.6.1 Testing for the specificity of hnRNP K in resisting apoptosis 
Given that the downregulation of hnRNP K resulted in the onset of apoptosis in 
HCC cells, it was next investigated whether this apoptosis induced by its reduction 
was indeed hnRNP K-specific, i.e. whether restoring the levels of hnRNP K in these 
cells can reduce the extent of apoptosis induced.  
To test the specificity of hnRNP K in resisting the onset of apoptosis, an 
experimental setup was designed as shown in Figure 3.15. Following the introduction 
of siRNA (si-hnRNP K), endogenous level of hnRNP K would presumably be 
downregulated. Concurrently, plasmids overexpressing hnRNP K would be 
introduced exogenously in an attempt to restore the reduced levels of the endogenous 
protein. Nonetheless, if these plasmids have DNA sequences identical to endogenous 
hnRNP K, they would likely be targeted and downregulated by the siRNA as well. 
Thus, to ensure that the levels of hnRNP K could be restored with the concurrent 
downregulation of the endogenous protein, silent mutations would have to be 
introduced into the sites that the siRNA targets on the plasmids. With this, functional 
assays for apoptosis can be subsequently carried out to compare cells with restored 
hnRNP K levels and those with its expression reduced.  
To date, only two protein isoforms of hnRNP K have been described in detail, 
where isoform–a is slightly longer than isoform–b with key difference at the C-
terminus. As the siRNA utilised (si-hnRNP K) targets a common region on the ORF 
of hnRNP K, both protein isoforms would presumably be downregulated. Hence, 
given the intention to restore hnRNP K levels with exogenously introduced plasmid 




To create the constructs, the ORF of hnRNP K (isoform–a or –b) previously 
amplified from HepG2 and cloned into pcDNA3.1+ (Ng et al., 2005) were utilised as 
templates for PCR with designed primers. Purified PCR products were subsequently 
enzyme digested with XhoI and SmaI before being individually inserted into XhoI- 
and SmaI-digested pXJ40-HA vector downstream of both the CMV promoter (PCMV) 
and HA (Hemagglutinin) epitope tag, as well as upstream of the SV40 
polyadenylation site to produce the parental pXJ40-HA-hnRNP K (isoform–a or –b) 
constructs (Figure 3.16A).  
After analysing the sequence of si-hnRNP K (Stealth Select RNAi
TM
 siRNA 
HSS179311) as shown in Figure 3.16C, nucleotide positions 1182, 1188, 1197 and 
1203 of hnRNP K ORF were chosen for site-directed mutagenesis to create silent 
mutations at amino acid positions 394, 396, 399 and 401 respectively. Being evenly 
spaced out on the target sequence of the ORF, these sites were chosen such that their 
mutation would disrupt the complementary base pairing with si-hnRNP K to prevent 
plasmid degradation. The DNA chromatographs of the pXJ40-HA-hnRNP K that 
underwent four rounds of step-wise sequential site-directed mutagenesis are shown in 
Figure 3.16D, which yielded the resultant SDM-pXJ40-HA-hnRNP K (isoform–a or –
b) expression plasmids (Figure 3.16B). The expression plasmids harbouring the four 
silent mutations were subsequently examined for their ability to express hnRNP K 













Figure 3.15 Schematic workflow to test the specificity of hnRNP K in the 
apoptosis induced by its reduction  
In order to prevent hnRNP K expression plasmid from being targeted by si-hnRNP K 
for degradation so as to restore its protein levels, pXJ40-HA-hnRNP K–a or –b were 
subjected to site-directed mutagenesis to introduce four silent mutations to generate 
SDM-pXJ40-HA-hnRNP K–a or –b. As such, si-hnRNP K introduced into the cells 
will target endogenous hnRNP K for degradation while the exogenously introduced 
plasmids would be spared, thereby restoring the level of hnRNP K in cells for 
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Figure 3.16 Generation of the SDM-pXJ40-HA-hnRNP K (isoform–a/b) 
constructs 
(A) Plasmid map of pXJ40-HA-hnRNP K–a or –b. hnRNP K–a and –b were 
amplified from hnRNP K isoform–a and –b expression vectors cloned in previous 
study (Ng et al., 2005) and sub-cloned into pXJ40-HA vector to form pXJ40-HA-
hnRNP K–a or –b. (B) Plasmid map of SDM-pXJ40-HA-hnRNP K–a or –b. With the 
use of pXJ40-HA-hnRNP K–a or –b as template in site-directed mutagenesis, four 
silent mutations (in red) were introduced to generate SDM- pXJ40-HA-hnRNP K–a 
or –b to prevent si-hnRNP K from targeting the expression vectors for degradation. (C) 
The sequence of si-hnRNP K and the region on the ORF of hnRNP K that the siRNA 
targets. (D) DNA chromatographs of hnRNP K expression plasmids showing the 
nucleotide changed (in red) in each successive site-directed mutagenesis of the four 
selected nucleotides for silent mutations (highlighted in yellow). The 4
th
 SDM 



















To evaluate if the expression plasmids were able to express hnRNP K when co-
transfected with si-hnRNP K, Hep 3B cells were transfected with either 20 nM of 
non-specific control siRNA (si-ctrl) or si-hnRNP K together with 2 μg of either 
expression plasmids or empty vector control. Total hnRNP K levels (endogenous and 
exogenously introduced) as well as exogenously introduced hnRNP K levels were 
examined using western blot analyses with the use of antibody-specific against 
hnRNP K and HA-tag respectively (Figure 3.17).  
From Figure 3.17B, it could be observed that si-hnRNP K was able to reduce 
levels of the endogenous protein as previously shown in Figure 3.8B. As si-hnRNP K 
was able to target pXJ40-HA-hnRNP K –a and –b for degradation, reactions with the 
co-transfection of si-hnRNP K and these two plasmids had no protein detected with 
the antibody specific for HA tag (Figure 3.17C and D). In addition, the levels of 
endogenous hnRNP K were also observed to be reduced in these two reactions.  
In contrast, plasmids SDM-pXJ40-HA-hnRNP K–a and –b that carried the four 
silent mutations were not targeted by si-hnRNP K for degradation and had stable 
protein expression after 24 h of transfection as detected by antibody against HA-tag 
(Figure 3.17E and F). As the antibody specific against hnRNP K detects both 
endogenous and exogenously introduced hnRNP K, it could be observed that the 
protein levels were no longer reduced in reactions where they were attempted to be 
restored.  
In all, the four silent mutations introduced into expression plasmids pXJ40-HA-
hnRNP K–a and –b were able to prevent the plasmids from being targeted by si-
hnRNP K for degradation. These plasmids were hence employed in subsequent 









Figure 3.17 hnRNP K expression constructs with four silent mutations escape 
degradation induced by si-hnRNP K  
The ability of si-hnRNP K to target SDM-pXJ40-HA-hnRNP K–a or –b for 
degradation was tested. Western blot analyses examining total hnRNP K and 
exogenously introduced hnRNP K (HA-tagged) protein expression at various time 
points indicated in Hep 3B cells co-transfected with (A) 2 μg pXJ40HA empty vector 
and 20 nM si-ctrl, (B) 2 μg pXJ40HA empty vector and 20 nM si-hnRNP K, (C) 2 μg 
pXJ40HA-hnRNP K-a (abbreviated as K-a) and 20 nM si-hnRNP K, (D) 2 μg 
pXJ40HA-hnRNP K-b (abbreviated as K-b) and 20 nM si-hnRNP K, (E) 2 μg SDM-
pXJ40HA-hnRNP K-a (abbreviated as SDM-K-a)and 20 nM si-hnRNP K, (F) 2 μg 
SDM-pXJ40HA-hnRNP K-b (abbreviated as SDM-K-b) and 20 nM si-hnRNP K. β-
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3.6.2 Restoration of hnRNP K levels reduces apoptosis 
Having demonstrated that the introduction of four silent mutations in the hnRNP 
K expression constructs could prevent si-hnRNP K mediated degradation, transfection 
treatments were formulated (Table 3.2) to investigate hnRNP K’s specificity and anti-
apoptotic property in apoptosis induction resulting from its downregulation.  
Table 3.2 Transfection combinations for the investigation on hnRNP K's 
specificity and anti-apoptotic property 
Transfection Treatments siRNA (20 nM) Expression construct (2 μg) 
Control si-ctrl pXJ40-HA-vector 
hnRNP K Downregulation si-hnRNP K pXJ40-HA-vector 
Rescue hnRNP K–a si-hnRNP K SDM-pXJ40-HA-hnRNP K–a 
Rescue hnRNP K–b si-hnRNP K SDM-pXJ40-HA-hnRNP K–b 
 
 With the formulated transfection combinations, Hep 3B cells were transfected 
and subjected to TUNEL assay analysis as shown in Figure 3.18A. Consistent with 
the results presented earlier (Figure 3.12B), increase in percentage of apoptotic cells 
could be observed in cells with hnRNP K reduced as compared to control, as 
exemplified by the increase in percentage of TUNEL positive cells in the total cell 
population sampled (Figure 3.18B). It was also observed that with the restoration of 
hnRNP K levels, the percentage of TUNEL positive cells in the total cell population 
sampled was reduced. hnRNP K downregulation treatment had 40.8±6.5% of TUNEL 
positive cells while rescue hnRNP K–a and –b treatments had 23.58±2.6% (p<0.01) 
and 30.7±0.54% (p<0.05) of TUNEL positive cells respectively. The results have thus 
indicated that the apoptosis induced was indeed hnRNP K-specific and suggested that 
both isoforms of hnRNP K possess anti-apoptotic property. 
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Figure 3.18 Restoring hnRNP K levels reduces the percentage of TUNEL positive 
cells 
(A) TUNEL assay experimental procedure, where Hep 3B cells were reseeded into 
chamber slides 48 h post-transfection and cells were fixed, permeabilised, labelled 
before mounting with mounting agent containing DAPI. (B) Differentially transfected 
cells were observed under fluorescence microscope, where DAPI-stained and FITC-
stained cells represented total cell population and cells undergoing apoptosis 
respectively. DAPI-stained and FITC-stained cells for each slide were counted with 
Image-Pro software and data were expressed as the mean ± SD % of FITC-stained 
cells of the total cell population (DAPI-stained) obtained from triplicates. (*p<0.05, 





























To further examine whether the restoration of hnRNP K levels could reduce the 
extent of induced apoptosis following its reduction, Hep 3B cells were differentially 
transfected with the various transfection combinations listed in Table 3.2, fixed, 
stained with propidium iodide and subjected to subsequent cell cycle analysis, where 
hypodiploid cells (sub-G0/G1 peak) were quantified with fluorescence-activated cell 
sorter (FACS).  
From the FACS quantification data depicted in Figure 3.19, it could be observed 
that hnRNP K reduction resulted in an increase in percentage of hypodiploid cells as 
compared to control at 72 h post‐transfection. This was consistent with the results 
presented earlier that indicated the induction of apoptosis following hnRNP K 
downregulation.  
In addition, the percentage of hypodiploid cells for both rescue hnRNP K–a and –
b treatments were lower as compared to hnRNP K knockdown treatment. The 
percentage of hypodiploid cells in rescue hnRNP K–a and –b treatments was 15.3% 
and 18.6% respectively while that in cells with hnRNP K downregulated was 24.6%. 
Taken together with the findings from the TUNEL assay, the results have indicated 
that the extent of apoptosis induced by hnRNP K reduction was significantly reduced 
following the attempt to restore its expression levels.  
Interestingly, by comparing the data from the TUNEL assay (Figure 3.18B) and 
the cell cycle analysis (Figure 3.19), it was observed that the restoration of hnRNP K 
isoform–a was able to reduce the extent of apoptosis induced slightly better than 
isoform–b. As depicted in Figure 3.18B, percentage of TUNEL positive cells in 
rescue hnRNP K–a treatment was slightly lesser than in rescue hnRNP K–b treatment 
(23.6±2.6% versus 30.7±0.6%). Moreover, as revealed by cell cycle analysis, the 
percentage of hypodiploid cells for rescue hnRNP K–a treatment was lower as 
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compared to hnRNP K–b treatment (15.3% versus 18.6%). This was likely to be due 
to the slight increase in the expression level or stability of hnRNP K isoform–a as 
compared to isoform–b (Figure 3.17B), which resulted in a slight decrease in 
percentage of apoptotic cells in rescue hnRNP K–a as compared to hnRNP K–b 
treatment. Nonetheless, restoration of hnRNP K expression levels with either isoform 
was able to reduce apoptosis that was induced by hnRNP K downregulation, thus 
suggesting that the observed apoptotic effect was indeed hnRNP K-specific and also 







Figure 3.19 Restoration of hnRNP K expression levels decreases the percentage 
of subG0/G1 cells 
Cell cycle profiles of the differentially transfected Hep 3B cells (according to Table 
3.2) and their percentage of hypodiploid cells (subG0/G1) for each transfection 
reaction at both 72 h post-transfection were indicated. Results from a representative 



















































Taken together, the various functional assays performed in this current study 
(Table 3.3) have established that the downregulation of hnRNP K indeed induces 
apoptosis. As observed with WST-1 assay and FACS quantification of hypodiploid 
cells, loss of cell viability and increase in cell death were observed following the 
reduction of hnRNP K. Furthermore, the detection of DNA fragmentation observed in 
apoptosis with the use of TUNEL assay, coupled with the detection of apoptosis-
specific events such as activation of caspase-3/7 activity and production of caspase-
cleaved 89kDa PARP-1 fragment all pointed towards the specific induction of 
apoptosis. The data has also revealed that extended period of hnRNP K reduction 
induces apoptosis, specifically only from 72 h post-transfection onwards, regardless 
of whether HCC cells were transfected with 20 nM or 40 nM of hnRNP K-specific 
siRNA. Taken together with the observation where restoration of hnRNP K 
expression levels reduces the extent of apoptosis induced, the results have indicated 
that the downregulation of hnRNP K most likely caused the cells to lose their ability 
to inhibit apoptosis and suggested that hnRNP K exerts an anti-apoptotic effect in 














Table 3.3 Summary of results for functional assays investigating the effect of 
hnRNP K's downregulation 
Functional 
Assays 
Expected Outcomes in different 
types of Programmed Cell Death* 
Current Study  
(With decreased hnRNP K) 
Results 




Does not distinguish between 
apoptosis and necrosis, only indicates 








Found only in apoptotic cells, other 
cleavage pattern present in necrotic 






Gold standard to detect apoptosis in 
situ, but false positive may result from 
necrotic death in some cases such as 







Caspase activation found only in 
apoptotic and not in necrotic cells; but 
caspase activation may occur in cell 











Cell death monitored by the 
quantification of events with DNA 
content lesser than diploid (Kroemer et 
al., 2009); not only specific for 











3.7 Chapter Summary 
With the use of various HCC cell lines, hnRNP K has been demonstrated to be 
abundant at the protein level. Similar to several other chemotherapeutic drugs that can 
reduce the levels of hnRNP K as well as result in cell death (Barboro et al., 2009; 
Benelli et al., 2009; Enge et al., 2009; Rahman-Roblick et al., 2007), 5-FU that has 
been utilised for HCC treatment can downregulate hnRNP K independently of p53 at 
the mRNA level. As 5-FU is able to reduce the viability of HCC cells and the levels 
of hnRNP K concurrently, it is proposed that the reduction of hnRNP K is likely one 
of the mechanisms for 5-FU to cause cell death observed in HCC cell lines. Indeed, 
downregulation of hnRNP K solely with specific siRNA reduced cell viability and 
changed the morphology of HCC cells. Further functional analyses provided evidence 
for the onset of apoptosis brought about by hnRNP K reduction and that this 
phenomenon observed was indeed hnRNP K-specific. Moreover, it was also shown 
that the apoptosis induced by the reduction of hnRNP K was p53-independent. 
Current data also indicated that hnRNP K plays an anti-apoptotic role, for its 
downregulation only induces apoptosis specifically at 72 h post-transfection even with 
different amount of siRNA specific against hnRNP K. These have indicated that 
hnRNP K downregulation compromises the HCC cells’ ability to inhibit apoptosis, 





Chapter 4 The Anti-apoptotic Mechanism of hnRNP K  
  
CHAPTER 4 
The Anti-apoptotic Mechanism 




In Chapter 3, it was demonstrated that the reduction of hnRNP K induces 
apoptosis in HCC cell lines. In this chapter, the mechanism behind hnRNP K’s anti-
apoptotic effect was further examined.  
Of the various studies that have shown that the downregulation of hnRNP K 
induced cell death, few have attempted to dissect the mechanism behind this 
phenomenon. Evidence for the involvement of the intrinsic pathway was shown by 
White et al. (2010), where the downregulation of hnRNP K in Sy5y neuroblastoma 
cell line induced apoptosis that was accompanied by the translocation of PKCδ to the 
mitochondria. Conversely, Chen et al. (2010) demonstrated the sensitization of 
nasopharyngeal carcinoma (NPC) cells to TRAIL-induced apoptosis after 48 h of 
hnRNP K downregulation, which the authors attributed to the downregulation of 
cFLIP, a downstream transcriptional target of hnRNP K. This indicated that possible 
involvement of the extrinsic apoptotic pathway. Hence, the exact anti-apoptotic 
property that hnRNP K confers is still unclear, particularly in HCC cells. Therefore, 
this chapter aims to elucidate the anti-apoptotic mechanism of hnRNP K with the use 
of HCC cell lines.  
Given that caspases are well-known executors of apoptosis and that caspase-3/7 
activity correlates positively with apoptosis induced by hnRNP K downregulation (as 
shown in Chapter 3), the anti-apoptotic mechanism of hnRNP K was studied 
primarily with the measurement of caspase-3/7 activity. In addition, as hnRNP K 
downregulation in Hep 3B cells had revealed a significant decrease of its nuclear 
expression (Figure 3.2), its role as a transcription factor was also briefly explored in 
an attempt to elucidate its anti-apoptotic function.  
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4.2 Caspase-8 is essential for downstream caspase-3/7 activation in apoptosis 
induced by hnRNP K reduction 
As suggested by previous studies, both the extrinsic and intrinsic apoptotic 
pathways could possibly contribute to the apoptosis induction observed following 
hnRNP K reduction. Hence, to examine the contribution of the extrinsic and intrinsic 
apoptotic pathway, as represented by caspase-8 and caspase-9 respectively, to the 
apoptosis induced in HCC cells by hnRNP K downregulation, the two caspases were 
individually silenced simultaneously with hnRNP K using siRNAs in Hep 3B and 
HepG2 cells. The activity of caspase-3/7 was subsequently measured at 72 h post-
transfection, a time point where apoptosis induction had been repeatedly detected as 
shown in the previous chapter. 
The results intriguingly revealed a dramatic decrease in caspase-3/7 activity when 
caspase-8 was silenced together with hnRNP K (Figure 4.1A). As compared to cells 
with only hnRNP K downregulated, the caspase-3/7 activity observed in cells with co-
knockdown of caspase-8 and hnRNP K decreased by 71.6% (p<0.01) and 90.6% 
(p<0.01) in Hep 3B and HepG2 respectively. This indicated that caspase-8 is crucial 
in facilitating hnRNP K downregulation-induced apoptosis at 72 h post-transfection, 
as the knockdown of caspase-8 resulted in a strong inhibition of caspase-3/7 
activation. 
In contrast, the co-knockdown of caspase-9 and hnRNP K resulted in an increase 
in caspase-3/7 activity. As compared to cells with solely hnRNP K downregulated, the 
caspase-3/7 activity observed in cells with co-knockdown of caspase-9 and hnRNP K 
increased by 51.0% (p<0.01) and 124.1% (p<0.01) in Hep 3B and HepG2 
respectively. Unlike caspase-8, the knockdown of caspase-9 failed to reduce caspase-
3/7 activation induced by hnRNP K downregulation and instead intensified the 





Figure 4.1 Silencing caspase-8 prevents caspase-3/7 activation following hnRNP 
K reduction 
(A) Caspase-3/7 activity in differentially transfected Hep 3B and HepG2 cells was 
measured at 72 h post-transfection. Cells were transfected with 20 nM of si-hnRNP K 
with or without 20 nM of si-caspase-8 or si-caspase-9 as indicated. Data was 
expressed as relative caspase-3/7 activity of that transfected with si-hnRNP K and 
presented as mean ± SD % of triplicates. Results are from a representative experiment 
of at least two with similar trend. (B) Reduction of the respective caspases by their 
specific siRNAs at 48 h post-transfection was verified with western blot and β-actin 
protein level that served as loading control was also examined. (C) Protein levels of 
pro-caspase-3 as well as activated and cleaved caspase-3 were also examined in 




























































































































































si-caspase-9 - + - + - + - +
Hep 3B HepG2


















have clearly indicated that caspase-8 apoptotic signalling is essential for downstream 
caspase-3/7 activation observed during hnRNP K downregulation.  
Reduction of the respective caspases by their specific siRNAs was also verified at 
the protein level (Figure 4.1B). When levels of caspase-3 were examined in Hep 3B, 
activated and cleaved forms were detected only in cells with hnRNP K knocked-down 
but not in cells with caspase-8 simultaneously downregulated. Moreover, the levels of 
pro-caspase-3 were comparable across the differentially transfected cells, indicating 
that the observed reduction in caspase-3/7 activity following co-knockdown of 
hnRNP K and caspase-8 was not due to a reduction of effector caspases expression 
levels. These strongly suggest that hnRNP K exerts its anti-apoptotic effect on the 
caspase-8 apoptotic signalling pathway. 
 
4.3 hnRNP K downregulation amplifies the apoptotic effect of TRAIL 
4.3.1 Intact TRAIL-mediated apoptotic signalling in HCC cell lines 
Having demonstrated that hnRNP K exerts its anti-apoptotic effect mainly via 
caspase-8 signalling and that apoptosis occurs spontaneously only after 72 h of 
hnRNP K downregulation (Figure 3.13), it was further examined whether the anti-
apoptotic effect of hnRNP K could have been affected at earlier time points of hnRNP 
K downregulation i.e. 24 h post-transfection.  
To investigate this possibility, caspase-8 apoptotic signalling pathway that is best 
represented by the extrinsic apoptotic pathway was induced using death ligands after 
24 h of hnRNP K downregulation and cells were examined for any amplification in 
death signals induced. As FAS-ligand (FASL) and TRAIL are capable of inducing 
apoptosis in hepatocytes (Malhi et al., 2010), their ability to induce apoptosis in HCC 
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cells was first tested, by treating Hep 3B and HepG2 cells with increasing 
concentrations of each ligand before subjecting them to Caspase-Glo® 3/7 Assay.  
As shown in Figure 4.2, with increasing amount of FASL from 2-100 ng/ml, 
there was an increase in the activity of caspase-3/7 in HepG2, over an incubation 
period of 2 h to 8 h. Activity of caspase-3/7 was the strongest with 8 h of 100 ng/ml 
FASL treatment in HepG2, with a normalised caspase-3/7 activity of 175.6±4.0% as 
compared to untreated control. On the contrary, caspase-3/7 activity remained at its 
basal state in Hep 3B even with increasing concentrations of FASL. This observation 
for Hep 3B was consistent with a previous report that the resistance of Hep 3B to 
FAS-mediated apoptosis is due to a lack of surface expression of functional FAS 
(receptor) (Lamboley et al., 2002).  
In contrast to FASL, TRAIL as shown in Figure 4.3, was able to increase 
caspase-3/7 activity in both Hep 3B and HepG2 with increasing concentrations of 2-
50 ng/ml over the incubation period of 2 h to 8 h. Specifically in HepG2, the increase 
in caspase-3/7 activity correlated with both the increase in TRAIL concentration as 
well as treatment time. However, it could be observed that the caspase-3/7 activity in 
Hep 3B peaked at 4h post-TRAIL treatment and thereafter declined slightly. 
Nonetheless, comparing the effect of TRAIL with FASL in the induction of apoptosis, 
as exemplified by the increase in caspase-3/7 activity, TRAIL but not FASL was able 
to increase caspase-3/7 activity in Hep 3B. Taken together, these suggested that 
signalling pathway in HepG2 and Hep 3B for TRAIL-mediated apoptosis were 
functional and TRAIL was hence utilised as a death ligand for the induction of 




Figure 4.2 Hep 3B is resistant to apoptosis induced by FASL 
The ability of FASL in activating caspase-3/7 in Hep 3B and HepG2 was examined. 
Hep 3B (upper panel) and HepG2 (lower panel) cells were treated with different 
concentrations (0-100 ng/ml) of FASL over an incubation period of 2-8 h as indicated 
before caspase-3/7 activity was measured with Caspase-Glo® 3/7 assay. Caspase-3/7 
activity was expressed as caspase-3/7 activity of each differentially treated cell 
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Figure 4.3 TRAIL signalling is intact in Hep 3B and HepG2 
The ability of TRAIL in activating caspase-3/7 in Hep 3B and HepG2 was examined. 
Hep 3B (upper panel) and HepG2 (lower panel) cells were treated with different 
concentrations (0-50 ng/ml) of TRAIL over an incubation period of 2-8 h as indicated 
before caspase-3/7 activity was measured with Caspase-Glo® 3/7 assay. Data was 
expressed as caspase-3/7 activity of each differentially treated cell normalised to that 







































































0 2 4 6 8



































4.3.2 hnRNP K downregulation sensitises HCC cells to TRAIL-mediated 
apoptotic signals 
TRAIL has been demonstrated to induce apoptosis mainly via the extrinsic 
pathway upon its binding to DR4 or DR5 as introduced in Section 1.2.3 and its 
signalling pathway was also revealed to be intact in both Hep 3B and HepG2 cells 
(Figure 4.3). Hence, to examine whether the anti-apoptotic effect of hnRNP K could 
have been affected at earlier time point of hnRNP K downregulation, where apoptosis 
induction was not detected, Hep 3B and HepG2 with hnRNP K reduced for 24 h were 
treated with low dose of TRAIL (2 ng/ml) before their caspase-3/7 activity was 
determined (Figure 4.4A).  
From Figure 4.4, it could be observed that the reduction of hnRNP K resulted in 
an enhancement of caspase-3/7 activity in TRAIL-treated Hep 3B and HepG2 cells. 
Firstly, in both cell lines without TRAIL treatment, no significant difference in 
caspase-3/7 activity was observed between cells with or without hnRNP K 
downregulated at the various time points tested. This was consistent with the results 
demonstrated in Chapter 3, where earlier time points of hnRNP K reduction did not 
result in the onset of apoptosis.  
Next, comparing the caspase-3/7 activity in differentially transfected Hep 3B 
cells treated with 2 ng/ml TRAIL, there was an increase in caspase-3/7 activity of 
45.4% and 174.3% following 2 h and 8 h of TRAIL treatment respectively in hnRNP 
K downregulated cells as compared to control (Figure 4.4B). Moreover, in HepG2, 
the increment in caspase-3/7 activity was higher, where an increase in caspase-3/7 
activity of 471.3% and 541.7% following 2 h and 8 h of TRAIL treatment 
respectively was observed in hnRNP K downregulated cells as compared to control 




Figure 4.4 hnRNP K downregulation enhances TRAIL-induced caspase-3/7 
activity 
(A) Experimental workflow to examine the anti-apoptotic function of hnRNP K with 
TRAIL. Hep 3B and HepG2 cells were transfected with 40 nM of either si-ctrl or si-
hnRNP K for 24 h before the addition of 2 ng/ml of TRAIL. Cells were collected 
following 2 h and 8 h of incubation with TRAIL before the measurement of caspase-
3/7 activity. Caspase-3/7 activity of differentially transfected and treated (B) Hep 3B 
and (C) HepG2 was shown and data was expressed as caspase-3/7 activity of each 
differentially transfected and treated cells normalised to that in cells transfected with 
si-ctrl and untreated with TRAIL at each time point and presented as mean ± SD% of 
triplicates. (**p<0.01). Results are from a representative experiment of at least two 









































































































time points did not induce apoptosis, it was able to sensitise cells to TRAIL-induced 
apoptosis. 
Having demonstrated that hnRNP K downregulation augmented caspase-3/7 
activity in TRAIL-treated cells, it was subsequently examined whether this effect was 
hnRNP K-specific. Thus, increasing concentrations of si-hnRNP K were transfected 
into Hep 3B and HepG2 cells to generate a gradient of hnRNP K knockdown. 
Following 24 h of transfection, the cells were treated with low dose of TRAIL before 
caspase-3/7 activity measurement (Figure 4.5A).  
As reflected from Figure 4.5B, the enhancement in TRAIL-induced caspase-3/7 
activity increased in both Hep 3B and HepG2 with greater hnRNP K downregulation 
using increasing concentrations of si-hnRNP K from 0 nM to 20 nM. Caspase-3/7 
activity in TRAIL-treated cells that were pre-transfected with 10 nM and 20 nM of si-
hnRNP K increased by 82.9% and 150.2% respectively in Hep 3B (p<0.01) and by 
960% and 1308.7% in HepG2 (p<0.01) as compared to control. 
However, when the concentration of siRNA increased from 20 nM to 40 nM, 
augmented TRAIL-induced caspase-3/7 activity was observed to decrease instead. A 
plausible explanation could be that the enhanced caspase-3/7 activity brought about 
by 40 nM of si-hnRNP K had attained its peak at earlier time points of TRAIL 
treatment and had subsequently started to decline. In addition, it was also observed 
that there was a huge percentage difference in the enhancement of TRAIL-induced 
caspase-3/7 activity between both cell lines following hnRNP K downregulation. 
Though this disparity is unclear, it could be a result of cell line difference.  
Nonetheless, the trend in enhancement of TRAIL-induced caspase-3/7 following 
hnRNP K reduction was similar in both cell lines and this indicated that the observed 
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enhancement of caspase-3/7 activity in TRAIL-treated Hep 3B and HepG2 was 
indeed hnRNP K-specific. 
 
 
Figure 4.5 Enhancement of TRAIL-induced caspase-3/7 activity depends on 
hnRNP K 
hnRNP K’s specificity in enhancing TRAIL-induced caspase-3/7 activity was 
examined. (A) Hep 3B and HepG2 were transfected with increasing concentrations of 
si-hnRNP K for 24 h before 8 h of incubation with 2 ng/ml of TRAIL and subsequent 
caspase-3/7 activity measurement. (B) Increased knockdown of hnRNP K at the 
protein level with increased concentration of siRNA was verified in both Hep 3B and 
HepG2 at 24 h post-transfection. (C) Caspase-3/7 activity of the differentially 
transfected and treated cells were shown. Data was expressed as caspase-3/7 activity 
of each differentially transfected and treated cells normalised to cells transfected with 
si-ctrl and untreated with TRAIL at each time point and presented as mean ± SD% of 

















































































































As knocking-down hnRNP K with increasing concentrations of siRNA increased 
the enhancement in caspase-3/7 activity induced by TRAIL, the direct anti-apoptotic 
function of hnRNP K on TRAIL-induced caspase-3/7 activation was next examined. 
For this purpose, the two protein isoforms of hnRNP K were first individually 
overexpressed in both HCC cell lines and cells were subsequently treated with TRAIL 
before caspase-3/7 activity measurement (Figure 4.6A).  
Results from the caspase-3/7 assay revealed that with the overexpression of 
hnRNP K regardless of isoform was able to reduce the caspase-3/7 activity induced 
by TRAIL. As shown in Figure 4.6B, the overexpression of hnRNP K isoform–a and 
–b reduced TRAIL-induced caspase-3/7 activity when compared to control by 22.4% 
and 15.0% respectively in Hep 3B and 23.6% and 30.4% respectively in HepG2. This 
has provided a direct indication of the anti-apoptotic function of hnRNP K on TRAIL-
induced apoptosis and was in concordance with the previous observations in Chapter 
3 that hnRNP K possesses an anti-apoptotic function.  
Together, the data from Figure 4.5 and Figure 4.6 indicates that the levels of 
hnRNP K negatively correlate with the level of TRAIL-induced caspase-3/7 activity, 
indicating that hnRNP K likely exerts its anti-apoptotic effect directly or indirectly on 










Figure 4.6 hnRNP K overexpression reduces TRAIL-induced caspase-3/7 activity  
The anti-apoptotic effect of hnRNP K on TRAIL-induced caspase-3/7 activity was 
examined. (A) Hep 3B and HepG2 cells were first transfected with 2 μg of empty 
pXJ40-HA vector or SDM-pXJ40-HA-hnRNP K (isoform–a or –b) for 30 h before 8 
h of incubation with 10 ng/ml of TRAIL and subsequent caspase-3/7 activity 
measurement. (B) Caspase-3/7 activity of the differentially transfected and treated 
cells were shown.  Data was expressed as TRAIL-induced caspase-3/7 activity of 
each differentially transfected cells normalised empty vector-transfected cells. Results 
were also presented as mean ± SD% of triplicates from a representative experiment of 
at least two with similar trend. (**p<0.01, *p<0.05). 
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4.3.3 Enhanced TRAIL-induced caspase-3/7 activity by hnRNP K 
downregulation as a result of increased caspase-8 activity 
Given that the downregulation of hnRNP K augmented TRAIL-induced caspase-
3/7 activation, it was examined whether this effect could have been brought about by 
enhanced BID cleavage, which could then amplify the apoptotic effect via the 
intrinsic apoptotic pathway. To investigate this possibility, the profile of TRAIL-
induced caspase-3/7 activity was first studied in HepG2 cells that revealed higher 
enhancement in TRAIL-induced caspase-3/7 activation upon hnRNP K reduction. 
Thus, hnRNP K was first downregulated in HepG2 and subsequently differentially 
treated with increasing concentrations of TRAIL (0-50 ng/ml) before caspase-3/7 
activity measurement.  
As shown in Figure 4.7A, the profiles of TRAIL-induced caspase-3/7 activity in 
HepG2 cells treated with non-specific control siRNA (si-ctrl) and si-hnRNP K were 
strikingly different and it was observed that treating si-hnRNP K transfected cells 
with 2 ng/ml of TRAIL produced similar caspase-3/7 activity as compared to control 
cells treated with 50 ng/ml of TRAIL (3569.0% as compared to 3610.6%). This 
indicated that the loss of hnRNP K amplified TRAIL-induced caspase-3/7 activity 
such that a lower concentration of TRAIL (2 ng/ml) could induce caspase-3/7 activity 
that was normally achieved only with a high TRAIL concentration (50 ng/ml).   
Having known the profiles of TRAIL-induced caspase-3/7 activity in HepG2, 
BID cleavage induced by TRAIL was examined. Western blot analyses of full length 
BID in HepG2 cells treated with increasing concentrations of TRAIL revealed 
increased cleavage of BID as depicted by the decrease in amount of full length BID 
with increasing TRAIL concentration, which was particularly evident in cells treated 





Figure 4.7 Enhanced TRAIL-induced caspase-3/7 activity by hnRNP K 
downregulation is independent of BID cleavage 
(A) Enhancement in TRAIL-induced caspase-3/7 activity by hnRNP K 
downregulation was examined in HepG2, where 40 nM of si-ctrl or si-hnRNP K 
transfected cells for 24 h were treated with increasing concentrations of TRAIL for 8 
h before caspase-3/7 activity was measured. Data expressed as normalised caspase-
3/7 activity relative to cells transfected with si-ctrl and untreated with TRAIL and 
presented as mean ± SD% of triplicates. (B) The extent of BID cleavage in HepG2 
treated with the indicated TRAIL concentrations was examined by western blot 
analyses of full-length BID protein level with β-actin as loading control. Intensities of 
full length BID protein level were measured with ImageJ, normalised to β-actin, 
expressed relative to that untreated with TRAIL and indicated beneath each band. (C) 
hnRNP K and full-length BID protein levels with β-actin as loading control were 
examined with western blot in HepG2 and Hep 3B that were transfected with 40 nM 
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As 2 ng/ml of TRAIL generated similar amount of caspase-3/7 activity in si-
hnRNP K transfected cells as compared to si-ctrl transfected cells treated with 50 
ng/ml TRAIL (Figure 4.7A), the amount of full length BID was examined in HepG2 
with hnRNP K downregulated and treated with 2 ng/ml of TRAIL. Interestingly, it 
was observed in Figure 4.7C that the levels of full length BID were similar in 
differentially transfected HepG2 cells treated with 2 ng/ml of TRAIL regardless of 
hnRNP K downregulation. In addition, the level of full length BID in HepG2 with 
hnRNP K reduced and treated with 2 ng/ml of TRAIL (Figure 4.7C, left panel) was 
significantly higher than that in HepG2 cells treated with 50 ng/ml of TRAIL (Figure 
4.7B). Likewise, when the level of BID in differentially transfected Hep 3B cells 
treated with 2 ng/ml of TRAIL for 8 h were analysed with western blot, the levels of 
full length BID were also similar in the differentially transfected cells (Figure 4.7C, 
right panel). These indicated that the observed enhancement in TRAIL-induced 
caspase-3/7 activity by hnRNP K downregulation was independent of BID cleavage 
and thus suggested it to be a direct effect from caspase-8 signalling to caspase-3/7.  
Therefore, to investigate whether the enhanced TRAIL-induced caspase-3/7 
activity was a direct effect of increased caspase-8 activity, HCC cells with hnRNP K 
downregulated and treated with low dose of TRAIL (as outlined in Figure 4.4A) had 
their caspase-8 activity measured. 
The caspase-8 assay results demonstrated an increase in TRAIL-induced caspase-
8 activity in both Hep 3B and HepG2 that had hnRNP K downregulated as compared 
to control. With a reduction in hnRNP K, the increase in caspase-8 activity following 
TRAIL treatment for 2 h and 8 h was 48.7% and 115.3% respectively in Hep 3B 
(Figure 4.8B) and 296.4% and 338.0% respectively in HepG2 cells (Figure 4.8C). The 
results were in agreement and correlated well with the enhanced TRAIL-induced 
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caspase-3/7 observed following hnRNP K reduction demonstrated earlier in this study 
(Figure 4.4B and C), strongly suggesting that the enhanced caspase-3/7 activity was a 
direct result from the increased caspase-8 activity. 
Moreover, levels of full length caspase-8 in the differentially transfected cells 
were also examined with western blot and demonstrated to be expressed to a similar 
extent, indicating that hnRNP K downregulation did not affect the expression levels 
of caspase-8 (Figure 4.8A). This eliminates the possibility that the increase in TRAIL-
induced caspase-3/7 activity was due to an increase in the expression level of caspase-
8 upon hnRNP K downregulation. Taken together, the results indicate that the 
enhanced TRAIL-induced caspase-3/7 activity following hnRNP K downregulation is 





Figure 4.8 Enhanced TRAIL-induced caspase-8 activity following hnRNP K 
downregulation 
 (A) hnRNP K and full-length caspase-8 protein levels with β-actin as loading control 
in HepG2 and Hep 3B that were transfected with 40 nM si-ctrl or si-hnRNP K for 24 
h were examined with western blot. Caspase-8 activity in (B) Hep 3B and (C) HepG2 
cells with hnRNP K downregulated and treated with 2 ng/ml TRAIL for 2 h and 8 h 
was examined. Data was expressed as normalised caspase-8 activity relative to cells 
transfected with si-ctrl and untreated with TRAIL and presented as mean ± SD% of 
























































































4.4 Reduction of hnRNP K downregulates the mRNA expression levels of anti-
apoptotic genes  
4.4.1 Identifying potential hnRNP K downstream targets associated with 
caspase-8 signalling pathway 
Having shown that the enhanced TRAIL-induced caspase-3/7 activity caused by 
hnRNP K downregulation is independent of BID cleavage and likely contributed by 
the direct increase in caspase-8 activity, it was postulated that mediators involved in 
caspase-8 signalling or the extrinsic apoptotic pathway likely contributed to the 
increased TRAIL sensitivity resulting from hnRNP K downregulation. Hence, 
coupled with the knowledge that hnRNP K functions as a transcription factor, it was 
next examined whether the reduction of hnRNP K could have affected the expression 
levels of the mediators involved in the above-mentioned pathways. For this purpose, 
hnRNP K was first downregulated with siRNA in Hep 3B cells for 24 h and 48 h. 
Following which, RNA was extracted and gene expression profiles of the 
differentially transfected cells were examined with the use of exon array and analysed 
as detailed in Chapter 2. 
To specifically uncover the genes involved in the apoptotic pathway associated 
with caspase-8 signalling that are likely to be regulated by hnRNP K, data from exon 
array analysis were analysed specifically for genes involved in the extrinsic apoptotic 
pathway and/or interact with caspase-8. As such, genes that were annotated to interact 
with caspase-8 as well as being involved in the extrinsic apoptotic pathway were first 
collated from BioGRID
3.1 as well as genes listed under gene ontology term ‘Extrinsic 
Apoptotic Signaling Pathway’ with accession GO:0097191. From the compilation, the 
expression profiles of a total of 109 genes could be identified from the exon array data. 
These 109 genes were then categorised into anti-apoptotic or pro-apoptotic function 




Figure 4.9 Work process in elucidating genes in the extrinsic apoptotic pathway 
or interactors of caspase-8 that are regulated by hnRNP K 
(A) Flowchart depicting the steps in work process. Genes involved in the extrinsic 
apoptotic pathway as well as interactors of caspase-8 were collated and 109 genes 
with expression profiles present in exon array data yielded from Hep 3B cells 
transfected with 40 nM of si-ctrl or si-hnRNP K for 24 h and 48 h were further 
analysed. These genes were further classified into anti-apoptosis, pro-apoptosis, both 
or neither based on Gene Ontology’s terms and ID as indicated as well as manual 
classification. (B) Pie-chart representing the number of selected genes in each 
classification as described above. 
  








































process’ (GO: 0043066) and ‘Positive regulation of apoptosis’ (GO:0043065) coupled 
with  subsequent  manual  classification  (Figure  4.9A).  Through this categorization, 
these genes were classified as pro-apoptosis, anti-apoptosis, neither (anti- nor pro-
apoptosis) or both (anti- and pro-apoptotic) as shown in Figure 4.9B and listed in 
Table 4.1.  
Upon attaining the list of anti- and pro-apoptosis genes, their expression profiles 
from the exon array data were examined. Gene expression values with a log2 fold 
change between -0.2 and 0.2 were classified as unchanged and the genes were 
subsequently ranked in order by their expression values at 24 h followed by that in 48 
h of hnRNP K downregulation. In addition, only genes with consistent progressive 
change from 24 h to 48 h of hnRNP K reduction were selected for further analyses. 
Given that hnRNP K downregulation has been demonstrated earlier on in current 
study to induce apoptosis, genes of interest would thus be anti-apoptotic genes that 
were downregulated and pro-apoptotic genes that were upregulated following the 
downregulation of hnRNP K.  
Having applied these criteria, genes in both pro- and anti-apoptosis categories 
that revealed progressive change from 24 h to 48 h post-transfection are depicted in 
Figure 4.10A and B respectively. Intriguingly, TNFSF10 that encodes for TRAIL 
protein was the pro-apoptotic gene that had the highest gene expression as reflected 
by exon array data, at both 24 h and 48 h post hnRNP K downregulation (Figure 
4.10A). As for the anti-apoptotic genes, BIRC3, CFLAR and XIAP had lowered gene 
expression at 24 h post-transfection. Of these three genes, BIRC3 and XIAP are 
members of the IAP family (Srinivasula and Ashwell, 2008) and CFLAR has been 
demonstrated by a previous study to be a downstream target of hnRNP K (Chen et al., 
2010).   
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Taking into consideration that the enhancement of TRAIL-induced caspase-3/7 
activity was observed following 24 h of hnRNP K downregulation, pro-apoptotic gene 
TNFSF10 that was observed to have the strongest gene expression, as well as BIRC3, 
CFLAR and XIAP that were observed to have decreased gene expression at 24 h post-
hnRNP K reduction, were selected for subsequent downstream quantitative real-time 





Table 4.1 Classification of the 109 collated genes by their pro- or anti-apoptotic 
function 
   
 Function: Pro-apoptosis Anti-apoptosis Neither* Both#  
   
 
 
APAF1 AIF1 BCAP31 BCL2L1  
 BAD ARHGDIA CASP1 CAV1  
 BCL10 BAG4 CHD3 FAS  
 BID BCL2 CHUK MCL1  
 CASP10 BIRC2 EZR RIPK1  
 CASP14 BIRC3 FYN RIPK2  
 CASP2 CBL HDAC7 SQSTM1  
 CASP3 CFLAR JAK1 UBC  
 CASP4 GDNF KHDRBS1   
 CASP6 HIPK3 MAP1LC3A   
 CASP7 HTT MAP1LC3B   
 CASP8 IKBKB MSN   
 CASP8AP2 ITCH NACA   
 CASP9 KRT18 NR1H4   
 CRADD MAP3K14 PPP2R1B   
 CYLD NOL3 RALBP1   
 DAP3 PAK2 RALGDS   
 DAXX PARK7 RET   
 DEDD PEA15 RYBP   
 DEDD2 PRKCZ SUMO1   
 FADD RHOA TFCP2   
 FAF1 SIAH2 USP2   
 FASLG SRC VIM   
 HIP1 TNFAIP3 ZMYND11   
 IFT57 TRAF1    
 IKBKG TRAF2    
 JAK2 TSC22D3    
 LCK XIAP    
 LTBR     
 MAPK8     
 MIB1     
 MLLT11     
 NLRC4     
 NOD1     
 PML     
 PTEN     
 RIPK3     
 SH3RF1     
 STAT1     
 TNF     
 TNFRSF10A     
 TNFRSF10B     
 TNFRSF12A     
 TNFRSF1A     
 TNFRSF21     
 TNFSF10     
 TRADD     
 TRAF3     
 UNC5B     
       




Figure 4.10 Heatmap of selected pro- and anti-apoptotic genes that revealed 
progressive expression change following hnRNP K downregulation 
Expression profiles of selected genes that had been classified as (A) pro-apoptosis and 
(B) anti-apoptosis showing progressive expression change over the two time points 
(24 h and 48 h post-hnRNP K knockdown) from the exon array data. Orange and blue 
represent the increase and decrease in gene expression level and the intensity of 
colour correlates to the log2 fold change as indicated. Genes with no change in 


































































































































































4.4.2 Real-time quantitative PCR validation of potential hnRNP K regulated 
genes  
Real-time quantitative PCR validation for the four selected genes was carried out. 
As the enhancement of TRAIL-induced caspase-3/7 activity caused by 24 h of hnRNP 
K downregulation was observed in both cell lines, these selected genes were validated 
in both Hep 3B and HepG2 cells with primers designed to amplify region that spans 
across exon-exon junction of each gene. In addition, for a gene to be potentially 
regulated by hnRNP K, the mRNA expression of the gene of interest should reflect 
similar expression trend in both HCC cell lines.  
As revealed in Figure 4.11A, the mRNA fold expression level of the pro-
apoptotic TNFSF10 was upregulated in Hep 3B but downregulated in HepG2 cells 
following 24 h of hnRNP K downregulation. This upregulation of TNFSF10 at the 
mRNA level in Hep 3B was consistent with the gene expression profile of TNFSF10 
in exon array (Figure 4.10A), but this increase in TNFSF10 mRNA expression was 
lower than expected as its log2 fold change in the selected exon array data was the 
highest. Nonetheless, as its expression trend was disparate in both cell lines, 
TNFSF10 was not selected for further analysis.  
The mRNA expression levels of the anti-apoptotic genes were next investigated. 
Apart from BIRC3 and XIAP, BIRC2 that is also a member of the IAP family 
(Srinivasula and Ashwell, 2008) was similarly found in the list of anti-apoptotic genes 
seen in Figure 4.10B, but with no expression change at 24 h post-hnRNP K 
downregulation as revealed by the exon array data. Hence, the mRNA expression 
level of BIRC2 was also investigated to determine whether its mRNA expression level 
correlated with the gene expression profile observed in exon array. The results 
revealed that the mRNA expression level of BIRC2 was not significantly altered 
following hnRNP K downregulation for 24 h in both HCC cell lines (Figure 4.11B), 
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which was consistent with the observed gene expression profile from the exon array 
data analysis demonstrated in Figure 4.10B, and also indicated that BIRC2 served as a 
good negative control.  
From Figure 4.11C, it was observed that all three anti-apoptotic genes, BIRC3, 
CFLAR and XIAP were significantly downregulated at the mRNA level in both HCC 
cell lines following 24 h of hnRNP K downregulation, which was consistent with the 
results from the exon array (Figure 4.10B). This downregulation of CFLAR mRNA 
expression following 24 h of hnRNP K downregulation was expected as it has been 
previously demonstrated to be a direct downstream target of hnRNP K (Chen et al., 
2010), and hence indirectly served as a positive control. On the contrary, it was 
demonstrated for the first time that the other two anti-apoptotic proteins of the IAP 
family, BIRC3 and XIAP, were downregulated at the mRNA level following the 
reduction of hnRNP K.  
Taken together, the results have indicated the reliability of the selected exon array 
data and suggested BIRC3 and XIAP as potential downstream targets of hnRNP K that 
would require further study. With this in mind, XIAP that is the best characterised 
IAP thus far and deemed as the most potent caspase inhibitor (Srinivasula and 
Ashwell, 2008) was first chosen for further examination.  
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Figure 4.11 Real-time quantitative PCR validation of selected genes based on 
exon array gene expression profile 
The mRNA expression levels of selected genes were examined in Hep 3B and HepG2 
cells transfected with 40 nM si-ctrl or si-hnRNP K for 24 h with the use of real-time 
quantitative PCR. These genes were selected based on their function in apoptosis and 
gene expression data from exon array: (A) TNFSF10 encoding for TRAIL, pro-
apoptosis; (B) BIRC2 serving as a negative control, anti-apoptosis; (C) Anti-apoptotic 
genes, BIRC3 encoding for cIAP2, XIAP encoding for XIAP as well as the previously 
identified downstream target of hnRNP K, CFLAR that encodes for cFLIP. Data 
presented as mean ± SD of duplicates and expressed relative to control after 
normalisation to HPRT expression level. (**p<0.01, *p<0.05). Results are from a 
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4.5 XIAP mRNA and protein levels are downregulated following hnRNP K 
reduction 
X-linked IAP (XIAP) has been recognised as the most potent endogenous caspase 
inhibitor (Shiozaki and Shi, 2004) as it has been demonstrated to inhibit the activity of 
processed caspase-3/7 and sequester processed caspase-9 in a monomeric state 
(Shiozaki and Shi, 2004). Moreover, XIAP has been demonstrated to negatively affect 
caspase-8 and caspase-3 activities upon treatment with death ligands (Schile et al., 
2008), indicating the pivotal role it possesses in inhibiting apoptosis. 
Having shown that XIAP mRNA expression levels decreased following hnRNP 
K downregulation, it was next determined if there was any corresponding decrease in 
its protein levels. Western blot analyses in Figure 4.12 revealed that XIAP protein 
expression was similarly downregulated in both Hep 3B and HepG2 following 24 h as 
well as 48 h of hnRNP K downregulation. This indicated that the reduction of hnRNP 
K can result in a downregulation of XIAP protein, thereby decreasing the inhibition 
on caspase-3/7 as well as its activity. This hence likely contributed to the enhanced 
TRAIL-induced caspase-3/7 activity following hnRNP K reduction previously 















Figure 4.12 hnRNP K downregulation reduces XIAP protein expression 
Reduction of XIAP protein levels following downregulation of hnRNP K in both 
HCC cell lines. β-actin served as a loading control in the total cell lysates of HepG2 
and Hep 3B that were transfected with 40 nM si-ctrl (indicated by ‘-’) or si-hnRNP K 
for 24 h and 48 h. Intensities of XIAP protein level, indicated beneath each band, 
were measured with ImageJ, normalised to β-actin’s, expressed relative to cells 
transfected with si-ctrl at each time point. 
  
 
Next, as a preliminary investigation to examine whether XIAP is a downstream 
transcriptional target of hnRNP K, the mRNA expression level of XIAP was 
quantitated with real-time PCR in Hep 3B cells with hnRNP K downregulated over 
time. The real-time quantitative PCR results in Figure 4.13A revealed that the mRNA 
level of XIAP was downregulated progressively over time following hnRNP K 
downregulation, indicating that the mRNA expression level of XIAP was dependent 
on the level of hnRNP K present.  
However, due to the multifunctional property of hnRNP K, the observed 
downregulation in XIAP mRNA expression level could be a result of either decreased 
XIAP mRNA transcription or a decrease in XIAP mRNA stability following hnRNP 
K downregulation. Hence, to further elucidate whether XIAP is regulated by hnRNP 
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24 48
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mRNA following hnRNP K downregulation was examined. For this purpose, Hep 3B 
cells with hnRNP K downregulated for 48 h were treated with 5 μg/ml of 
Actinomycin D to block de novo mRNA synthesis and the level of XIAP mRNA was 
measured with quantitative real-time PCR at the various time points post-treatment as 
indicated. As observed in Figure 4.13B, the half-life of XIAP mRNA in control cells 
was similar to those cells with hnRNP K downregulated, with values of 5.9±0.3h and 
6.2±0.1h respectively. This strongly suggests that the regulation of XIAP by hnRNP 
K did not occur at the post-transcriptional level but likely at the transcriptional level. 
This also indicated that the anti-apoptotic function of hnRNP K could in part be 
conferred by its ability to transcriptionally activate XIAP, which is a well-known anti-
apoptotic protein. 
Taken together, the results demonstrate that the anti-apoptotic function that 
hnRNP K possesses and exerts on the caspase-8 apoptotic signalling pathway is likely 
conferred by its ability to regulate various anti-apoptotic genes, CFLAR, BIRC3 and 





Figure 4.13 XIAP as a potential downstream transcriptional target of hnRNP K  
 (A) Real-time quantitative PCR analyses of XIAP mRNA level in Hep 3B cells 
transfected with 40 nM of si-ctrl or si-hnRNP K for the various time points indicated. 
Data presented as mean ± SD of duplicates and expressed relative to control after 
normalisation to HPRT expression level (**p<0.01). (B) The half-life of XIAP 
mRNA in Hep 3B with hnRNP K downregulated. The half-life of XIAP in Hep 3B 
cells transfected with 40 nM of si-ctrl or si-hnRNP K for 48 h were analysed with 
real-time quantitative PCR following treatment with Actinomycin D (Act D) for the 
time points indicated. Data presented as mean ± SD of duplicates and expressed 
relative to those without Act D treatment after normalisation to HPRT expression 







































































































4.6 Chapter Summary 
Having shown that the induction of apoptosis occurred only after extended 
duration of hnRNP K downregulation in the previous chapter, the anti-apoptotic 
mechanism of hnRNP K was investigated in this chapter using HCC cell lines. By 
silencing caspase-8 or caspase-9 simultaneously with hnRNP K, caspase-8 was shown 
to be pivotal for the apoptosis observed at 72 h post-hnRNP K knockdown. As 
caspase-8 is a well-known initiator caspase of the extrinsic apoptotic pathway, the 
anti-apoptotic function of hnRNP K was examined with TRAIL that triggers the 
extrinsic apoptotic pathway. Intriguingly, a mere 24 h hnRNP K downregulation with 
siRNA enhanced TRAIL-induced caspase-3/7 activity dramatically, of which was 
hnRNP K-specific and did not involve any BID cleavage. Further analyses 
nonetheless revealed the increase in caspase-8 activity following hnRNP K 
downregulation, indicating that the anti-apoptotic effect of hnRNP K is likely exerted 
on the caspase-8 and caspase-3/7 axis (Figure 4.14).  
To understand this novel hnRNP K-caspase-8 pathway, an exon array was 
performed on hnRNP K siRNA treated Hep 3B cells and the genes associated with 
caspase-8 signalling were selected for further analysis. Anti-apoptotic genes, BIRC3, 
XIAP and CFLAR were identified to have progressively reduced gene expression over 
time with the reduction of hnRNP K (Figure 4.14). Subsequent quantitative real-time 
PCR validation of these selected genes revealed their mRNA expression levels to be 
significantly downregulated following 24 h of hnRNP K downregulation, of which 
BIRC3 and XIAP was demonstrated for the first time to be regulated by hnRNP K. 
XIAP in particular, a known potent inhibitor of caspase-3/7, was also selected for 
preliminary analysis in this study and was demonstrated to be downregulated at the 
protein level following hnRNP K downregulation. Moreover, results also 
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demonstrated that hnRNP K likely regulates XIAP at the transcriptional level. 
Together, these results strongly indicate that hnRNP K can exert its anti-apoptotic 
effect by regulating the expression levels of various anti-apoptotic genes at the 






Figure 4.14 hnRNP K regulates anti-apoptotic genes that inhibit the caspase-8 
and caspase-3/7 axis 
Figure summarises results from Chapter 4. Results from the caspase assays have 
revealed enhanced TRAIL-induced caspase-8 and caspase-3/7 activities following 
hnRNP K reduction (↓hnRNP K), while data from the expression array and real-time 
PCR demonstrated the reduction of the anti-apoptotic genes that inhibit caspase-8 and 
caspase-3/7 activation. These indicated that hnRNP K can exert its anti-apoptotic 
effect by regulating the expression levels of various anti-apoptotic genes at the 
















Caspase Assays Expression Data
139 
 






5.1 hnRNP K inhibits apoptosis in HCC cells 
hnRNP K is upregulated in various cancers including HCC, which is the third 
highest cause of cancer-related deaths globally (El-Serag and Rudolph, 2007) with 
apoptosis dysregulation as one of its hallmarks (Fabregat, 2009). Even though many 
studies have reported the elevated levels of hnRNP K in HCC (Table 3.1), its role in 
HCC has yet to be elucidated.  
As hnRNP K has been demonstrated to transcriptionally regulate several 
oncogenes (Michelotti et al., 1995; Ritchie et al., 2003), its upregulation in various 
cancers has been deemed to contribute towards accelerated growth in cancer cells. 
Interestingly, recent studies have revealed an association between hnRNP K and 
apoptosis, albeit with contrasting results. Therefore, the role of hnRNP K in apoptosis 
induction was investigated with the use of HCC cell lines. 
 
5.1.1 hnRNP K functions as an anti-apoptotic protein in HCC 
A decrease in HCC cell viability was observed following hnRNP K 
downregulation (Figure 3.10 and 3.11), which is consistent with that previously 
reported (Inoue et al., 2007) and indicated the involvement of hnRNP K in cell 
survival. This decrease in cell viability is likely due to cell death, of which apoptosis 
might play a role, given earlier reports that suggested an association of hnRNP K 
expression levels with apoptosis. However, these reports were disparate, with 
Charroux et al. (1999) and Neo et al. (2005) reporting the association of hnRNP K 
overexpression with apoptosis, though more recent studies reported the 
downregulation of hnRNP K with apoptosis instead (van Domselaar et al., 2012; 
White et al., 2010).  
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Consequently, the involvement of hnRNP K downregulation with cell death was 
further investigated using in vitro functional analyses specific for different 
biochemical features of apoptosis (Table 3.3). The results established that the 
extended downregulation of hnRNP K, i.e. 72 h post-transfection, induced apoptosis 
in HCC cell lines (Figure 3.12A and 3.13). Interestingly, it was noted that increased 
hnRNP K downregulation was ineffective in bringing forward the initiation of 
apoptosis (Figure 3.13 and 3.14). Thus, it is hypothesised that hnRNP K functions as 
an anti-apoptotic protein where its downregulation at earlier time points, i.e. 24 h and 
48 h post-transfection, may have compromised the cells’ ability to inhibit apoptosis 
without the active initiation of apoptosis. Spontaneous induction of apoptosis was 
observed only after an extended duration of hnRNP K downregulation, but this trigger 
is still currently unclear.  
The apoptosis induction observed following extended hnRNP K downregulation 
in HCC cell lines is in concordance with three recent studies that had similarly 
downregulated its expression levels in other cell lines; an increase in hypodiploid 
(subG0/G1) HT29 colorectal cancer cells was observed at 72 h post-transfection (Gao 
et al., 2009), increased caspase-3/7 activity and TUNEL positive cells in Sy5y 
neuroblastoma cells was reported at 72 h post-transfection (White et al., 2010), and an 
increase in annexin-V positive cells as well as caspase-3/7 activity was revealed in 
HeLa cells at 120 h post-transfection (van Domselaar et al., 2012). Taken together 
with the results from this study, it has been shown that apoptosis can be induced in 
various cell-types following hnRNP K downregulation, albeit with differences in 
duration of its reduction, which could be a cell-type specific response.  
Given that extended hnRNP K downregulation led to apoptosis induction, the 
hypothesis that its reduction at earlier time points compromises cells’ ability to inhibit 
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apoptosis concurred with a study which reported that hnRNP K downregulation in 
nasopharyngeal carcinoma (NPC) cell lines did not induce apoptosis, but sensitised 
the cells to death ligand-induced apoptosis (Chen et al., 2010). This also implies that 
the discrepancy in the required duration of hnRNP K downregulation for induction of 
apoptosis in different cells could be dependent on the availability and type of 
apoptotic stimuli present in each cell-type. Hence, these have together provided an 
explanation for the absence of cell viability changes or apoptosis induction observed 
in immortalised MRC5 lung fibroblast cell line despite extended hnRNP K 
downregulation (Moumen et al., 2005), as certain cell types may lack the apoptotic 
trigger or require an even longer period of hnRNP K reduction before apoptosis could 
be observed.  
Therefore, it can be concluded that hnRNP K plays an important role in inhibiting 
apoptosis induction in various cell-types. Moreover, this study has demonstrated for 
the first time that hnRNP K likely serves as an anti-apoptotic protein that maintains 




5.1.2 hnRNP K protein isoforms possess similar anti-apoptotic function  
There are several hnRNP K protein isoforms (Dejgaard et al., 1994; Kimura et al., 
2010), of which only isoform–a and –b are fully described. In an attempt to study 
hnRNP K’s specificity in the apoptosis induced upon its downregulation with siRNA, 
isoform–a  and –b expression plasmids were generated to restore its reduced levels 
(Figure 3.15 and 3.16). A decrease in extent of apoptosis was observed upon 
restoration of hnRNP K expression levels, thus demonstrating that the apoptosis 
induced following its reduction was indeed hnRNP K-specific and also further 
validated hnRNP K’s role as an anti-apoptotic protein. However, restoration of 
hnRNP K levels was unable to completely abrogate the apoptosis induced (Figure 
3.18 and 3.19). A plausible explanation would be that the siRNA treatment resulted in 
the downregulation of all hnRNP K isoforms, thus the use of either isoform–a or –b 
expression plasmids solely would be insufficient for total abrogation of the apoptosis 
induced. In line with the results shown in Figure 3.18 and 3.19, the stable 
overexpression of hnRNP K (isoform–a) in Sy5y cell line has been shown to suppress 
hnRNP K-downregulation-induced apoptosis, though the induction of apoptosis could 
not be inhibited completely (White et al., 2010). 
It is noted that the restoration of hnRNP K expression levels with isoform–a 
resulted in a better inhibition of induced apoptosis when compared to isoform–b 
(Figure 3.18 and 3.19). However, it cannot be concluded that isoform–a exerted a 
stronger anti-apoptotic effect as compared to isoform–b as structural modelling of 
both hnRNP K isoforms’ KH3 domain (inclusive of the C-terminals) has revealed no 
structural differences (Leopoldino et al., 2007). In terms of their function, it was 
reported in a study on HBV replication that there was no significant difference 
between either isoform in enhancing viral load (Ng et al., 2005). Thus, the observed 
144 
 
difference in suppression of hnRNP K-downregulation-induced apoptosis could 
possibly be due to a slightly higher expression level of isoform–a as compared to –b 
(Figure 3.17E and F). 
In summary, this study has provided experimental evidence that both hnRNP K 
isoform–a and –b possess similar anti-apoptotic functions, maintaining HCC cells’ 
ability to inhibit apoptosis. In addition, it has been demonstrated that the apoptosis 





5.2 The mechanism behind hnRNP K-downregulation-induced apoptosis in 
HCC 
Although several studies have reported the induction of apoptosis following 
hnRNP K downregulation, the underlying mechanism has not been well elucidated. 
Based on the experimental findings presented in the previous section, it is 
hypothesised that hnRNP K is an anti-apoptotic protein where its downregulation at 
early time points (i.e. 24 h and 48 h) merely compromised the cell’s ability to inhibit 
apoptosis, while the trigger behind the apoptosis induced following extended hnRNP 
K downregulation remains to be characterised. Thus, this has prompted a closer 
examination of hnRNP K’s anti-apoptotic ability, as well as further investigation on 
the trigger for the induction of apoptosis. 
 
5.2.1 Caspase-8 signalling is pivotal in triggering apoptosis in HCC cells 
following hnRNP K downregulation 
When caspase-8 or -9 apoptotic signalling was assessed for their contribution in 
apoptosis induction following hnRNP K downregulation, the results intriguingly 
revealed the importance of caspase-8 in apoptosis initiation. The co-knockdown of 
hnRNP K and caspase-8 almost completely abrogated the activity of caspase-3/7 
activity, while co-knockdown of hnRNP K and caspase-9 yielded an increase in 
caspase-3/7 activity instead (Figure 4.1). The mechanism behind the increase in 
caspase-3/7 activity following downregulation of both caspase-9 and hnRNP K is 
currently unknown, though heightened apoptosis following caspase-9 downregulation 
has been previously reported (Shah et al., 2004).  
Nonetheless, it is revealed for the first time that the trigger initiating apoptosis 
functions via caspase-8 in HCC cells, hence demonstrating the importance of caspase-
8 apoptotic signalling in hnRNP K-downregulation-induced apoptosis. This is in line 
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with the observation by a previous study that hnRNP K regulates the expression of 
cFLIP, a caspase-8 inhibitor (Chen et al., 2010). In contrast, White et al. (2010) 
revealed the translocation of PKCδ to the mitochondria following hnRNP K reduction, 
thus attributing the induction of apoptosis to the intrinsic apoptotic pathway. However, 
the activation of intrinsic apoptotic pathway would have allowed for caspase-3/7 to 
remain activated even in the absence of caspase-8, which is contrary to this study’s 
findings. As discussed previously, such discrepancy could be a cell-type specific 
effect. Hence, while it has been demonstrated that caspase-8 apoptotic signalling is 
important for the initiation of apoptosis following hnRNP K reduction in HCC cells, 
other possible sources of apoptosis initiators such as reactive oxygen species 
production following extended durations of hnRNP K downregulation or cell-type 
specific differences should not be disregarded (van Domselaar et al., 2012). 
Although current findings have revealed the pivotal role of caspase-8 in apoptosis 
induction following hnRNP K reduction in HCC cells, the exact initiator that triggers 
the activation of caspase-8 remains to be elucidated. Nonetheless, as caspase-8 is 
directly involved in the extrinsic apoptotic pathway (Elmore, 2007), mediators in this 





5.2.2 hnRNP K confers HCC cells with resistance to apoptotic stimuli 
In line with the hypothesis that hnRNP K downregulation compromises the 
ability of HCC cells to inhibit apoptosis at earlier time points, it was revealed that the 
downregulation of hnRNP K was able to sensitise HCC cells to TRAIL-induced 
apoptosis as exemplified by the significant increase in caspase-3/7 activity (Figure 
4.4). This is consistent with previous findings in which an increase in TUNEL 
positive cells was reported following 48 h of hnRNP K downregulation and 
concurrent TRAIL treatment in NPC cells (Chen et al., 2010). Such sensitization to 
cell death following hnRNP K downregulation is not limited to death-ligand induced 
apoptosis only, as a recent study has also demonstrated that the loss of hnRNP K 
could sensitise HeLa cells to cytotoxic lymphocyte-mediated killing (van Domselaar 
et al., 2012).  
The anti-apoptotic effect of hnRNP K in HCC cells was also further demonstrated, 
where increasing concentrations of hnRNP K siRNA were able to specifically 
increase TRAIL-induced caspase-3/7 activity in a dose-dependent manner (Figure 
4.5). Conversely, the overexpression of hnRNP K was able to reduce TRAIL-induced 
caspase-3/7 activity significantly (Figure 4.6). The overexpression of either hnRNP K 
isoforms resulted in a similar reduction in TRAIL-induced caspase-3/7 activity, 
further supporting the deduction that both isoforms possess similar anti-apoptotic 
capabilities. Thus, these findings have indicated that hnRNP K confers HCC cells 
with the ability to resist apoptosis. In addition, as HCC cells have been reported to be 
resistant to apoptosis mediated by several death receptors (Fabregat, 2009), results 
from this study have also suggested the possibility of sensitizing HCC cells to death 




5.2.3 hnRNP K regulates expression of anti-apoptotic genes  
hnRNP K is a multifunctional protein involved in various cellular processes and 
its nuclear functions include that of a transcriptional factor and a regulator for 
alternative splicing (Bomsztyk et al., 2004). In recent years, several studies have 
implicated hnRNP K in the alternative splicing of apoptotic proteins (Revil et al., 
2009; Venables et al., 2008). Notably, anti-apoptotic protein cFLIP has been 
demonstrated to be a direct downstream transcriptional target of hnRNP K (Chen et 
al., 2010), indicating that hnRNP K could directly regulate the expression of genes 
involved in apoptosis as a transcription factor.  
In this study, the correlation between hnRNP K’s role as a transcription factor 
and its observed anti-apoptotic function was examined. The experimental results 
revealed a significant decrease in hnRNP K expression in the nucleus upon its 
reduction with siRNA (Figure 3.10), suggesting that hnRNP K’s nuclear functions are 
likely to be affected following siRNA treatment. Coupled with the importance of 
caspase-8 apoptotic signalling in HCC cells elucidated in this study, the expression of 
genes involved in the extrinsic apoptotic pathway as well as interactors of caspase-8 
were examined based on an exon array performed with the use of siRNA-treated Hep 
3B (Figure 4.9). In view of the fact that hnRNP K affects the expression of other 
transcription factors such as c-Myc (Michelotti et al., 1996) and the androgen receptor 
(Wang et al., 2008), emphasis was placed on genes that showed greatest differential 
expression at 24 h post-hnRNP K downregulation to exclude possible unwanted 
secondary effects of hnRNP K downregulation on gene expression. 
Intriguingly, the results revealed that the three anti-apoptotic genes with the 
greatest expression reduction in the exon array, BIRC3 (cIAP2), CFLAR (cFLIP) and 
XIAP (XIAP), were all downregulated at the mRNA level following hnRNP K 
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downregulation in both HCC cell lines tested (Figure 4.10 and 4.11). This indicated 
that hnRNP K positively regulates the expression level of these three anti-apoptotic 
genes, of which the observations for cFLIP were consistent with a previous study 
(Chen et al., 2010). Nonetheless, this is the first demonstration of cIAP2 and XIAP 
gene expression regulation by hnRNP K.  
In addition, preliminary analyses examining the regulation of XIAP by hnRNP K 
have revealed a decrease in its protein levels following hnRNP K downregulation 
(Figure 4.12), and also demonstrated that hnRNP K likely affects XIAP’s expression 
at the transcriptional level (Figure 4.13). These findings strongly indicated that 
hnRNP K transcriptionally regulates XIAP but future validation with in-depth 
promoter analyses for XIAP would be required to affirm it as a direct downstream 
target of hnRNP K. However, hnRNP K can transcriptionally regulate genes via 
binding to a CT-rich region on promoters such as that for c-Src, c-Myc, thymidine 
kinase, neuronal acetylcholine receptor β4 subunit (Michelotti et al., 1996; Ritchie et 
al., 2003; Lynch et al., 2005; Hsieh et al., 1998; Du et al., 1998) or in the absence of 
direct DNA contact such as that observed for COX-2, p21 and MDM2 (Shanmugam 
et al., 2008; Moumen et al., 2005) or through interfering the activity of other 
transcription factors (Denisenko et al., 1996; Miau et al., 1998). As such, it is only 
with the identification of the exact promoter region on XIAP that hnRNP K exerts its 
positive regulative effect, before it could be systematically uncovered whether hnRNP 
K transcriptionally regulates XIAP via direct contact to a CT-rich region or through 
other transcription factors. This could also be further substantiated with additional 
validation studies, such as ‘rescue experiments’ by overexpressing XIAP following 
hnRNP K depletion, where the overexpression of XIAP that is a potent inhibitor of 
effector caspases is most likely to extensively reduce the extent of induced apoptosis. 
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Similarly, these future validation studies can also be applied to cIAP2 identified from 
this study. Nonetheless taken together, the experimental results have demonstrated 
that hnRNP K is an upstream regulator of the three anti-apoptotic genes that can 
contribute to the maintenance of HCC cells’ ability to inhibit apoptosis. 
Having demonstrated that the three anti-apoptotic genes involved in the extrinsic 
apoptotic pathway are regulated by hnRNP K, this has shed light on the p53-
independent apoptosis observed following hnRNP K downregulation (Figure 3.12 and 
3.14). As the extrinsic apoptotic pathway is the most well-established p53-
independent apoptotic pathway (Ashkenazi, 2008), the demonstration that hnRNP K 
regulates the above-mentioned anti-apoptotic proteins has strongly suggested that the 
p53-independent apoptosis observed following hnRNP K downregulation is via the 
extrinsic apoptotic pathway. This further supports the proposal that apoptosis 
observed following hnRNP K reduction was initiated by a trigger that signals via the 
extrinsic apoptotic pathway. 
Therefore, experimental findings from this current study have collectively 
revealed the underlying mechanism of apoptosis induction observed in HCC cells. As 
shown in Figure 5.1, though hnRNP K downregulation at early time points of 24 h 
and 48 h did not induce apoptosis spontaneously, it reduced the cells’ anti-apoptotic 














Figure 5.1 Underlying mechanism behind hnRNP K-downregulation-induced 
apoptosis in HCC 
HCC cell survival requires the active inhibition of apoptosis. Downregulation of 
hnRNP K results in a decrease of HCC cells’ ability to inhibit apoptosis, due to the 
reduction in anti-apoptotic proteins. Subsequent apoptotic trigger that signals via 
caspase-8 between 48 h and 72 h of hnRNP K downregulation results in apoptosis 

















5.3 Dysregulated apoptosis in HCC as a result of elevated hnRNP K levels 
Dysregulation of apoptosis is a part of the multistep event leading to the 
formation of aggressive HCC (Fabregat, 2009; Feitelson et al., 2002; Hussain et al., 
2007). In HCC, the dysregulation of apoptosis is complex, involving a plethora of 
signalling pathways such as that of p53, survival signalling as well as various 
apoptotic pathways. In addition, HCC cells have been reported to be resistant to 
apoptosis mediated by several death receptor ligands at the extrinsic apoptotic 
pathway (Fabregat, 2009). Given that apoptosis dysregulation has been reported to be 
mainly due to upregulation of anti-apoptotic pathways, therapeutic strategies that 
selectively inhibit anti-apoptotic signals may aid in HCC treatment (Fabregat, 2009).  
Hence, as hnRNP K has been demonstrated in this study to be an upstream 
regulator of the anti-apoptotic proteins cIAP2, cFLIP and XIAP, these proteins could 
likely contribute to the apoptosis resistance of HCC cells and thus hnRNP K’s 
maintenance of the cells’ anti-apoptotic ability. 
cIAP2 is a multifunctional protein that is involved in many biological processes 
including apoptosis and regulation of NF-κB signalling. It possesses E3 ubiquitin-
protein ligase activity, capable of ubiquitinating various substrates such as caspase-8 
and RIPK1 (Gyrd-Hansen and Meier, 2010; Tenev et al., 2011). In addition, cIAP2 
has been demonstrated to be upregulated at the mRNA level in HCC cell line with 
integrated HBV genome (Lu et al., 2005) and upregulated at both mRNA and protein 
levels in recurrent HCC associated with HBV infection (Weng et al., 2012). Despite 
the association of cIAP2 with HCC in these two studies, there is currently no 
experimental evidence regarding its direct effect on HCC’s resistance to apoptosis. 
Nevertheless, given cIAP2’s anti-apoptotic functions (Gyrd-Hansen and Meier, 2010), 
it can be hypothesised that cIAP2 has a role in HCC’s resistance to apoptosis by 
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contributing to the cells’ anti-apoptotic ability maintained by hnRNP K. However, 
further studies would be required to evaluate its contribution in greater detail. 
In contrast to cIAP2, there are more reports on cFLIP and XIAP playing an 
important role in the dysregulation of apoptosis in HCC. cFLIP is a major inhibitor of 
caspase-8 activation mediated by death receptors (Irmler et al., 1997) and has been 
reported to be upregulated at the mRNA level (Lee et al., 2008) as well as at the 
protein level in HCC samples and cell lines (Okano et al., 2003). The downregulation 
of cFLIP with siRNA was able to sensitise HCC cells to death receptor-mediated 
apoptosis (Ganten et al., 2004; Okano et al., 2003). Thus, this indicated that cFLIP 
likely confers HCC cells with resistance to apoptosis. It also lends support to this 
study’s experimental findings that highlighted the importance of caspase-8 apoptotic 
signalling in hnRNP K-downregulation-induced apoptosis.  
XIAP is a potent inhibitor of caspase-3, -7 and -9 (Holcik and Korneluk, 2001) 
and possesses E3 ubiquitin-protein ligase activity, capable of ubiquitinating various 
substrates such as caspase-8 and RIPK1 (Schile et al., 2008; Van Themsche et al., 
2009). Apart from inhibiting apoptosis directly via caspase inhibition, XIAP can also 
cause the activation of JNK pathway as well as the subsequent activation of NF-κB, 
thereby promoting the survival pathways (Schimmer et al., 2006). Elevated XIAP 
mRNA levels have been reported in HCC samples and cell lines (Notarbartolo et al., 
2004; Tao et al., 2004). In addition, immunostaining of XIAP has revealed its 
overexpression in HCC, where 70% of the HCC samples showed moderate to strong 
cytoplasmic staining for XIAP while the surrounding non-tumour tissues as well as 
normal liver tissues revealed a lack of or weak XIAP expression (Shiraki et al., 2003; 
Vischioni et al., 2006). Furthermore, XIAP has been revealed to be upregulated in 
nearly 90% of samples from advanced HCC patients, which correlated with apoptosis 
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resistance and enhanced in-vitro invasiveness in HCC cell lines as reported by Shi et 
al. (2008b). Similar to cFLIP, downregulation of XIAP has been reported to sensitise 
HCC cells to TRAIL-induced cell death (Pan et al., 2008; Yamaguchi et al., 2005). 
Hence, both cFLIP and XIAP are able to confer HCC cells with resistance to 
apoptosis, thus playing a crucial role in HCC’s anti-apoptotic capability maintained 
by hnRNP K. 
Based on the experimental evidence from various studies discussed above, 
coupled with this study’s findings that hnRNP K reduction can result in the 
corresponding downregulation of both caspase inhibitors i.e. cFLIP and XIAP, it 
could be hypothesised that the enhancement in TRAIL-induced caspase-3/7 activity 
following hnRNP K downregulation (Figure 4.4) is a direct result of increase in 
caspase-8 activity. Indeed, it was demonstrated that TRAIL-induced caspase-8 
activity increased (Figure 4.8), indicating that the reduction of cFLIP upon hnRNP K 
downregulation has resulted in the direct removal of inhibition at caspase-8. It is thus 
conceivable that the corresponding reduction of XIAP also brought about an increase 
in caspase-3/7 activity due to increased caspase-8 activity, hence bypassing the need 
for cleavage of BID to enhance caspase-3/7 activity. This is also supported by Jost et 
al. (2009), where it was demonstrated that the loss of XIAP resulted in Fas-induced 
apoptosis independent of BID in mouse hepatocytes. The reduction of inhibition at the 
caspase-8 and caspase-3/7 axis following hnRNP K downregulation is in line with the 
findings that hnRNP K influences the expression of cFLIP and XIAP and hence 
affects caspase activity indirectly.  
Taken together, it is conceivable that a reduction in hnRNP K expression results 
in the downregulation of cFLIP and XIAP, which subsequently compromises the anti-
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apoptotic machinery. This would allow for the sensitization of HCC cells to death 
ligands such as TRAIL via the caspase-8 and caspase-3/7 axis.  
Therefore, with the results demonstrated in this study, a model of apoptosis 
resistance in HCC conferred by hnRNP K could be constructed as seen in Figure 5.2. 
hnRNP K plays a crucial anti-apoptotic role in HCC cells’ resistance to apoptosis by 
maintaining high levels of caspase inhibitors cFLIP and XIAP, which can directly 
inhibit the activities of caspase-8 and caspase-3/7. In addition, the high levels of 
cFLIP serves as a blockade for the activation of extrinsic pathway by death ligands 
such as TRAIL that is constitutively produced in HCC and HCC cell lines (Shiraki et 
al., 2005). Upon the downregulation of hnRNP K, the levels of cFLIP and XIAP 
decreased and resulted in the removal of caspase inhibition, causing downstream 
apoptosis. 
While many studies have reported the upregulation of hnRNP K in HCC (Table 
3.1), it was only recently that an in-depth study was conducted on the expression level 
of hnRNP K in cirrhotic liver as well as early- and late-stage HCC samples, where the 
authors proposed the use of hnRNP K as a specific tissue biomarker for distinguishing 
early-stage HCC from liver cirrhosis and that a positive hnRNP K staining could be 
taken as an indicator of HCC (Guo et al., 2012). Liver fibrosis and cirrhosis arising as 
a consequence of chronic liver injury with constant occurrence of apoptosis and 
inflammation can lead to the subsequent formation of HCC, where damaged 
hepatocytes accumulate multiple genetic changes that increase their proliferation and 
allow for evasion of apoptosis (Chakraborty et al., 2012). These findings correlate 
well in indicating that the expression level of hnRNP K is low in cirrhotic liver where 
apoptosis is constantly occurring but increases in HCC that has developed the ability 
to evade apoptosis. Thus, as it was revealed in this study that hnRNP K possesses a 
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strong anti-apoptotic function at the caspase-8 and -3/7 axis in HCC, this indicated 
that hnRNP K could potentially serve as a prognostic marker to indicate the extent of 
apoptosis resistance in HCC, in addition to its role as a diagnostic marker proposed by 
Guo et al. (2012). This would allow for early diagnosis of early-stage HCC and could 




























Figure 5.2 A model of apoptosis resistance in HCC conferred by hnRNP K 
hnRNP K maintains apoptosis resistance of HCC by maintaining high levels of 
caspase inhibitors e.g. cFLIP and XIAP, which can directly inhibit the activities of 
caspase-8 and caspase-3/7. High levels of cFLIP and XIAP serve as blockade at the 
caspase-8-3/7 axis for the activation of extrinsic pathway by death ligands such as 
TRAIL that is constitutively produced in HCC and HCC cell lines. With hnRNP K 
reduction i.e. during chemotherapeutic drug treatment, the levels of cFLIP and XIAP 
decrease and result in the removal of caspase inhibition, thereby contributing to the 
apoptosis induction. 
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5.4 The physiological relevance of hnRNP K downregulation during 
chemotherapeutic drug treatment 
Although elevated levels of hnRNP K have been constantly reported in various 
cancers as well as HCC (Table 3.1), various chemotherapeutic drugs that reduces cell 
viability have been shown to reduce the expression of hnRNP K in cancer cells, hence 
suggesting the association between reduced hnRNP K expression and cell death. The 
implications of this observed reduction in hnRNP K expression by chemotherapeutic 
drugs are discussed below. 
5.4.1 hnRNP K downregulation as a contributor to 5-Fluorouracil-induced 
apoptosis 
5-Fluorouracil (5-FU) is an anti-metabolite chemotherapeutic drug commonly 
used to treat various cancers, where it exerts its anticancer effects by inhibiting 
thymidylate synthase and incorporating its metabolites into RNA and DNA, thereby 
generating RNA and DNA damage (Longley et al., 2003). Despite the limited usage 
of 5-FU in various cancers due to the development of multi-drug resistance, it has 
been accepted as a first-line anti-cancer drug for HCC chemotherapy (Abdel-Hamid 
and Morsy, 2010; Patt et al., 2003; Porta et al., 1995; Stuart, 2012; Tetef et al., 1995; 
Tong et al., 2012; Uchibori et al., 2012).  
In this study, treating HCC and colorectal cancer cell lines with 5-FU resulted in 
hnRNP K downregulation (Figure 3.6). This observation is consistent with a previous 
report that proposed hnRNP K as a predictive marker for response to 5-FU treatment 
in colorectal cancer (Zhang et al., 2010), but it was uncertain if this downregulation 
was an outcome of apoptosis. To eliminate the possibility that the reduction of hnRNP 
K was due to cleavage by caspases, cells were pre-treated with a pan-caspase inhibitor 
prior to the addition of 5-FU. The results revealed that hnRNP K downregulation was 
not due to cleavage by caspases, but rather, a direct consequence of 5-FU addition 
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(Figure 3.7). This observation however, does not eliminate the potential of hnRNP K 
to be cleaved by caspases, as hnRNP K has been suggested to be a potential caspase 
substrate by two large scale screening studies (Dix et al., 2008; Mahrus et al., 2008). 
In addition, hnRNP K has been reported to be downregulated by activated PKCδ in a 
proteasome-dependent manner (Gao et al., 2009) and has also been shown to be a 
proteolytic target of calpain (Kimura et al., 2003) as well as granzymes (van 
Domselaar et al., 2012). Thus, it remains to be ascertained if any of these proteins had 
a role to play in the reduction of hnRNP K following 5-FU treatment.  
On the other hand, the experimental results have shown that 5-FU 
downregulates hnRNP K at the mRNA level (Figure 3.8), which would have played a 
major role in hnRNP K’s reduction at the protein level. This reduction of hnRNP K 
mRNA expression by 5-FU could have been a direct effect of the drug itself, as 5-FU 
is known to inhibit RNA processing (Longley et al 2003). Alternatively, 5-FU-
induced hnRNP K mRNA reduction could be mediated via other transcription factors 
such as c-Myc, as hnRNP K promoter region possesses its binding sequence 
(Carpenter et al., 2006). Indeed, 5-FU has been reported to reduce c-Myc mRNA 
expression level in a colorectal cancer cell line (Zhao et al., 2008a), indicating that 
reduced c-Myc following 5-FU treatment could have contributed to hnRNP K mRNA 
downregulation. However, as c-Myc is also a known downstream target of hnRNP K 
(Michelotti et al., 1996), it remains to ascertain whether the downregulation of c-Myc 
mRNA observed in the study by Zhao et al. (2008a) could have been a result of 
hnRNP K reduction instead.  
5-FU was also demonstrated to reduce cell viability of HCC cells (Figure 3.4) via 
apoptosis (Figure 3.7), which is in agreement with previous studies (Ganten et al., 
2004; Koike et al., 2006; Lasfer et al., 2006; Ma et al., 2011; Yi and Yang, 2003). In 
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addition, the experimental findings for both p53-null Hep 3B and HepG2 (p53+/+) 
(Figure 3.4 and Figure 3.7) are also consistent with previous reports that 5-FU causes 
apoptosis in both p53–dependent and –independent manners (Enge et al., 2009; Liu et 
al., 2006). Interestingly, this reduction of HCC cell viability by 5-FU in both cell lines 
with different p53 status correlated well with the demonstration that 5-FU-induced 
hnRNP K downregulation was independent of p53 (Figure 3.5 and 3.6). 
Given that the downregulation of hnRNP K with siRNA decreased HCC cell 
viability (Figure 3.11) and induced apoptosis independently of p53 (Figure 3.18), it is 
compelling to propose hnRNP K downregulation as one of the contributors to the 
decrease in cell viability following 5-FU treatment. 5-FU has been previously 
demonstrated to increase caspase-8 activity in Hep 3B (Koike et al., 2006) and HepG2 
cells (Yi and Yang, 2003), and can upregulate FASL death ligand at the 
transcriptional level in both Hep 3B and HepG2 cells (Eichhorst et al., 2000). This 
could provide an explanation for the marked decrease in Hep 3B and HepG2 cell 
viability 48 h post-5-FU treatment (Figure 3.4), where 5-FU-induced hnRNP K 
downregulation presumably decreased the expression levels of anti-apoptotic genes 
such as cFLIP and XIAP (Figure 4.11) while increased 5-FU-induced caspase-8 
activation (Koike et al., 2006; Yi and Yang, 2003) accelerates apoptosis.  
Furthermore, current findings might provide an explanation for the reported 
sensitization of TRAIL-resistant Hep 3B and HepG2 cells to TRAIL via the 
downregulation of cFLIP upon 5-FU addition (Ganten et al., 2004). It could be 
hypothesised that the reduction in hnRNP K induced by 5-FU (Figure 3.6) could have 
resulted in the corresponding downregulation of cFLIP at the transcriptional level 
(Figure 4.11 and Chen et al. (2010)), hence sensitizing the once TRAIL-resistant cells 
to TRAIL-mediated apoptosis.  
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Even though the downregulation of hnRNP K can contribute to p53-
independent apoptosis during 5-FU treatment, the reduction of hnRNP K coupled with 
the induction of p53 during this treatment likely enhanced the pro-apoptotic effect 
observed. 5-FU is a known inducer of p53 (Ju et al., 2007), which can transactivate 
downstream cell cycle arrest and apoptotic targets that in turn activate the intrinsic 
apoptotic pathway (Longley et al., 2003). Thus, this explains the greater reduction in 
cell viability observed in HepG2 as compared to Hep 3B following 5-FU treatment 
(Figure 3.4). 
Taken together, this current study has demonstrated for the first time that 5-FU 
treatment reduces hnRNP K expression level independently of p53 and that this 
reduction is not due to cleavage by caspases. Hence, the downregulation of hnRNP K 
by 5-FU can contribute to the decrease in cell viability observed during 
chemotherapeutic treatment. 
 
5.4.2 hnRNP K reduction as an indicator of cell death  
Apart from 5-FU, various chemotherapeutic agents such as mitomycin C, RITA, 
docetaxel and bicalutamide that can decrease cell survival have all been reported to 
downregulate hnRNP K (Barboro et al., 2009; Benelli et al., 2009; Enge et al., 2009; 
Rahman-Roblick et al., 2007). In contrast, various agents associated with proliferation 
or demonstrated to induce cell cycle arrest have been demonstrated to increase and 
stabilise hnRNP K levels, such as serum treatment, epidermal growth factor and 
heregulin-β1 that induce proliferation (Mandal et al., 2001; Ostrowski and Bomsztyk, 
2003), as well as DNA damage treatments e.g. ionizing radiation, ultra-violet 
treatments and phleomycin that induce cell cycle arrest (Moumen et al., 2005). As 
such, it could be hypothesised that there is a positive correlation between the levels of 
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hnRNP K and cell survival, of which the decreased hnRNP K levels corresponding 
with decreased cell survival becomes particularly important during cancer treatment 
with chemotherapeutic drugs.  
As illustrated in Table 5.1, the hnRNP K reduction following chemotherapeutic 
treatment could play a part in the induction of apoptosis, hence resulting in decreased 
cell viability as demonstrated in the treatment of HCC cells with 5-FU. Nevertheless, 
this decrease in hnRNP K could also occur simultaneously with the onset of apoptosis, 
e.g. various chemotherapeutic drugs treatments activated PKCδ, which downregulated 
hnRNP K in a proteasome-dependent manner and cleaved caspase-3 to bring about 
apoptosis (Gao et al., 2009). In addition, hnRNP K has been demonstrated to be a 
substrate for granzymes produced by cytotoxic T cells, which can also cleave caspase-
3 to bring about apoptosis (van Domselaar et al., 2012). Apart from the two 
aforementioned scenarios, the decrease in hnRNP K might also be a result of the onset 
of cell death or apoptosis, as hnRNP K has also been reported to be a substrate of 
calpain and caspase (Dix et al., 2008; Kimura et al., 2003; Mahrus et al., 2008). Thus, 
the decrease in hnRNP K during chemotherapeutic treatment could function as a 
mechanism to induce apoptosis, be a simultaneous effect observed during apoptosis 










Table 5.1 Roles for hnRNP K reduction during chemotherapeutic therapy 
Roles for hnRNP K 
reduction 
Example References 
1. Contribute to apoptosis 
induction 
 
 5-Fluorouracil Current study 
2. A simultaneous effect 
observed during apoptosis 
 Activated PKCδ downregulates 
hnRNP K and cleaves caspase-3 
Gao et al. (2009) 
 
 Both caspase-3 and hnRNP K are 
granzyme substrates 
van Domselaar et al. 
(2012) 
3. A consequence of cell 
death 
 A caspase substrate (Apoptosis) 
Dix et al. (2008); 
Mahrus et al. (2008) 
 A calpain substrate (Necrosis) Kimura et al. (2003) 
 
 
As this current study has demonstrated the anti-apoptotic function of hnRNP K 
in HCC cells with supporting evidence from other studies in various cancers, it can 
thus be inferred that the reduction in hnRNP K following treatment with various 
chemotherapeutic agents functions as a mechanism to remove barriers that resist cell 
death. In fact, hnRNP K was observed to be upregulated in neuroblastoma cells that 
are resistant to etoposide treatment (Urbani et al., 2005), further illustrating the 
importance of hnRNP K’s anti-apoptotic role in preventing reduction in cell viability. 
Overall, the decline in hnRNP K is a direct indication of reduced cell viability 
during various chemotherapeutic treatments, which can serve as a surrogate measure 
of these treatments’ therapeutic effect. Thus, hnRNP K could potentially serve as a 
therapeutic marker of HCC treatment, indicating the response to chemotherapeutic 




hnRNP K has been consistently reported to be upregulated in various cancers, 
including HCC that possesses apoptosis dysregulation as one of its hallmarks. While 
it has been previously reported that hnRNP K is implicated in apoptosis, its precise 
role in this process has never been clearly defined.  
In this current study, the experimental findings have established the importance 
of hnRNP K in HCC cell survival, having demonstrated its contributions towards 
HCC’s resistance to apoptosis. The role of hnRNP K in maintaining HCC cells’ 
ability to inhibit apoptosis was revealed for the first time to be via the regulation of 
anti-apoptotic proteins that inhibits apoptosis induction at the caspase-8 and caspase-
3/7 axis. It was also revealed that caspase-8 apoptotic signalling was pivotal for 
apoptosis induced in HCC cells following extended hnRNP K downregulation with 
siRNA. 
Furthermore, given that the addition of a chemotherapeutic agent, 5-FU, to HCC 
cells downregulated hnRNP K independently of p53 and caspase cleavage, it is 
suggested that this reduction of hnRNP K by downregulation contributes to apoptosis 
induction in cancer cells.  
Thus, the various findings in this study have shed light on hnRNP K’s anti-
apoptotic role in HCC, highlighting its potential as both prognostic and therapeutic 
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APPENDIX I: Media, Buffers and Solutions 
 
Media and buffers for cell culture use 
FBS (Fetal Bovine Serum)  
Thaw 500 ml of FBS (Invitrogen) at 37°C water bath and heat inactivate at 56°C for 
30min. Aliquot into 50 ml falcon tubes and store at -20°C till next use. 
 
DMEM culture medium with 10%FBS (DMEM/10%FBS) 
Component    Volume 
DMEM (Invitrogen)   450 ml 
FBS (heat inactivated)  50 ml 
Total Volume    500 ml 




Component    Volume 
DMEM (Invitrogen)   45 ml 
FBS (heat inactivated)  45 ml 
DMSO     10 ml 
Total Volume    100 ml 
Filter and store at 4°C till next use. 
 
 
PBS (Phosphate Buffered Saline) 10X 
Component    Weight (1L) 
NaCl     80g 
KCl     2g 
KH2PO4    2.4g 
Na2 hPO4    14.4g 
Dissolve in 800 ml of Milli-Q water and adjust pH to 7.4 with HCl and top volume to 






Buffers and solutions for molecular cloning 
 
TBE Buffer (Tris-Borate-EDTA) 10X 
 
Component    Weight (1L) 
Tris base    108g 
Boric acid    55g 
EDTA     9.3g 
Dissolve in 1L Milli-Q water, autoclave and store at room temperature. 
 
 
Luria Bertani Broth (LB Broth) 
 
Component   Weight (for 1L) Final concentration (w/v) 
Tryptone   10g   1% 
Yeast Extract   5g   0.5% 
NaCl    10g   1% 
Dissolve and top up with Milli-Q water to 1L, autoclave and store at 4°C. 
 
 
Luria Bertani Agar (LB Agar) 
 
Component   Weight (for 400 ml) Final concentration (w/v) 
Tryptone   4g   1% 
Yeast Extract   2g   0.5% 
NaCl    4g   1% 
Agarose   6g   1.5% 
Dissolve and top up with Milli-Q water to 400 ml and autoclave. Cool to room 





Dissolve ampicillin powder in Milli-Q water to obtain stock concentration of 200 
mg/ml. Add appropriate amount into LB broth or agar to attain working concentration 






Buffers and Solutions for SDS-PAGE and Western Blot 
 
NP-40 Cell Lysis Buffer 
 
Component   Stock    Volume (100 ml) 
50mM Tris-HCl (pH7.8) 1M Tris-HCl (pH7.8)  5 ml 
150mM NaCl   5M NaCl   3 ml 
1% Nonidet P-40  Nonidet P-40 (100%)  1 ml 
Top up with Milli-Q water to 100 ml and store at 4°C till next use. Add in complete 
mini (Roche) and PMSF (working concentration 1mM) freshly before use.  
 
 
PMSF (phenylmethylsulfonyl fluoride) 
 
Dissolve PMSF powder in isopropanol to yield concentration of 200mM and store at -
20°C till next use. Ensure that the solids fully dissolve before use. 
 
 
Complete Mini (25X) 
 
Dissolve 1 tablet (Roche) in 420 μl of RNase/ DNase free water to obtain 25X stock 




SDS- Polyacrylamide Gel Recipe 
      Separating gels 
      10%    12.5% 
Component/ Volume 
Water      8.0 ml   6.4 ml 
30% acrylamide mix (Bio-Rad)  6.6 ml    8.3 ml 
1.5M Tris (pH8.8) (Bio-Rad)  5.0 ml    5.0 ml 
10% SDS     200 μl    200 μl 
10% APS (Bio-Rad)    100 μl    100 μl 
TEMED (Bio-Rad)    20 μl    20 μl 
Total Volume (for 2 gels)   20 ml    20 ml 










       5% 
Component/ Volume 
Water       2.84 ml 
30% acrylamide mix (Bio-Rad)   0.83 ml 
0.5M Tris (pH6.8) (Bio-Rad)   1.25 ml 
10% SDS      50 μl 
10% APS (Bio-Rad)     25 μl 
TEMED (Bio-Rad)     5 μl 
Total Volume (for 2 gels)    5 ml 
Add in the order indicated, swirl well. 
 
 
2X SDS-PAGE Sample Buffer 
 
Component    Stock      Volume (100 ml) 
50mM Tris-HCl (pH7.8)  1M Tris-HCl (pH7.8)    12.5 ml 
20% Glycerol    100% Glycerol    20 ml 
4% β-mercaptoethanol  β-mercaptoethanol    4 ml 
0.4% Bromophenol Blue (w/v) Bromophenol Blue (Powder)   0.4g 
4% SDS (w/v)    SDS (Powder)     4g 
Top up with Milli-Q water to 100 ml and store aliquots in -20°C till next use. 
 
 
10X Tris-Glycine SDS-PAGE Running Buffer 
 
Component   Weight (1L)     Final concentration (w/v) 
Tris base   30.2g      25mM 
Glycine   144g      192mM 
Top up with Milli-Q water to 1L. To obtain 1X buffer, add in 10% SDS to a final 
working concentration of 0.1% to 100 ml of 10X buffer and top up to 1L. 
10X Transfer Buffer 
 
Component   Weight (1L)     Final concentration (w/v) 
Tris base   58.2g      48mM 
Glycine   29.3g      39mM 
Top up with Milli-Q water to 1L. To obtain 1X buffer, add in 3.75 ml of 10% SDS 










Component   Stock      Volume (1L) 
20mM Tris-HCl (pH7.6) 1M Tris-HCl, pH7.6    20 ml 
150mM NaCl   5M NaCl   30 ml 
0.1% Tween-20  Tween-20   1 ml 









Buffers and Solutions for Flow Cytometry Analysis 
RNase A  
 
Dissolve RNase A (Sigma) in RNase/DNase free water (Invitrogen) to obtain 1 mg/ml 
stock. Aliquot and store at 4°C. Dilute 10X with RNase/DNase free water to 100 
μg/ml working concentration before use 
 
PI (propidium iodide)  
 
Dissolve PI (Sigma) in RNase/DNase free water (Invitrogen) to obtain 2 mg/ml stock. 
Aliquot and store at 4°C in dark. Dilute 40X with RNase/DNase free water to 50 





Buffers and Solutions for Immunofluorescence 
PFA (paraformaldehyde, 4% in PBS) (freshly prepared) 
Dissolve 0.4g paraformaldehyde in ~8 ml PBS, warm at 56°C water bath. Add 10N 
NaCl drop wise until solution clears. Top up to 10 ml with PBS 
 
Triton-X100 (0.1% in PBS) 
Add 1 ml Triton-X100 (Bio-Rad) to 99 ml PBS to prepare 1% stock. 10 × dilution 
with PBS to make 0.1% Triton-X100 before use 
 
BSA (bovine serum albumin, 5% in PBS) (freshly prepared) 
Dissolve 0.5g BSA in 10 ml PBS before use. 
 
PBST 




APPENDIX II: Supplementary Results 
 
 
Appendix II Figure 1. Low hnRNP K mRNA levels in HepG2 
Semi-quantitative RT-PCR results of hnRNP K mRNA levels in the various cell lines. 
PCR primers targeting different regions of hnRNP K detect for common regions 
found in the different alternatively spliced mRNA variants (1 to 3). hnRNP K mRNA 
levels remained consistently low in HepG2 even with the use of primers targeting 
different regions of hnRNP K, ruling out possible mutation(s) in the coding region of 
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